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 Abstract 
 
      Invasive fungal infection, a major cause of morbidity and mortality in 
immuno-compromised hosts, is of importance and is significantly 
increasing in incidence in recent years. Although there are a number of 
antifungal agents currently available, they are associated with various 
limitations. Being inhibitors of fungal cell wall biosynthesis, the class of 
echinocandins is characterized by outstanding safety profiles and great 
potential in combination antifungal therapy, but they fall short in oral 
bioavailability. A discovery of peptidomimetic analogues of echinocandin 
B, with potential inhibitory activity against 1,3-β-D-glucan synthase (an 
enzyme essential for the biosynthesis of fungal cell walls), was initiated 
by our research group. A series of structurally related derivatives 
(chlorogenic, quinic, caffeic and dihydrocaffeic acid derivatives) were 
later designed to mimic the backbone of echinocandins.  
      Further studies have been carried out on optimization of synthesis and 
modifications of a caffeic acid derivative. Due to the instability problems 
of previously reported compounds, a new molecule, a dihydrocaffeic acid 
derivative, has been designed and synthesized. It was found that adopting 
a few optimized procedures can not only improve the yield and purity of 
the caffeic acid derivatives, but also save a lot of time in synthesis.  
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Chapter 1. Introduction 
 
1.1   Fungi and fungal infections 
 
1.1.1   Fungi 
        Fungi are actually primitive plants on Earth and can be found in air, 
in soil, on plants, and in water. [1] Although there is still no body fossil 
evidence for the earliest organisms like fungi, biologists believe that fungi 
are an ancient group that must have evolved relatively early in geologic 
time, perhaps more than 1.5 billion years ago. [2] They are a large group of 
eukaryotic organisms including microorganisms such as mushrooms, 
yeast, mold, and mildew. Despite their completely different appearance, 
fungi share many features in common with human beings, which creates a 
unique opportunity for them to cause severe infections. Eukaryotic cells, 
membrane-bound organelles and a nucleus, are key components for both 
humans and fungi. [ 3 ] Due to their similarity to humans, certain 
opportunistic fungi can cause severe fungal infections that are 
characterized by high morbidity and mortality. Moreover, cell walls of 
fungi, as major components of these organisms, are different from plants, 
protists and bacteria. Instead of cellulose, which constitutes the cell walls 
of plants and some protists, chitin is the critical element of the cell walls 
of fungal cells.  
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1.1.2   Fungal infections 
        Among pathogenic microbes, eukaryotic pathogens, which include 
fungi and parasites, are receiving more and more attention from all over 
the world. This is due to the fact that drug resistance has been clinically 
observed more often than before, and fewer drugs or vaccines are 
available, compared to antibacterials and antivirals. [4] Fungal infections 
of animals, including humans, are known as mycoses, with many 
different environmental and physiological factors contributing to the 
development of fungal diseases. Some fungi reproduce by spreading 
microscopic spores (Figure 1.1). These spores are often present in the air, 
where they can be inhaled or come into contact with the surfaces of the 
body, primarily the skin. As a result, fungal infections usually begin in 
the lungs or on the skin.  
 
         
   
    
 
 
 
 
Figure 1.1. Fungal reproduction 
Synthesis and characterization of caffeic and dihydrocaffeic acid derivatives as antifungal agents 3 
        External factors, mainly environmental conditions, can trigger 
genetically-determined developmental states that lead to the emergence of 
specialized structures for sexual or asexual reproduction. As a critical 
element in fungal reproduction, the specialized structures are able to 
disperse spores or spore-containing propagules to facilitate the process. 
Different species of fungi have their own characteristics in reproduction. 
By comparing yeasts with molds, yeasts grow as solitary cells, while 
molds grow in the form of multicellular filaments called hyphae. As for 
reproduction, yeasts usually reproduce asexually through mitosis, also 
known as budding. On the other hand, molds are characterized by the 
development of hyphae through dispersing small spores, which can be 
either sexual or asexual (Figure 1.1). [5] However, it is common that many 
fungi reproduce by using more than one method of propagation. In 
addition to budding yeast cells, yeasts such as Candida albicans (C. 
albicans) may also form pseudohyphae or even true hyphae as well.  
        Yet, of the wide variety of spores that land on the skin or are inhaled 
into the lungs, most do not cause infection, i.e., not all species of fungi 
would cause disease in human. Many different kinds of fungi live inside 
the human body in a benign equilibrium with it. When the body's immune 
system is weakened due to an illness or treatment such as with patients 
who have had hematopoietic stem cell (HSC) and solid organ transplants 
(SOT) or chemotherapy, the balance can be disturbed, allowing fungi to 
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overgrow causing disease. [6] In fact, many fungi that cause mycoses may 
be part of the normal body flora (e.g., Candida), and opportunists (e.g., 
Aspergillus), existing in the environment, infect mainly immuno-
compromised people. Moreover, dimorphic organisms that are spore-
forming molds in nature are able to convert into yeasts after entry into the 
human body, often by inhalation (e.g., Histoplasma). [7] It is noteworthy 
that dimorphic fungi can cause infections even in immunocompetent 
people. Statistically, the most frequent aetiological fungi are C. albicans, 
Cryptococcus neoformans and Aspergillus fumigatus. The estimated 
annual incidence of invasive mycoses due to these pathogens is 72-228 
infections per million population for Candida species, 30-66 infections 
per million population for Cryptococcus neoformans, and 12-34 infections 
per million population for Aspergillus species. [8,9,10,11] 
        Symptoms of fungal infections vary depending on the area of the 
body infected, which normally includes eyes, nails, skin, mouth, lung, 
genitals, and digestive tract. When the infection happens on the skin, itch, 
red rash, scaling and flaking of the skin are general symptoms. The most 
common symptom of onychomycose is the nail becoming thickened, 
discolored and maybe even bulged out or separated from the finger or toe 
completely. In addition, fungal infections in the lung and systemic fungal 
infections are characterized by cough, loss of appetite, and persistent 
fever of unknown cause.   
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        As mentioned earlier, fungi do not always mean pathogenicity, since 
there are other factors contributing to actual fungal infections. With 
dimorphic fungi and some other fungal species, the transformation in 
growing forms plays a key role in the development of fungal infections. 
Due to thermotolerance, dimorphic fungi have the ability to grow at 37°C 
by transforming from filamentous moulds to unicellular yeasts in the host. 
Some opportunistic fungi can also grow in different forms depending on 
the infection sites, which has shown the flexibility in morphogenesis and 
metabolism of fungi (Figure 1.2). [12] This may have been the result of 
fungi evolvement in order to adapt to various environments.   
Figure 1.2. Morphogenesis in different fungal species, adapted from 
Romani L. [12] 
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        However, in recent years, patient characteristics, antifungal 
prophylaxis, and other factors appear to have contributed to a change in 
the spectrum of invasive fungal pathogens. [13] Non-albicans Candida, 
Non-fumigatus Aspergillus, and molds other than Aspergillus have 
become more common pathogens causing invasive fungal infections (IFI). 
Many of these fungi were previously thought to be nonpathogenic and are 
now recognized as causes of invasive mycoses in immunocompromised 
patients. And most of these emerging fungi are resistant to or less 
susceptible than others to standard antifungal treatments, which makes the 
invasive infections caused by these previously rare fungi more difficult to 
diagnose and treat. 
        IFI is a fungal infection that can occur when fungi enter the 
bloodstream. For example, when Candida yeasts enter the bloodstream, it 
can cause invasive candidiasis (IC). IFI, as a major cause of morbidity 
and mortality in immunocompromised hosts, is of importance and has 
significantly increased in incidence in recent years. [14] A few reasons 
have been proposed for the increase in IFIs, including the use of 
antineoplastic and immunosuppressive agents, broad-spectrum antibiotics, 
and prosthetic devices and grafts, and more aggressive surgery. [15] The 
rate of sepsis due to fungal organisms in the United States alone increased 
by 207% during the period from 1979 through 2000. [16] In order to have 
efficient management of established IFI, the critical step is assessing the 
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clinical situation carefully and evaluating the risk factors that might have 
contributed to its emergence. [13] Based on the current situation, some 
approaches have been developed to manage these infections, including 
prevention, antifungal prophylaxis, and empirical antifungal treatment 
(EAT). Lately, due to the recognition of risk factors that contribute to the 
development of IFIs, a few alternative management strategies, such as 
preemptive therapy and targeted prophylaxis, have been proposed to 
protect those patients who are at a very high risk. The main aim of 
management strategies is to prevent, or promptly treat, patients at risk. [23] 
However, the management of IFIs currently has two major challenges: (1) 
In addition to difficulties in treatment, IFIs are also difficult to diagnose. 
The limited number and impact of current diagnostic techniques is largely 
responsible for the fact that many IFIs are only detected at quite a late 
stage. (2) The lack of reliability in diagnosis of IFIs has led to the 
categorization of patients according to the certainty of the diagnosis on 
their fungal infection, such as “possible”, “probable” or “proven” 
infection. The uncertainty of diagnosis together with poor prognosis have 
driven many researchers to come up with better antifungal strategies. [13] 
Several studies have investigated the risk factors associated with IFI. 
Some of the common risk factors for developing IFI are summarized in 
Figure 1.3.  
 
Synthesis and characterization of caffeic and dihydrocaffeic acid derivatives as antifungal agents 8 
 
 
        Due to the absence of standardization in the statistical analysis used 
in studies of risk factors for developing IFI, the results may be different 
from study to study. However, many studies of risk factors have revealed 
the trend for certain individuals to be at higher risk for acquiring IFI as a 
result of their underlying medical conditions. [17,18]  
        With regard to risk factors and patients at high risk, patients in 
intensive care units (ICUs) are definitely on the top of the list that needs 
attention. Since Candida species are the most common cause of IFIs in 
humans, IC also has long been established as a major problem in ICUs, 
with a ten times higher incidence in this setting than in general medical 
Risk Factors 
The use of immuno-
suppressive drugs 
Chemotherapeutic Agents 
Corticosteroids 
Drugs to prevent rejection 
of an organ transplant 
Disorders 
AIDS 
Burns (extensive) 
Diabetes 
Lymphomas 
Kidney 
failure 
Leukemia 
Lung disorders (such as 
emphysema) 
Figure 1.3. Risk factors for developing IFI 
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and surgical wards. [19] The Infectious Disease Society of America (IDSA) 
guidelines of 2009 outlined the therapeutic response to Candidemia and 
also highlighted the main risk factors including the use of broad-spectrum 
antimicrobials, the presence of central venous catheters, use of total 
parenteral nutrition, neutropenia, immunosuppression and renal 
replacement therapy in the ICU setting. [20]  
 
1.2   Diagnostic methods for fungal infections 
 
        Despite the emergence of new advanced techniques, traditional 
diagnostic tests for IFIs such as histology, microscopy and 
microbiological culture-based tests remain the foundation and routine 
methods to determine whether a subject is infected. For many superficial 
skin, nail and yeast infections, a clinical examination of the potentially 
infected person and microscopic examination of the samples (e.g. 
scrapings of scale, nail clippings, skin biopsy or swab from a mucosal 
surface) might be sufficient to determine if a fungal infection is present. 
In the case of IFIs, examinations of cultures of tissue, blood or other 
fluids are conducted to identify the presence of specific fungi. The sample 
collected needs to be transferred onto a medium such as Sabouraud's 
dextrose agar containing cycloheximide and chloramphenicol. If it is a 
mold that requires identification, cycloheximide is left out. Furthermore, 
susceptibility testing performed on fungi isolated from a culture is used to 
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determine which antifungal agent is the best to use for treatment. 
However, the conventional methods are associated with problems, such as 
low-yield and time-delay, which has significantly limited their impact on 
the management of potential fungal infection in clinical settings. [21] 
Growing fungi, incubated in cultures at 25-30°C, may take several weeks 
for results to become available.  
        Due to the presence of severe thrombocytopenia, aggressive 
procedures such as biopsy of the infected site may have to be precluded. 
Although the culture-based tests are inexpensive and provide valuable 
material upon which to perform drug-sensitivity testing, cultures only 
become positive at a late stage of infection and organisms may take 
weeks to grow in culture, which would lead to the delay of diagnosis and 
therapy. [22] Insisting on irrefutable evidence of deep tissue infection 
before any therapeutic intervention not only exposes many patients to 
invasive, potentially life-threatening tests but also results in an 
unacceptable delay of potentially life-saving therapy. 
        New diagnostic approaches have been developed with the 
knowledge of non-culture based methods, which are generally less 
invasive and usually provide an earlier diagnosis than morphologic 
evaluation by culturing. Recent advances in detecting fungal cell-wall 
components and genomic deoxyribonucleic acid (DNA) allow earlier 
diagnosis than conventional tests. [23] Among all the new advanced 
Synthesis and characterization of caffeic and dihydrocaffeic acid derivatives as antifungal agents 11 
diagnostic technologies, the use of biomarkers has become prevalent in 
recent years, since it can provide critical information in a short period of 
time by relatively noninvasive specimen sources beyond the routine 
traditional methods. Two fungal biomarkers have been extensively 
researched and published over the last 20 years: galactomannan (GM) and 
1,3-β-D-glucan (BDG).  
 
1.2.1   GM antigen test 
        GM is a polysaccharide cell-wall component that is released by the 
fungus during its growth, especially for Aspergillus spp., in serum, 
bronchoalveolar lavage (BAL) fluid, and other body fluids. [24] It is 
considered specific for aspergillosis because it contains higher levels of 
GM than other fungi species. The GM antigen test, which is now 
commercially available as a kit and marketed as the PlateliaTM Aspergillus 
Ag (Bio-Rad), is a noninvasive technique used for the early identification 
of invasive aspergillosis (IA). [ 25 ] The test is an enzyme-linked 
immunosorbent assay (ELISA), which employs the rat monoclonal 
antibody EB-A2 and recognizes the (1à5)-β-D-galactofuranosyl side 
chains of the GM molecule, and serial tests are recommended to attain the 
greatest yield. Results are expressed as the ratio (index) of the optical 
density (OD) obtained from the patient serum sample to that of the 
control serum containing 1 mg of GM per mL. Compared to conventional 
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approaches, an obvious superiority of the GM test is time-saving, since 
results can be available within 3 hours. [24] A single result of GM index 
≥0.8 or two continuous results of ≥0.5 should be treated as indication of 
IA and a full diagnostic process should be started. Furthermore, 
quantitative GM testing is a useful diagnostic tool, which is mainly used 
in high-risk haemato-oncological patients when it is combined with 
computed tomography (CT) imaging, in the detection of early IA. [26]  
        However, limitations of this test include relatively low sensitivity 
(50–80%) and cross-reaction with other fungi (e.g., Penicillium species, 
Histoplasma species, and Blastomyces species). [27] Due to the species-
specificity of the assay, some emerging non-Aspergillus mycoses cannot 
be detected by this method. It is also suggested in some studies that the 
GM assay has a limited impact on SOT recipients, due to relatively poor 
sensitivity and specificity, compared to hematology-oncology patients. [28] 
However, it does not seem to make sense by comparing these two groups 
of patient populations in clinical settings. In addition, certain penicillin 
antibiotics have been reported to produce a false-positive GM test, likely 
because they are derived from Penicillium species. [29] Among these 
antibiotics, piperacillin-tazobactam (PT) (a widely prescribed drug 
combination in patients with cancer who have febrile neutropenia) was 
one of the antibiotic combinations identified as causing false positive 
results, which has been reported by several authors. [30,31,32,33] Since the rat 
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monoclonal antibody has also been shown to recognize constituents of 
molds from other genera, such as Penicillium species, the antibiotics that 
are semisynthetic penicillins, including piperacillin, tazobactam, and 
amoxicillin, may be able to cross-react with the Platelia Aspergillus GM 
test. [34] As a result, it has been indicated that maybe GM is carried 
through the production process of this antibiotic into batches designed for 
therapeutic use. Another study indicates that a positive Platelia Aspergillus 
test with PT is likely due to the presence of GM in PT rather than to a 
cross-reaction with the antibiotic. [ 35 ] Some food products, including 
hospital meals, canned vegetables, pasta, and cereals, which may be 
contaminated with GM, can also be one of the sources of false-positive 
results. Also, damage to the intestinal mucosa could allow ingested GM 
to enter the bloodstream. [36] The occurrence of false-positive GM assay 
results due to treatment with PT is a matter of concern because it may 
lead to unnecessary CT scans, undesirable (semi)-invasive investigations, 
over-treatment with expensive antifungal drugs that may produce toxicity 
and undesirable side effects. However, for all these years, opinions are 
divided on this point. Some studies indicated that they did not find any 
association between PT and GM positivity. [37,38,39] In a previous study 
from Turkey, 28 of 43 sera (65.1%) were positive in patients receiving 
concomitant PT in the absence of IA. [34] While another institution from 
Turkey analyzed the false positivity of GM due to PT treatment with the 
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same method during the same period, surprisingly only 5 of 40 non-IA 
febrile episodes tested positive (false positive rate 12.5%). [ 40 ] The 
conflicting results appeared to undermine the previous hypothesis 
regarding PT to be concerned as one of the major causes of false 
positivity. It was also reported in one study that they tested several PT 
batches and found that their GM content was reduced over the time of 
study. As a result, the authors speculated about the possibility of a 
modification in the manufacturing process to have occurred over time, 
resulting in better purity and less GM contamination. [41] In the same study, 
[41] besides the variable GM contamination in PT batches, their results 
also showed that the risk of false-positive GM tests can be minimized by 
performing blood sampling before PT administration and by using 
separate tubes of the central venous line for blood sampling and for 
administration of antibiotics. Some studies also come to the conclusion 
that the false positivity rate of GM antigen testing may be decreased by 
serial sampling by taking into account at least two consecutively positive 
values and by using a higher cut-off level (0.7 instead of 0.5). [34,38,42]  
 
1.2.2   BDG detection assay 
        BDG is a major cell wall polysaccharide that can be found in most 
fungi, with the exception of the Cryptococci, the zygomycetes, and 
Blastomyces dermatitidis, which either lack the glucan entirely or produce 
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it at minimal levels. [22] BDGs are 1,3-β-D-glucopyranosyl polymers with 
randomly dispersed single β-D-glucopyranosyl units held by 1,6-β 
linkages, giving a comb-like structure. Although being common in fungi, 
yeasts, algae and bacteria, BDG cannot be found in prokaryotes and 
viruses, as well as human cells. [43] Many studies indicated that glucans are 
released from fungal cell walls into the systemic circulation of patients 
with proven or probable IFIs, no matter if they were receiving antifungal 
medications. Therefore, the BDG’s presence in blood or other normally 
sterile body fluids may be a good serological marker of systemic fungal 
infection. [21] Many BDG detection assays have been developed in the past 
two decades and some of them are commercially available: Fungitell 
(Associates of Cape Code, Inc., East Falmouth, MA, USA), Wako (Wako 
Pure Chemical Industries, Ltd., Tokyo, Japan), Fungitec-G (Seikagaku, 
Kogyo, Tokyo, Japan), and Maruha (Maruha-Nichiro, Foods Inc., Tokyo, 
Japan). However, the Fungitell assay is the only one that has been 
approved by the Food and Drug Administration (FDA) in 2003 for the 
diagnosis of invasive mycoses in serum in the United States. [44] This 
assay is a chromogenic, quantitative enzyme immunoassay (EIA) 
designed to detect BDG by using purified, lysed horseshoe crab (Limulus 
polyphemus) amebocytes. These cells contain components of the Limulus 
clotting cascade, including Factors C and G, which initiate coagulation in 
the presence of bacterial liposaccharide and BDG, respectively. By 
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eliminating Factor C from the lysate, the activation of the cascade has 
been limited to BDG alone, which assures the specificity of the assay. [45]  
        The use of BDG assay is included in the revised IFI diagnosis 
criteria of the European Organization for Research and Treatment of 
Cancer/Mycoses Study Group (EORTC/ MSG) criteria. According to the 
new edition, a positive BDG result can be treated as mycological 
evidence of infection meeting their criteria. [46] However, no guideline has 
been provided to standardize the use of BDG assays and also its analysis. 
As a consequence, inconsistency was found in results from various 
studies while comparing data, because different patient populations, 
cutoff values, and sites of infections (e.g. deep-seated colonization vs. 
fungal superficial colonization) [47] have been taken into account in studies 
of BDG and other fungal biomarkers. [48]  
        It has been reported in a meta-analysis of 15 studies assessing the 
overall accuracy of BDG in the diagnosis of IFI that BDG assays have a 
high specificity in patients with hematologic disorders but relatively low 
performance in SOT recipients. [49] Although the number of measurements 
required for defining a positive BDG test result has not been standardized 
yet, compared to a single positive result, according to the same study, [49] 
requiring two consecutive BDG results reduced the overall sensitivity 
value, but enhanced the overall specificity value.  
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        In a study about the kinetics of BDG in persistently neutropenic 
rabbits with IA, the results suggested that both cell wall components (GM 
and BDG) appeared to be comparable and provided similar information 
regarding the extent and stage of infection. For the models with invasive 
pulmonary aspergillosis, concentrations of both biomarkers begin to rise 
within the first 24 h of infection, well before pulmonary infarction is 
evident, supporting the concept that these molecules, when circulating, 
signal invasive disease almost immediately after host defenses are 
breached. [50] Another intriguing meta-analysis, which included six cohort 
studies, reported a diagnostic odds ratio (DOR) of 111.8 versus 16.3 for 
the presence of IFIs in neutropenic hemato-oncological patients following 
two consecutively positive BDG assays compared to a single positive 
BDG assay. [51] Both the analysis of the kinetics of BDG levels and DOR 
results in the meta-analysis suggest that at least two sequential positive 
BDG results are required for indirect mycological criteria to allow 
possible invasive fungal diseases to be upgraded to probable invasive 
fungal diseases and also for higher diagnostic performance and better 
homogeneity of test results.  
        Recently, a meta-analysis, which covered 28 individual studies, 
provided a new direction in this area, i.e., assessing the diagnostic 
accuracy of serum BDG for IFIs on different cutoff values. The cutoff 
value of 60 pg/mL has the best diagnostic accuracy according to the 
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EORTC/MSG criteria, and it also shows the best diagnostic accuracy with 
the Fungitell assay compared to other BDG detection assays. [44] The area 
under the curve of the summary receiver operating characteristic (AUC-
SROC) analysis has been recommended to represent the performance of a 
diagnostic test, based on data from a meta-analysis. Therefore, sensitivity, 
specificity, DOR and AUC-SROC were estimated in this study, based on 
different cutoff values. [44] When the AUC-SROC is between 0.80 and 
0.90, it is usually considered as a good diagnostic test accuracy, and a 
value >0.90 indicates a very high overall diagnostic accuracy of the test. 
In their general analysis, patients who had proven or probable IFIs were 
compared with patients who did not have IFIs for serum BDG 
measurement with the AUC-SROC being 0.8855. It suggested that the 
BDG assay had a good diagnostic accuracy for the diagnosis of IFIs. 
When it comes to the diagnostic accuracy of different cutoff values of 
BDG, the analysis of cohort studies indicated that the cutoff value of 
BDG at 80 pg/mL had the best diagnostic accuracy (with an AUC-SROC 
of 0.9284), whereas the case-control studies indicated that the cutoff 
value of 20 pg/mL had the best diagnostic accuracy (with an AUC-SROC 
of 0.9943). When using the EORTC/MSG criteria as a reference standard, 
the cutoff value of 60 pg/mL has the best diagnostic accuracy, with an 
AUC-SROC of 0.8804. [44]  
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        Being one of the useful noninvasive diagnostic tools, a key 
advantage of the BDG assay is the required specimen source being serum, 
which is readily available and easily accessible, regardless of patient 
conditions. However, similar to GM assays, BDG assays also suffer from 
false positivity, which may result from: glucan-contaminated blood-
collection tubes and surgical gauze dressings; dialysis with cellulose 
membranes; bacteremia due to several gram-positive organisms, 
particularly Streptococcus pneumoniae; use of products with cellulose 
depth filters such as albumin; gut inflammation; and use of antibiotics 
such as amoxicillin-clavulanate. [52,53,54]  
        Although it did not improve the sensitivity of each test, the 
combination of BDG and GM detection was very useful in confirming the 
existence of IA. Furthermore, the use of both assays could be useful to 
identify the false positive results as well, due to discrepancies in positivity 
of each test. [49] A number of groups have reported that among critically ill 
patients with proven or probable IFIs, many developed detectable BDG 
antigenemia prior to the onset of clinical symptoms or radiologic signs or 
the return of positive culture results. The percentages of patients in whom 
this occurs vary between studies (64 to 87%), as do the numbers of days 
between BDG and culture (blood, biopsy, or BAL fluid) positivity (1 to 
10 days). [43,55,56,57,58] However, positive results from the tests still need 
verification in the course of systematic monitoring of consecutive serum 
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samples to exclude false-positive results and warrant the use of other 
diagnostic methods, for example radiological studies, including high 
resolution CT (HRCT). In patients with proven IA, the BDG antigen level 
corresponded with the response to the antifungal therapy. In patients with 
regression of the illness, a decrease in serum BDG was noted but 
continuously high levels of antigen were observed in patients not 
responding to therapy, so tracking quantitative values following initiation 
of antifungal therapy may be used as a prognostic marker for patient 
response. [43]  
        Although biomarkers are prevalent clinically in the care of high-risk 
patients with suspected IFI, biomarkers fall short in many respects. As 
mentioned earlier, GM assays have a high sensitivity among patients with 
hematologic malignancies (72%) and among bone marrow transplant 
recipients (82%), but it is decreased among SOT recipients (22%). [28] It 
also suffers from false-positive or false-negative results, because certain 
antibiotics, fungal infection due to Histoplasma species, and even the 
ingestion of certain foods may increase GM levels, whereas antifungal 
therapy may rapidly decrease GM levels. Meanwhile, BDG is a helpful 
serological marker of systemic fungal infection, but it is nonspecific, 
since it can be found in many different fungal cell walls, such as those of 
Fusarium species, Acremonium species, or Pneumocystis jirovecii, and 
even certain foods. In addition, biomarkers can neither detect all fungal 
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pathogens nor identify to the species level and sometimes cannot even 
reliably identify organisms to the genus level. Therefore, biomarker 
assays (both GM and BDG) are recommended to be used together with 
other diagnostic tools as corroborative evidence.  
 
1.2.3   Polymerase chain reaction (PCR) assay 
        The PCR method for DNA amplification was developed by Kary 
Mullis and colleagues in 1984 and was rapidly adapted to detect a variety 
of infectious agents, particularly viruses. [59] Along with the progress in 
PCR in recent years, it has become more popular in detecting fungal 
pathogens in human infections. Clinical samples such as blood and BAL 
fluid often contain only a small number of fungal cells, which may lead to 
a low sensitivity in other routine assays. However, PCR can be used to 
amplify the number of fungal DNA in samples providing better 
performance in other diagnostic tests. In order to achieve the amount for 
PCR-based fungal diagnostic assays, extraction methods need to be 
applied to lyse all available fungal cells to maximize DNA quantity. [60] 
Appropriate selection of the target gene is of great importance because of 
the opportunity it can provide to increase the sensitivity of a PCR assay. 
The detection limits of PCR assays can be a few gene copies per reaction, 
providing the ability to detect a fraction of an organism when targeting 
genes present in multiple copies per fungal genome. [61] In fact, targeting 
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multicopy genes has the advantage of increasing their sensitivity, 
compared with single-copy genes. The common multicopy targets are the 
18S ribosomal ribonucleic acid (rRNA) and 28S rRNA genes, the 
internally transcribed spacer (ITS) regions, and mitochondrial gene 
regions.  
        The key for the PCR process is a uniquely synthesized pair of 
oligonucleotide primers that flank and define the DNA segment of 
interest. The highly conserved regions of the fungal rRNA gene are used 
to “prime” the synthesis of the remainder of the gene. With the fungal 
DNA extracted from the fungi or clinical sample, a DNA polymerase is 
added to react with the target DNA strand to which the primer has bound 
as a template to synthesize a complementary strand of DNA (cDNA). [62] 
The source or product of amplification or replication is also known as an 
amplicon. There are several different approaches for detection and 
analysis of the targeted amplicon. First of all, the most classical approach 
for amplicon detection is agarose gel electrophoresis, which is capable of 
separating amplicons according to their specific length. However, due to 
the inability to differentiate amplicons with identical or similar lengths, 
this procedure has a deficiency in specificity. [62] In order to get better 
interpretation of data, oligonucleotide probes are specifically designed to 
bind complementary sequences in the target DNA, showing characteristic 
dye chemistries, including fluorescence resonance energy transfer, 
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hydrolysis, molecular beacon, and Scorpion systems. The amplified 
products are hybridized to DNA probes specific for each organism, 
allowing for a greater degree of specificity than the use of primers alone. 
[63] Another method to identify fungal species is amplicon sequencing, 
when amplicon contains species-specific base pairs. Even if only minor 
differences exist, one base pair between different species are often 
sufficient for identification. After sequencing, comparative analysis of the 
nucleotide sequence is performed to find a match in public databases. [64]  
        Among all these approaches, real-time PCR has become a research 
hot topic in recent years. Real-time PCR technology combines nucleic 
acid target amplification using standard PCR chemistry and detection 
using fluorescent probes in a simultaneous, single-well reaction. [ 65] 
Compared to conventional PCR testing, real-time PCR assay can decrease 
time for testing by eliminating the necessity to perform post-amplification 
processing and detection. Since the real-time PCR procedure can be 
completed in a single, closed-reaction vessel, it can reduce the possibility 
of environmental contamination with amplified nucleic acids, which is 
particularly important for fungal diagnostics. [66] It has been reported that 
Aspergillus species DNA can be detected by PCR-based assays of blood 
for a mean duration of 14 days before the clinical diagnosis of IA. [67] 
PCR positivity can also precede positive GM assay results (median, 17 
days; range, 4–63 days) or positive CT findings (median, 8 days; range, 
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1–84 days), which shows the outstanding performance of PCR-based 
assays in the ability of providing earlier diagnosis. [68]  
        Due to many different reasons and risk factors, the epidemiology of 
fungal infections is rapidly evolving, and non-Aspergillus, non-Candida 
species and other rare fungi have emerged as major opportunistic 
pathogens with even more difficulties in diagnosis and treatment. In a 
recent study with 51 patients involved, a considerable number of fungi (8 
of 18, 44.4%) other than major ones such as Aspergillus and Candida 
species were identified by PCR, when reliable serological diagnostic 
methods are generally absent for these organisms. [69] Therefore, DNA 
analysis might be the only diagnostic tool when no information can be 
gained from the culture study, which not only indicates the importance of 
PCR technology but also attracts our attention to the further development 
of DNA analysis.  
        Nevertheless, there are still some major shortcomings in PCR-based 
assays that might hinder the implementation of its clinical utility. First, 
there is lack of standardization for the use of PCR-based assays and the 
EORTC/MSG did not include PCR tests in the diagnostic criteria of 
probable IFI. As a result, different laboratories use different primer pairs, 
various interpretations of positive results and a wide range of 
amplification protocols. [61,64,70] Second, the impact of PCR-based assays 
on clinical decisions is limited by the non-negligible percentage of false-
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positive results due to colonization or contamination of the sample. [59] 
The factors contributing towards false-positivity can be divided into 
procedural false positivity and clinical false positivity. Procedural false 
positivity can be caused by contamination from the environment, 
previously amplified PCR products, or cross-reactivity of PCR primers 
and probes with non-target fungi or other organisms. On the other hand, 
clinical false positivity could be caused by colonization of human tissue 
surfaces with fungi. Whereas it is not a reflection of inadequacies in assay 
design or protocol, since the assay has detected something that it was 
designed to do. [65,71] To avoid or at least reduce the possibility of false 
positivity, more attention should be paid on adopting rigorous quality 
control measures, optimizing DNA extraction methods and PCR platforms.  
 
1.3 Antifungal agents 
 
        Although the number of agents available to treat fungal diseases has 
increased by 30% since 2000, the medications that have been approved 
for clinical use are still less than 20. Depending on the modes of action, 
current antifungal agents fall into the following three categories, polyenes, 
azoles and echinocandins.  
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1.3.1   Polyenes 
        As the principal member of the polyene class of antifungals, 
amphotericin B (AmB), 1, deoxycholate is a broad-spectrum antifungal 
agent (the structure of AmB is shown in Figure 1.4). AmB has been used 
as the standard treatment for IFIs for more than 30 years [13] by acting on 
ergosterol of the fungal cell membrane. Since ergosterol is the main sterol 
of the fungal cell, by forming a complex with ergosterol, polyenes can 
thereby perturb the fungal plasma membrane function, which can result in 
increased membrane permeability, leakage of the cytoplasmic contents 
and ultimately death of the fungal cell. [24] The antifungal selectivity of 
AmB is based on the conformational difference between the fungal 
ergosterol molecule and the mammalian cholesterol. Ergosterol has a 
cylindrical three-dimensional structure, while cholesterol has a sigmoidal 
shape. [72,73] However, the selectivity is low, which leads to toxicities for 
mammalian cells, particularly causing nephrotoxicity. Moreover, AmB 
has also been associated with other adverse effects including low blood 
potassium, infusion-related acute reactions (such as chills, fever, 
hypoxaemia, and hypotension), especially when administered over a short 
period of time. [74]  
        In an effort to reduce AmB toxicity, a variety of its lipid preparations 
have been introduced, including AmB lipid complex, AmB colloidal 
dispersion and liposomal AmB (L-AmB). [ 75 ] After enclosing the 
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amphotericin molecule within a liposome or other lipid carrier, to release 
free amphotericin, it needs to be dissociated from the AmB-lipid complex 
within the body. Therefore, it may reduce the time of exposure of 
amphotericin resulting in diversion from potentially vulnerable tissues, 
most importantly, the kidney. [76] In a systematic review of the literature, 
studies showed that lipid-based formulations significantly reduced all-
cause mortality risk by about 28 %, compared with conventional AmB. [77] 
It also has been reported that the use of lipid AmB (versus AmB 
deoxycholate) can provide better outcomes and clinical benefits in SOT 
recipients with cryptococcal meningitis. [78] So far, despite the higher costs, 
for the treatment of many IFIs, an AmB lipid formulation seems to 
provide a safer alternative than AmB deoxycholate, with at least 
equivalent efficacy. However, due to the limited data available regarding 
therapeutic equivalency between lipid AmB and conventional AmB, more 
well designed, randomized trials are needed to compare these 
formulations in different clinical settings. [79]  
 
 
 
 
 
 
Figure 1.4. Structure of amphotericin B (AmB) 1. 
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1.3.2   Azoles 
        While the use of AmB has been limited by its side effects, the arrival 
of azoles such as fluconazole and itraconazole brought a major advance 
for the treatment of fungal infections. Since it was first introduced for 
clinical use in the early 1980s, the azole class of antifungal agents has 
rapidly become the most widely used in antifungal therapy and 
prophylaxis. [80 ] Similar to the polyenes, azoles also take effect on 
ergosterol, although via a different mechanism. In addition to being the 
major component of fungal cell membrane, ergosterol participates in the 
regulation of membrane fluidity, asymmetry and integrity, as well as 
stimulating fungal growth and proliferation. [81] The primary molecular 
targets of azoles are the P450 enzymes that catalyze the oxidative removal 
of the 14α-methyl group of lanosterol. [82] Consequently, the main effect 
of azoles is to inhibit 14α-demethylation of lanosterol in the ergosterol 
biosynthetic pathway, resulting in a decreased ergosterol synthesis and a 
concomitant accumulation of 14-methylated sterols, which changes the 
permeability and fluidity of the fungal membrane. [83] Meanwhile, due to 
the fact that the same P450 enzymes are responsible for production of 
cholesterol in mammalian liver cells, azoles are also able to block this 
biosynthesis, which is directly associated with their adverse effects. [84] 
On the other hand, since one of the 14-methylated intermediates of 
lanosterol, 14-methyl-ergosta-8,24(28)-dien-3,6-diol, is toxic, some 
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authors have suggested that the accumulation of toxic intermediates may 
have played the key role for azoles to inhibit fungal growth. [85]  
        The first generation of antifungals in this class was the N-substituted 
imidazoles introduced in the late 1960s. Over the last few decades, the 
imidazole has been replaced by a triazole nucleus as the active 
pharmacophore, to enhance the specificity of coupling with fungal P450 
enzymes, which leads to the introduction of triazole antifungals like 
fluconazole, itraconazole and the recent triazole derivatives, such as 
voriconazole and posaconazole. [83] After being metabolized by CYP450 
enzymes in the liver, the inactive metabolites of azoles are eliminated via 
the urinary and gastro-intestinal tracts. Due to this metabolic pathway, 
there is a long list of drug-drug interactions, including the use of 
benzodiazepines, prednisolone, methyl-prednisolone, digoxin, phenytoin, 
carbamazepine, cyclosporine, rifampin, and other drugs in common use, 
which can cause problems for physicians in treating critically ill patients 
who receive multiple medications. [81,86,87,88] 
        Resistance to azoles has already been observed and well documented. 
[24] A large number of studies have been performed on the mechanisms of 
antifungal resistance. As for Candida species, there are four principal 
mechanisms suggested with respect to azole resistance. [89,90] Firstly, many 
of the studies indicated the induction of efflux pumps, which leads to 
decreased drug concentrations at the target within the fungal cell. [89] 
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Upregulation of efflux pumps encoded by either multidrug resistance 
(MDR) or Candida drug resistance (CDR) genes is usually associated 
with drug resistance with some differences according to species. [91] In 
addition, point mutations in the gene (ERG11) encoding for the target 
enzyme lanosterol C14α-demethylase lead to an altered target with 
decreased affinity or incapacity for azoles to bind to the enzymatic site. [92] 
Thus, overexpression of the mutated gene or upregulation of the altered 
target enzyme can also become a cause of resistance, which results in 
higher levels of azole cellular targets that cannot be bound by therapeutic 
concentrations of azole antifungals. [89] As the last potential mechanism of 
azole resistance, the development of an alternative pathway of sterol 
synthesis can be caused by another mutation on the ERG3 gene, which 
leads to replacement of ergosterol with 14α-methylfecosterol. [93] The 
unusual accumulation of ergosta-7,22-dienol-3β-ol in azole-resistant C. 
albicans clinical isolates allows the cells to bypass the synthesis of the 
toxic sterol and thereby makes the effects of azoles on the ergosterol 
biosynthetic pathway negated. [94] Due to the ERG3 mutation, the fungal 
cell membrane that cannot be affected by azole does not contain 
ergosterol, and this absence of ergosterol provides a mechanism for cross-
resistance to polyene antifungals. [95] Fluconazole 2, voriconazole 3 and 
posaconazole 4 are important members in the azole class and their 
structures are illustrated in Figure 1.5.  
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Fluconazole (Diflucan®) 
        Although some newer antifungal agents in the azole class have been 
introduced to clinical use, fluconazole still remains one of the most 
frequently prescribed triazole antifungal agents because of its great 
bioavailability and low toxicity, combined with low cost and availability 
as both intravenous and oral formulations. [96] Among azole antifungals, 
fluconazole is the most frequently used agent for prophylaxis and EAT, 
which is appropriate for patients with low risk for mold pathogens (e.g. 
Aspergillus species). [97]  
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Figure 1.5. Structures of Fluconazole 2, Voriconazole 3 and 
Posaconazole 4. 
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        The oral bioavailability of fluconazole is generally good with more 
than 80% of ingested drug being found in the circulation. Moreover, 
fluconazole is also characterized as the only azole to achieve therapeutic 
levels in urine, with 60% to 70% of the drug being excreted unchanged in 
the urine. [98] For many antifungal agents, it is difficult for them to 
penetrate the blood-brain barrier and achieve therapeutic cerebrospinal 
fluid (CSF) concentrations, since they are relatively large molecules. 
Noteworthily, fluconazole presents a relatively large volume of 
distribution with good penetration into various tissues including 
penetration into the CSF, which enables it to achieve good levels in the 
brain and CSF. [99,100] However, although fluconazole is active against 
most Candida spp., it is inactive against Candida krusei and Candida 
glabrata isolates. [ 101 ] Fluconazole also shows no activity against 
Aspergillus spp., Fusarium spp., Scedosporium spp., or the Zygomycetes, 
which greatly limits its clinical use. [102]  
Voriconazole (Pfizer®) 
        Voriconazole is a second-generation azole antifungal agent and a 
synthetic derivative of fluconazole with broadened antifungal spectrum. 
Among all of the second-generation triazoles, voriconazole was the first 
to be approved by the FDA for the treatment of IA, serious infections 
caused by Fusarium and Scedosporium apiospermum, and fluconazole-
resistant invasive Candida infections. [103] By adding an α-methyl group 
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and replacing one of the triazole moieties with fluorinated pyrimidine, 
voriconazole exhibits a broader spectrum of activity when compared to 
fluconazole. [104] Voriconazole is active against Aspergillus spp., Fusarium 
spp. and all Candida species (including the fluconazole resistant or less 
susceptible spp. of C. glabrata and C. krusei), except Zygomycetes. [105]  
        Similar to fluconazole, voriconazole is available as oral and 
intravenous forms and the latter form depends on sulfobutyl ether β–
cyclodextrin sodium (SBECD) for solubility. Since SBECD is excreted 
via the kidneys, where accumulation of SBECD could occur, dose 
adaptation is required in cases of renal impairment. [ 106 ] The oral 
bioavailability of voriconazole is more than 90% when the stomach is 
empty, but it decreases when food is present. Fatty foods have been found 
to reduce bioavailability by 80%. [107 ,108] Voriconazole is distributed 
widely in humans with a reasonable penetration of the blood-brain barrier 
and CSF levels being around 50% of plasma levels. [109] Due to the fact 
that the efficiency and distribution of a drug may be affected by the 
degree to which it binds to the proteins within blood plasma, it is a very 
important factor in determining the amount of active drug present at a 
given site of infection. As for voriconazole, it is 58% protein bound and 
has a large volume of distribution, while polyene agents and many other 
azole antifungals are highly protein bound (>90%). [104]  
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        Voriconazole undergoes extensive hepatic metabolism via the 
CYP450 enzymes, primarily by CYP2C19 and to a lesser extent by 
CYP2C9 and CYP3A4. [110,111] Several metabolites are excreted in urine, 
with <2% being unchanged. Unfortunately, none of the voriconazole 
metabolites exhibit antifungal activity. [112] Due to the metabolic pathway 
by CYP450 isoenzymes, the potential for drug-drug interactions with 
voriconazole is high. Specifically, inducers of CYP450, such as rifampin, 
long-acting barbiturates, and carbamazepine, can cause decreased 
voriconazole concentrations, so that concurrent use of these drugs with 
voriconazole should be avoided. On the other hand, voriconazole can also 
interfere with the metabolism of several other drugs through inhibition of 
either the CYP3A4 or the CYP2C9 pathway, and coadministration can 
lead to toxic levels of those common drugs. [113]  
        Although voriconazole is generally well tolerated, there is a common 
side effect associated with the use of voriconazole, being not previously 
noted with other azoles, a reversible disturbance of vision (photopsia). 
This side effect occurs in about 30% of patients but rarely leads to 
discontinuation of the drug, since the visual effect is transient and no 
permanent damage to the retina has been noted. [114,115] Other well-known 
adverse effects of voriconazole include skin rash (phototoxicity-related 
rash sometimes) and transaminase elevation, which are all reversible after 
discontinuation of the therapy. [116,117] Despite the side effects it may 
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suffer from, voriconazole has become the first choice of antifungal agents 
with regard to IA in most of the cases. [80,81] According to a multicenter, 
randomized, comparative study of IA with great significance, 
voriconazole was superior to AmB in efficacy (53% vs. 32% response) 
and resulted in improved 12-week survival (71% vs. 58%), which makes 
voriconazole the primary treatment choice for IA and oral voriconazole is 
preferred for ‘step-down’ or maintenance therapy. [114]  
 
Posaconazole (Noxafil®) 
        Being approved by the FDA in 2006, posaconazole is characterized 
as a lipophilic second-generation of the antifungal triazole with a broad 
spectrum of activity. [118] Since posaconazole has a low solubility in 
aqueous and acidic media, no intravenous formulation is available. To 
determine what oral formulation would provide better bioavailability, a 
suspension of posaconazole was compared with the tablet formulation. [119] 
It turned out that being administered as a cherry-flavored 40-mg/mL 
suspension using polysorbate 80 as an excipient helps lower sedimentation 
of solid particles because of the greater surface area and enhanced gastric 
mixing of the drug. [120] Its oral bioavailability also varies depending on 
dosage regimen and food intake, which is potentially problematic for 
clinical use. Unlike the high bioavailability of voriconazole with an 
empty stomach, food intake significantly increases the oral bioavailability 
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of posaconazole, with either a nonfat or high-fat meal (168% and 290%, 
respectively) or with a nutritional supplement. [121,122]  
        Posaconazole has a large volume of distribution after oral 
administration suggesting extensive extravascular distribution and 
penetration into intracellular spaces. [ 123 ] In general, posaconazole 
primarily circulates in plasma and then is widely distributed to the tissues 
and is slowly eliminated. However, posaconazole is highly protein bound 
(>98%), predominantly to albumin and binding is concentration 
independent. As a result, the penetration of posaconazole into CSF was 
found to be poor. [124] Although posaconazole is eliminated primarily 
unchanged, its main metabolites come from glucuronidation produced 
through Phase II biotransformations via uridine diphosphate (UDP) - 
glucuronosyltransferase (UGT) enzyme pathways. [125] According to a 
study of eight healthy male subjects, elimination of posaconazole 
occurred primarily through fecal excretion (79.6%), mainly as unchanged, 
and to a lesser extent through the urinary route (14%). [ 126 ] Since 
posaconazole is metabolized by the liver and mainly excreted in the 
faeces, the limited renal elimination allows for the use of posaconazole 
without dosage adjustment in patients with renal impairment, which 
makes it an appropriate alternative to AmB for patients with renal 
dysfunction. [124,127] Unlike voriconazole, which is a substrate and an 
inhibitor of CYP3A4, CYP2C9 and CYP2C19, posaconazole is not 
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significantly metabolized through the CYP450 enzyme system. [113,128] 
However, posaconazole has been found to greatly decrease the hepatic 
activity of CYP3A4, which can inhibit the clearance of drugs metabolized 
by CYP3A4 resulting in increased plasma concentrations of these drugs. 
[129] Depending on the chemical structure of the substrate and the CYP 
isoforms involved, the degree of inhibition varies. [130] For instance, 
coadministration of posaconazole with some of the CYP3A4 substrates is 
contraindicated due to the risk of corrected QT interval (the time between 
the start of the Q wave and the end of the T wave in the heart's electrical 
cycle) prolongation, while for some other CYP3A4 substrates, the doses 
should be reduced to counteract the increased exposure and the whole-
blood concentrations of these agents should be carefully monitored. [131]  
        Overall, posaconazole appears to be well tolerated in clinical trials so 
far and rarely requires discontinuation because of adverse effects. The 
most frequently reported side effects have been associated with 
gastrointestinal disturbances (14-18%, nausea, vomiting, abdominal pain, 
diarrhoea, etc.) and hepatic toxicities (3%, transaminase elevation and 
hyperbilirubinemia). [81,123,132] In a long-term safety study, 428 patients with 
refractory IFIs (n = 362) or febrile neutropenia (n = 66) who received 
posaconazole, 38% of the patients reported treatment-related adverse 
effects. It is noteworthy that among all of the 428 patients, 109 of them 
received posaconazole therapy for more than six months and no severe 
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side effect was observed, suggesting that posaconazole is well tolerated 
for long-term use. [133]  
        As the first-line choice for prophylaxis of invasive Aspergillus and 
Candida infections in severely immunocompromised patients, 
posaconazole has been proven to be effective by several studies. In a 
double-blind multicenter study, 600 allogeneic HSC recipients with graft-
versus-host disease were enrolled. Based on the situation that patients had 
received intensive immunosuppressive therapy, posaconazole was 
compared with fluconazole for prophylaxis of invasive mycoses. [134] It 
was shown that posaconazole was as efficacious as fluconazole in 
preventing all IFIs (5.3% and 9.0%, respectively; P=0.07), and was 
superior to fluconazole in preventing IA with significantly lower 
incidence in the posaconazole group (2.3% vs. 7.0%; P=0.006) at the end 
of the 112-day treatment period. Posaconazole was also found to be 
superior to fluconazole in preventing breakthrough IFIs (2.4% vs. 7.6%, 
P=0.004), particularly in cases of IA (1.0% vs. 5.9%, P = 0.001). 
Although there was no significant difference in overall mortality, a 
significant difference was observed in the number of deaths from IFIs, 
which was much lower in the posaconazole arm than fluconazole arm (1% 
vs. 4%, P=0.046). Another multicenter, open-label study evaluated 
posaconazole oral suspension as salvage therapy for IA, which included 
107 posaconazole recipients and 86 control subjects (control subjects 
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could not receive any antifungal agents as standard therapy that were 
investigational at the time of their treatment, i.e., voriconazole or an 
echinocandin). [135] Patients were enrolled to receive posaconazole for 
salvage treatment if they were confirmed to have a diagnosis of IA, and if 
they were refractory to at least seven days of antifungal therapy or were 
intolerant of conventional therapy. The overall success rate was 42% (45 
of 107) for posaconazole recipients and 26% (22 of 86) for control 
subjects (P=0.006). The results also showed that posaconazole appeared 
to provide better survival rates, since in the arm of posaconazole the 
cumulative rates of survival at 30 days and at the end of therapy were 74% 
and 38%, respectively; for control subjects, those survival rates were 49% 
and 22%, respectively. Based on the favorable results in both efficacy and 
safety, the current dosage regimen for posaconazole is 200 mg three times 
daily for prophylaxis, and 800 mg divided in two or four doses in the 
salvage setting.  
 
1.3.3   Echinocandins 
        The changing pattern of fungal infections and increasing incidence 
of azole-resistance have led to the necessity of finding a new drug target 
for antifungal therapy. Notably, as a new drug class, the echinocandins, 
which aim at a drug target different from polyenes and azoles, have been 
approved for clinical use. [136] Being rigid structures, fungal cell walls are 
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composed of large polysaccharides BDG, 1,4-β-D-glucan, 1,6-β-D-glucan, 
chitin, mannan or GM, and α-glucans and various glycoproteins. [137,138] 
The target for echinocandins is the complex of proteins responsible for 
synthesis of BDG. By inhibiting this glucan synthase, it can impair cell 
wall integrity and ultimately lead to osmotic lysis and death of susceptible 
fungal cells. [139] Therefore, the activity spectrum of echinocandins is 
limited to fungi that rely on these types of glucan polymers, which makes 
them less broad than the activity spectra of polyene or azole agents. Still, 
the echinocandins have shown fungicidal activity against many 
pathogenic fungi such as Candida spp., Aspergillus spp. and 
Pneumocystis jirovecii. [72,139] Owing to their completely different drug 
target and mechanism of action, echinocandins are broadly active against 
azole-resistant Candida spp. [140]  
        The echinocandins are semisynthetic amphiphilic lipopeptides being 
composed of a cyclic hexapeptide core with an alkyl side chain (see 
Figure 1.7). As a result of the structural characteristics, the echinocandins 
are usually large molecular weight compounds (around 1200). [72,141]  
        The antifungal activity of echinocandins was discovered from 
prototypes, echinocandin B 5 and aculeacin A 6, by random screening in 
the 1970s. [73] The structures are shown in Figure 1.6. Both prototypes 
were obtained from products of fermentation of some fungi such as 
Zalerion arboricola or Aspergillus nidulans var. echinulatus. [142] With the 
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knowledge that both echinocandin B and aculeacin A showed some 
antifungal activity, further studies regarding antifungal efficacy and 
mechanism of action were performed. Later, studies found that besides 
the direct fungicidal and fungistatic activities, echinocandins also have 
immunomodulatory effects. [143] Inhibition of the biosynthesis of BDG 
synthase disrupts the equilibrium required to maintain cell wall structure, 
resulting in increased β-glucan exposure, which exhibits 
immunostimulatory properties. Due to the additional exposed antigens, 
antibody deposition will be triggered, which will cause further 
recognition by the host immune system. [81,143]  
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Figure 1.6. Structures of echinocandin B 5 and aculeacin A 6.  
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        At present, there are three members in use in the class of 
echinocandins: caspofungin 7, micafungin 8 and anidulafungin 9. [103] The 
structures are shown in Figure 1.7. All echinocandin preparations 
currently in use are for intravenous use only because of the poor oral 
bioavailability (only around 3%). [72,81,139]  In addition, echinocandins are 
highly protein bound (from 85% to 99%), which limits the amount of free 
drug available for activity. [121,144] Echinocandins undergo degradation 
mainly in the liver by hydrolysis and N-acetylation rather than through 
CYP450 (to a lesser extent). [145] For caspofungin, it is metabolized very 
slowly, because of the hepatic uptake after initial distribution, and it also 
undergoes degradation producing an inactive open ring compound in the 
liver. [121,146] Two inactive metabolites are produced during the metabolism, 
which are excreted in the bile and feces. [146,147] Owing to the metabolic 
pathway of caspofungin, dosage reduction is recommended for patients 
with severe hepatic dysfunction. [148] Micafungin undergoes non-oxidative 
metabolism to produce two metabolites. One of the metabolites is formed 
as the side chain of micafungin is hydrolyzed by CYP isoenzymes (mainly 
CYP3A). [149] Although micafungin is a substrate for, and a weak inhibitor 
of, CYP3A4 in vitro, hydrolysis plays only a minor role in the 
metabolism of this drug. [150] The main metabolic pathway of micafungin 
is facilitated by arylsulfatase with further decomposition by catechol-O-
methyltransferase. Unlike the two members in this class discussed above, 
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more than 90% of anidulafungin goes through non-enzymatic degradation 
resulting an inactive open-ring peptide that appears to be further degraded 
by plasma peptidases. [151] There is no hepatic metabolism mediated by 
CYP450 observed. As for elimination, anidulafungin is eliminated by 
fecal excretion, mainly as degradation products via biliary system, rather 
than passing into urine. [144] In addition, none of the members in the class 
of echinocandins can be dialyzed, and so no dosage adjustment is 
necessary for patients having renal replacement treatment. [139,145]  
 
 
 
 
 
 
         
Caspofungin 7 
Micafungin 8 
Anidulafungin 9 
Figure 1.7. Structures of Caspofungin 7, Micafungin 8 and 
Anidulafungin 9. 
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        Although fungi are eukaryotes like human beings, cell walls and 
targets of echinocandins do not exist in mammalian cells, which attributes 
to the minimal toxicity of this class of antifungal agents. [103,145] Therefore, 
compared with AmB, whether in complex with lipid or not, the 
echinocandins exhibit a better safety profile. [121]  
        However, histamine-mediated infusion-related reactions, such as 
facial swelling, rash, and vasodilatation, have been observed when rapid 
administration of echinocandins is given. Such reactions seem to be easily 
relieved by slowing the rate of infusion or premedicating with an 
antihistamine. [152] Since the echinocandins are poor substrates for the 
CYP450 enzymes, and are not substrates for intestinal or tissue P-
glycoprotein, fewer drug interactions have been reported for these 
compounds than for the azole antifungals. [139] Nevertheless, there are still 
some drug interactions that have been documented. The concentration of 
caspofungin can be diminished when administrated with CYP450 
inducers, such as rifampin and phenytoin, which merits a slight increase 
in dose. [ 153] Micafungin has shown weak inhibitory effects against 
CYP3A4 causing increased serum concentrations of substrates of this 
enzyme, like sirolimus and nifedipine. [121,139] Yet, anidulafungin does not 
seem to exhibit these CYP450-related interactions. [151] 
        Since being approved for clinical use, the echinocandins are 
considered to be the choice of treatment for IC due to their broad 
Synthesis and characterization of caffeic and dihydrocaffeic acid derivatives as antifungal agents 45 
antifungal spectrum and fungicidal activity against various species of 
Candida.  Along with the findings of many clinical studies and trials with 
regard to echinocandins, indications appropriate for oesophageal 
candidiasis, IC and candidemia, IA, and prophylaxis of IFIs have been 
explored as an intravenous drug. [145]  
        In 2001, caspofungin became the first member in the class of 
echinocandins approved by the FDA for treatment of patients with IA 
who cannot tolerate or who are refractory to other antifungal therapies. It 
was also approved for the EAT of fungal infections in febrile neutropenia, 
candidemia and the following Candida infections: oesophageal candidiasis, 
intra-abdominal abscesses, peritonitis and pleural space infections. 
[103,154,155,156] In a randomized double-blind multicenter trial of caspofungin 
versus AmB for treatment of IC (mainly candidemia), caspofungin was 
found to be as effective as AmB but less toxic. [155] Among patients who 
received intravenous antifungal therapy for 10 days, the rate of favorable 
response was 73.4% in the caspofungin group and 61.7% in the AmB 
group suggesting that caspofungin is at least equally efficacious as AmB. 
[155] On the other hand, the number of discontinuation due to adverse 
events was significantly higher in the AmB arm than that in the 
caspofungin arm (23.2% vs. 2.6%, respectively), which reveals the 
superiority of caspofungin on toxicity profiles compared to AmB. [155] 
Among three members of echinocandins, caspofungin is the only one that 
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has been studied in a large randomized double-blind controlled trial (RCT) 
for febrile neutropenia in which over 1000 patients were enrolled. [157] 
Both efficacy and safety of caspofungin have been assessed and 
compared with L-AmB for EAT in the study. The overall success rates 
were 33.9% for caspofungin and 33.7% for L-AmB, showing similar 
efficacy, while discontinuation occurred less often in the caspofungin 
group than in the L-AmB group (10.3% vs. 14.5%, P=0.03). [157] 
Caspofungin has also been studied as salvage therapy for IA in a 
noncomparative, multicenter clinical trial in which 83 patients were 
involved, who were either refractory to (71, 86%) or intolerant of (12, 
14%) previous antifungal therapy. [156] Among the 83 patients who 
received at least one dose of caspofungin, a favorable response was 
observed in 37 (45%) patients, which actually led to the first approval of 
the use of an echinocandin for treatment of IA in patients intolerant of or 
refractory to conventional antifungal treatment by North America and the 
European Union. [156]  
        The second echinocandin, micafungin, was approved in 2005 
initially for the treatment of esophageal candidiasis and prophylaxis of 
invasive Candida infections in patients undergoing HSC transplantation 
(HSCT). [103] Of echinocandin class, only micafungin has been formally 
evaluated, in two randomized trials for antifungal prophylaxis, and found 
to be effective in preventing invasive Candida infections and also be a 
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potential alternative to fluconazole as prophylaxis for IA. [158] Since it is 
common to use fluconazole for antifungal prophylaxis, two randomized, 
double-blind, multicenter, comparative trials of micafungin and 
fluconazole were designed to compare their efficacy and safety profile 
with different dosages of micafungin (a daily dose of 50 mg, 100 mg or 
150 mg) in the two studies. Both studies defined success as absence of 
suspected, proven, or probable IFIs through the end of prophylaxis 
therapy and no proven or probable IFI through the end of the 4-week 
period following treatment. [159,160] In the first study, either 50 mg of 
micafungin or 400 mg of fluconazole was administered once daily as a 
one-hour infusion. [159] A higher overall success rate was observed in the 
micafungin group (80%) than that of the fluconazole group (73.5%). [159] 
In the other study, patients were randomly assigned with either 
micafungin 150 mg or fluconazole 400 mg once daily. [160] Although the 
molar amount of micafungin and fluconazole (molecules, mole as unit) 
were not mentioned in the literature, it would have been better to compare 
their molar amount of substance, instead of their physical weights, due to 
a significant difference in their molar weights. Therefore, the comparison 
of 150 mg micafungin (1270.28 g/mol) with 400 mg fluconazole (306.27 
g/mol) is equal to 0.039 mmol micafungin and 1.306 mmol fluconazole. 
The results of the study showed that the overall success rate in the 
micafungin arm was comparable to that of the fluconazole arm (94% vs. 
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88%, respectively), which seems to suggest that micafungin could be 
treated as a new valuable option for antifungal prophylaxis. [160] Although 
50 mg of micafungin has been approved for IFI prophylaxis, a higher 
dose of micafungin (150 mg daily; 0.118 mmol) has been found to be 
significantly more effective in several trials (for the treatment of 
esophageal candidiasis; endoscopic cure rate: 89.8% vs. 68.8%, 
respectively). [161,162] In addition to the antifungal prophylaxis, the efficacy 
of micafungin for the treatment of severe IC has been studied in a Phase 
III randomized, double-blind, multinational trial of over 500 adult patients 
to compare micafungin (100 mg/day) with L-AmB (3 mg/kg per day). [163] 
Of 202 patients in the micafungin group, overall treatment success was 
seen in 181 patients (89.6%), which is comparable to the results in the L-
AmB group with an overall success observed in 170 of 190 patients 
(89.5%). [163] Meanwhile, fewer treatment-related adverse effects were 
found to be attributed to the use of micafungin than with L-AmB, which 
was consistent with reports about safety profiles from other reports. [163] 
However, a different unit system (mg/day vs. mg/kg per day) was used 
for dosage in the study, which may lead to untenable conclusions due to 
the difference in molar weight between micafungin and AmB. Still, 
several comparative studies have indicated micafungin being equally 
efficacious, yet less toxic than AmB, despite AmB and L-AmB being 
considered as the standard EAT for fungal infections. Therefore, a recent 
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study was designed and performed to evaluate micafungin for EAT of 
febrile neutropenia in patients with hematological malignancies. [164] Of 
53 patients who received chemotherapy for hematological malignancies, 
and more than 72 hours of systemic antibacterial therapy while fever and 
neutropenia persisted, resolution of fever during neutropenia was achieved 
in 37 patients (70%) by taking micafungin (150 mg/day). All patients who 
were positive for BDG or Aspergillus became negative. [164] According to 
the results, micafungin appears to be safe and effective as used in EAT 
for treating febrile neutropenia in hematologic malignancies.  
        Anidulafungin is the newest echinocandin approved in 2006 by the 
FDA to use in the treatment of oesophageal candidiasis, candidemia, 
peritonitis and intra-abdominal abscesses due to Candida spp. in this class. 
[103] As mentioned earlier, anidulafungin is unique because it undergoes a 
process of non-enzymatic biotransformation for degradation rather than 
being metabolized via CYP450 enzymes. Consequently, anidulafungin is 
endowed with an outstanding advantage and it is not affected by 
concomitant treatment with substrates, inhibitors, or inducers of the 
CYP450. [151,165] In addition, there is no need for dose adjustments for 
patients with any degree of renal or hepatic insufficiency for the use of 
anidulafungin. [ 166 ,167 ] In a randomized double-blind trial comparing 
anidulafungin with fluconazole for treatment of IC, eligible patients (245 
out of 261) were randomized to receive either intravenous anidulafungin 
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or intravenous fluconazole for 14-42 days. [168] At the end of intravenous 
therapy, there was a significantly better global response rate with 
anidulafungin (75.6%) than with fluconazole (60.2%; P=0.01). [168] Since 
C. albicans were isolated in 62% of the 245 patients as the major 
causative pathogen, it is noteworthy that the difference in the global 
response rates against C. albicans infections was evident between the two 
treatments (81.1% for anidulafungin vs. 62.3% for fluconazole, P=0.02). 
[168] It is well known that critically ill patients are the vulnerable 
population against nosocomial infections frequently caused by Candida 
spp. An echinocandin is recommended by the IDSA 2009 candidiasis 
guideline for the treatment of IC in patients who are considered to be 
“moderately severe or severely” ill. [20] Therefore, a post hoc analysis was 
conducted to compare the responses to anidulafungin with fluconazole in 
this population. [169] One hundred and sixty-three patients were identified 
from the original study [168] that met at least one criterion for critical 
illness (89 in anidulafungin group, 74 in fluconazole group). Global 
responses at the end of therapy were more favorable with anidulafungin 
(70.8%) than with fluconazole (54.1%, P=0.03), which supported the 
2009 IDSA guidelines for anidulafungin being more effective than 
fluconazole in treating critically ill patients with candidemia. [169] Since 
anidulafungin has a broad spectrum of activity against Candida species, 
including strains resistant to azoles and AmB, an open-label, non-
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comparative small-scale trial was performed to evaluate efficacy of 
anidulafungin in patients with azole-refractory oropharyngeal and 
esophageal candidiasis. [170] Nineteen patients, who had failed treatment 
of 14 days with either fluconazole or voriconazole, were enrolled in the 
study. At the end of the therapy, clinical success was observed in 18 of 19 
patients (95%) and 11 of 12 patients (92%) were defined as endoscopic 
success. [170] For the follow-up visit, the success rates were evaluated again, 
and 14 patients (47%) were found to remain successful, 10-14 days after 
end of therapy. Although this study was limited by the small sample size, 
it still provided some valuable information and suggested that 
anidulafungin could be an effective, well-tolerated treatment option for 
azole-refractory mucosal candidiasis. [170] 
        Yet, there are not many studies that have been performed to evaluate 
the safety profiles of anidulafungin in the use of clinical settings, and 
adverse events were rarely reported so far. A recent study was conducted 
to evaluate the safety profile of anidulafungin in adult SOT recipients. [171] 
Eighty-six SOT recipients from 14 centers were enrolled in this study 
over 14 months who received anidulafungin for at least 48 hours as the 
treatment of IFIs (24, 28%) or as prophylaxis (62, 72%). [171] The results 
showed that anidulafungin was generally safe and well tolerated in SOT 
recipients and there was no patient discontinued from anidulafungin due 
to severe adverse effects. In particular, there was no case of hepatotoxicity 
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or renal failure directly attributed to the use of anidulafungin and no need 
for modification of immunosuppressive drug doses due to anidulafungin 
therapy, which is important to SOT recipients. [171] 
 
1.4   Antifungal strategies 
 
        Due to the limited diagnostic techniques that are currently available 
and the fact that many IFIs can only be detected at a relatively late stage, 
developing more effective antifungal strategies has been very important 
for the management of IFIs. To be a successful antifungal strategy, it 
should not only match the individual case with proper treatment and 
regimen, but also be able to balance efficacy and safety (to avoid overuse 
and underuse). There are four general strategies available now for the 
management of IFIs, including prophylaxis, EAT, preemptive antifungal 
therapy and targeted therapy (treatment of established IFI). The definition 
of each strategy is described in Table 1.1.  
 
1.4.1   Antifungal prophylaxis 
        Before antifungal prophylaxis became widely used, about 20% of 
febrile neutropenic patients treated for acute leukemia or those 
undergoing HSCT had developed an IFI with Candida or Aspergillus 
species by day 20 of neutropenia. [172]  
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Table 1.1. Strategies for management of IFIs, modified from Segal B.H., 
et al. [13,173] 
        Due to the high mortality associated with IFIs in 
immunocompromised patients, antifungal prophylaxis has been 
recommended in selected high-risk patients. According to the 
recommendations of the ‘First European Conference of Infections in 
Leukaemia’ (ECIL 1) and the ‘Infectious Diseases Working Party of the 
German Society of Haematology and Oncology’, antifungal prophylaxis 
should be provided to patients with granulocytopenia (<500 cells µl-1) for 
more than seven days and also in allogeneic HSCT recipients. [174,175] For 
prophylaxis to get so much attention, one of the clinical trials played a 
very important role in the process. Back in 1992, a randomized, placebo-
controlled trial demonstrated the utility and benefits of using fluconazole 
Strategy   Definition  
Prophylaxis Antifungal agents are provided to patients at high risk of infection to 
prevent potential fungal infections  
Empirical 
treatment 
Treatment is initiated on an empirical basis in persistently febrile 
patients with neutropenia, which is without a known source and is not 
responding to adequate antibacterial therapy 
Preemptive 
therapy 
Although similar to empirical treatment to treat a suspected early IFI, 
preemptive therapy is usually based on clinical and/or laboratory 
findings suggesting IFI without microbiology identification 
Targeted 
therapy 
Targeted therapy is only used in patients with proven IFI based on 
pathogen identification and should be modified according to patient’s 
clinical presentation and previous antifungal therapy and prophylaxis 
Synthesis and characterization of caffeic and dihydrocaffeic acid derivatives as antifungal agents 54 
for prophylaxis. In the study, unexplained fever was observed in many of 
the patients in both fluconazole (101 of 179) and placebo (116 of 177) 
arms and empirical AmB therapy was provided to patients with persistent 
fever. [176] By analyzing the causes of fever in patients who received AmB 
therapy, IFIs occurred in 21 of 116 patients in placebo group, but in only 
1 of 101 in fluconazole group (18.1% vs. 1%, P<0.001). [176] In total, 
proven IFIs were present in 28 of 177 patients receiving placebo (15.8%), 
but in only 5 of the 179 patients receiving fluconazole (2.8%, P<0.001). 
[176] The positive results not only placed the foundation of using 
fluconazole as antifungal prophylaxis, but also prompted intensive 
evaluation on fluconazole and other antifungal agents for prophylaxis in 
the following decades.  
        However, whether an antifungal should be recommended and how to 
select the correct population still remain controversial in practical use, 
because it may increase the medical expenses and also cause possible 
exposure to unnecessary drug-related toxicity and induction of drug-
resistant fungal species. [158] Due to all of these concerns, the target groups 
for prophylaxis should be defined strictly. Primary prophylaxis, which 
aims at truly preventing fungal infection in patients with no history of 
IFIs, should be clearly separated from secondary prophylaxis, which 
targets prevention of recurrence of IFIs for patients at high risk. [158] 
Although fluconazole remains the most frequently prescribed agent for 
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prophylaxis, it lacks activity against moulds (e.g. Aspergillus spp.), and 
also many different fungal species have shown drug-resistance (e.g. C. 
krusei) or poor susceptibility (e.g. C. glabrata) towards fluconazole, which 
significantly limits its use. [177] Along with the development of newer 
antifungal agents and formulations with broader spectrum of activity, and 
better pharmacokinetic and safety profiles, there are more and more 
antifungal agents available for prophylaxis, such as L-AmB, posaconazole, 
voriconazole or echinocandins. In order to find better alternatives to 
fluconazole for antifungal prophylaxis, a large number of studies were 
initiated that focused on comparison of different antifungal agents used 
for prophylaxis. [158] The recommendations of antifungal prophylaxis using 
a grading system were included in 2009 IDSA guidelines on the 
management of candidiasis [20] and aspergillosis, [53] which includes 
fluconazole, itraconazole, posaconazole, caspofungin and micafungin for 
different populations.  
 
1.4.2   EAT 
        Although not proven with enough evidence, EAT remains the 
standard of care in patients with granulocytopenia and persistent or 
recurrent fever of unknown causes despite treatment with broad-spectrum 
antibiotics. [172] Two studies, which were conducted in the 1980s, showed 
that a lower incidence of IFIs in antibiotic-treated neutropenic patients 
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with persistent fever was attributed to EAT with AmB. [178,179] In the study 
with a larger sample size, the number of deaths from IFI was much lower 
in patients receiving empirical AmB compared with the control group (0 
vs. 4; P=0.05). [178] In the controlled study published in 1989, initiation of 
AmB after four days if antibiotics seemed ineffective was compared with 
continuation of antibiotics. The result suggested a decrease in 
breakthrough fungal infections during and after therapy and also an 
overall better response (defervescence). [179] Since then, 40-50% of high-
risk neutropenic patients received EAT without requiring any 
microbiological or radiological documentation of IFIs. [180] The rationale 
for the use of EAT is also supported by the evidence from previous 
studies indicating that withholding antifungal treatment until getting a 
conclusive diagnosis frequently leads to disseminated infection with high 
mortality. [177] Due to the lack of pathogen identification, the clinician has 
to select an EAT regimen covering the most likely causative pathogens 
based on local epidemiology and clinical presentations and symptoms. [181] 
A study in clinical practices showed that the choice of EAT regimen is 
also influenced by the previously used antifungal prophylaxis, in which 
case the clinician will want to avoid an antifungal agent from the same 
class as prophylaxis, due to the concern of cross-resistance. [182]  
        In recent years, EAT has been increasingly questioned, because the 
two historical studies supporting this approach are not convincing due to 
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the small sample size and questionable methodology that only compared 
AmB with placebo without showing significant effectiveness in reducing 
IFI incidence or mortality. [178,179] Moreover, when it comes to the entry 
point for initiation of EAT, it is also not well accepted. Although fever in 
neutropenic patients should be given attention and trigger further tests and 
evaluation, the appropriateness of using fever alone as a specific criterion 
for initiation of EAT has been widely debated, since there are many 
origins of fever in neutropenic patients. [173,182,183] In addition, at the time 
the trials were conducted, there were few diagnostic techniques available 
to provide early diagnosis for IFIs. [184] The development in antifungal 
agents and improvements in the treatment and clinical management of 
IFIs are significant over the years, which makes it difficult and untenable 
to draw comparison between the results of historic trials and current 
practices. [184] On the other hand, the cost of antifungals has a significant 
impact on the overall antimicrobial budget. Although the published data 
about antifungal consumption and cost-effectiveness are limited, it can 
still be inferred from the studies that the majority of antifungal budget 
was spent on antifungal prophylaxis and even more on EAT. [185] In a 
seven-year antimicrobial stewardship program conducted by a large 
tertiary hospital, data indicated that the average antifungal cost 
represented 29.5% of the overall antimicrobial expenditure ranging from 
47.7% ($3.7 million) to 18.8% ($1.2 million) before and after the program 
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implementation, which lays the emphasis on management and appropriate 
indications for EAT. [186]  
        Following the two historic studies of EAT, in which there was a 
control group who received no antifungal treatment, all subsequent trials 
have used different classes of antifungal agents as comparators, including 
various doses or formulations of AmB, azoles and also echinocandins to 
identify the most appropriate agent for EAT. [80,172] Nevertheless, all 
clinical trials of EAT performed during the last two decades have neither 
revealed a distinct superior antifungal agent with regard to efficacy, even 
with substantially larger sample sizes, nor indicated expected reduction in 
IFI incidence or IFI related mortality associated with EAT. [172,185] 
Moreover, as IFI symptoms are usually unspecific, EAT brings similar 
risks as antifungal prophylaxis, namely exposure of the patients without 
IFI to unnecessary drug-related toxicity and increased costs and also 
possible induction of antifungal resistance.  
        Although EAT of suspected fungal infections may not be the ideal 
approach to deal with the increasing incidence of IFIs, it has been well-
accepted as a standard therapy, since delayed treatment will clearly lead 
to increased morbidity and mortality. Without better diagnostic methods 
and novel antifungal agents, EAT will remain as a very important 
antifungal therapy, especially for patients at high risk. Overall, EAT 
remains the standard approach for management of presumed IFIs 
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allowing early exposure of fungal pathogens to adequate proper 
treatments and also helps to avoid the high mortality associated with 
various fungal species, limited early diagnostic methods and undetected 
infections. [172]  
 
1.4.3   Preemptive therapy 
        It is known that establishing a definitive diagnosis of IFI is difficult 
and time-consuming, because the symptoms are usually nonspecific and 
may not be present until very late stages of diseases. [72] With improved 
non-invasive diagnostic methods, advanced radiological tests and better 
understanding of the pathogenesis of fungal infections, new approaches 
should be proposed to restrict the administration of antifungal agents to 
patients without any evidence from diagnostic tests. The preemptive 
approach is based on the combination of clinical and laboratory findings 
suggesting early IFIs before the development of clinically overt disease, 
without pathogen identification. The original intentions of proposing 
preemptive approach included avoiding the unnecessary use of antifungal 
agents, as well as drug-related toxicities in patients with non-fungal 
caused fever. [173] Preemptive therapy is a newer and evolving approach 
for the management of IFIs that has been receiving increasing attention, 
but it is still at an exploratory level and does not have standardized 
criteria. [181] Due to the lack of standardization, various diagnostic 
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techniques are adopted in different approaches, mainly focused on high-
incidence infections, namely IA and IC. By using GM screening, BDG 
assay and CT scans, the common goal is to be more selective towards 
patients at risk of IFIs and decreased toxicity, costs and risk of emerging 
resistance. [177,185] However, use of different diagnostic methods, criteria 
used for initiating antifungal treatment and enrolling patients have caused 
tremendous difficulties in comparing the limited existing trials regarding 
preemptive therapy. [187]  
        Amongst all of the techniques adopted in the diagnosis of IFIs, 
radiology, particularly CT, plays a very important role. The typical 
radiological ‘halo’ or ‘air-crescent’ sign of an IA, which can be better 
observed by HRCT, is defined and allowed to support the diagnosis of 
probable or possible fungal infections according to EORTC/MSG criteria, 
even though the sign is not entirely specific for fungal infections. [13,187] 
Moreover, preemptive therapy is also guided by biomarker detection, 
including GM ELISA and BDG assays. Additionally, direct microscopy 
and culture-based tests are suggested on BAL fluid in patients with 
pulmonary infiltrates. [13,72,187] The combination of sequential monitoring 
of GM with HRCT was reported to reduce antifungal use by 78% (from 
35% to 7.7%) when compared with fever-driven EAT in a prospective 
feasibility non-randomized study. This study has also opened up new 
ways forward for similar algorithm incorporating non-culture-based 
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microbiological techniques with the use of HRCT to become well-
accepted by many other clinical trials. [188] However, there is no consensus 
on recommendations for variables in GM assay that can have a great 
impact on the performance, including GM index cutoff level (varying from 
0.5 to 1.0), test interval and required number of positive samples. [13,177,188] 
Generally, a GM assay should be carried out at least twice per week when 
the cutoff for positivity is 0.5 and two consecutive positive samples are 
required, while HRCT of the chest is suggested to be performed at least 
every 7-10 days. [187,188]  
        Although only limited data have been published comparing a 
preemptive with an empirical strategy, an open-label, randomized, 
controlled trial of empirical versus preemptive therapy in high-risk 
patients due to chemotherapy or HSCT has reported similar survival rates 
with both arms. [184] All patients were screened twice weekly by GM 
ELISA with the GM index ≥1.5 adopted as a cutoff level and chest 
radiograph together with CT as further confirmation in the group of 
preemptive therapy. [184] AmB or L-AmB, depending on patient’s renal 
function, was used as antifungal treatment in both groups. It was shown 
that there was no significant difference in overall survival between the 
two strategies (preemptive 95.1% vs. EAT 97.3%). [184] However, the 
incidence of IFI was significantly higher in the preemptive group than 
that in the EAT group (9.1% vs. 2.7%, respectively), so that the use of 
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antifungal agents was much lower in the preemptive arm (1 out of 56 
treated patients, 1.8%) compared with EAT arm (55 out of 92 treated 
patients, 59.8%, P<0.001). [184] Instead of using the combination of chest 
CT and non-culture laboratory findings as diagnostic methods, clinical 
symptoms were adopted in this study as criteria for preemptive therapy. 
Still, the results have shown that preemptive therapy was more selective 
towards patients at-risk, so that antifungal consumption decreased without 
increasing mortality. [184] With all of the uncertainty and questions, more 
research is needed to get preemptive therapy standardized and to compare 
preemptive with EAT strategies. Further studies are also required to 
investigate which diagnostic method, biomarker or clinical finding or 
both, should be dominant to guide preemptive therapy.  
 
1.4.4   Targeted therapy 
        As mentioned earlier, the classification of IFIs is based on the degree 
of diagnostic certainty, including proven, probable and possible IFIs. The 
reason for setting these strict diagnostic criteria of IFIs is to help 
standardize the target groups of patients in the clinical routine and studies. 
Yet, these criteria may not intend to guide therapeutic decisions in 
individual patients due to their limited flexibility and applicability. 
Although an increasing number of new technologies have become 
available as diagnostic methods, the definite diagnosis of IFI still can only 
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be obtained by sterile conditions (e.g. blood-cultures) and/or tissue 
specimens for histological tests, according to the criteria. However, the 
microbiological and histological detection of fungi is often associated 
with many problems, such as being time-consuming and relatively 
insensitive, also being too invasive to conduct, particularly on the deep-
seated infection sites. [13,21,24] The term “targeted therapy”, also known as 
treatment of established IFIs, is used for the treatment of patients with 
proven IFIs based on the pathogen identification achieved via 
microbiological and histopathological examinations. [13,173] Due to the 
known limitations of conventional diagnostic techniques, especially the 
risk coming along with invasive diagnostic procedures, targeted therapy is 
not always achievable or suitable for patients in different conditions. [177] 
Therefore, the first step before providing targeted therapy is elaborate 
evaluation of clinical presentations, risk factors that may lead to the 
emergence of IFI and previous antifungal treatment and prophylaxis. [177]  
        There have been many studies and guidelines with regard to targeted 
therapy in IFIs, especially in IC and IA, which aim at studying not only 
the effectiveness of the strategy itself, but also comparing various 
antifungal agents for different indications. [20,189,190,191,192] With regard to 
targeted therapy in IC, international guidelines recommend several agents 
for primary and second-line treatment for IC depending on the patient’s 
conditions, previous use of antifungal agents and local epidemiology. [185] 
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For non-neutropenic patients, fluconazole or an echinocandin is 
recommended as primary therapy in most international guidelines, and 
AmB is suggested as an alternative in case of intolerance. [20,189] Recently, 
the use of an echinocandin as first-line treatment of IC in non-neutropenic 
patients has become increasingly popular considering the risk of azole-
resistant Candida spp. strains, while more clinical trials are still needed to 
support this recommendation. [185] For neutropenic patients, caspofungin 
or micafungin is preferred as primary antifungal therapy and L-AmB 
remains a second-line treatment. [193] On the other hand, voriconazole is 
considered the agent of choice for first-line therapy in IA and L-AmB 
may be used as an alternative therapy with similar efficacy but higher 
toxicity. [177] Regardless of which drug is selected for targeted therapy, the 
regimen should be adjusted to fit the patient’s situation according to 
clinical presentation, concomitant medication and risk of resistance.  
 
1.4.5   Combination therapy 
        In order to fight against the high mortality and poor prognosis 
associated with IFIs, IA in particular, combination therapy tends to draw 
attention from clinicians as a salvage therapy based on the clinical 
situation. [13] Echinocandins have contributed to combination therapy and 
become even more attractive, since the new class of antifungal agents 
exhibits a distinctive mechanism of action. However, the benefits of 
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combination therapy are still controversial as a result of insufficient 
clinical trials, even though combination therapy is already recommended 
in the IDSA guidelines for second-line (salvage) therapy. [53] The basis of 
using combination therapy are the improvements in outcomes observed 
from a few in vitro and animal studies that indicated synergistic, or at 
least additive, effects when an echinocandin was added in the use of a 
mold-active triazole or AmB. [194,195] In the most recent review, a meta-
analysis was performed to compare mold-active triazoles or L-AmB plus 
an echinocandin to non-echinocandin monotherapy for acute IA. [196] The 
results did confirm that certain themes of combination therapy could lead 
to significantly improved 12-week survival and composite success over 
monotherapy in salvage setting of IA. [196] Nevertheless, routine use of 
combination therapy for initial target IA treatment is not well-supported. 
[196] Both the recent meta-analysis and a previous critical review [197] have 
come to the same conclusion in which the cumulative evidence is not 
strong enough to support combination therapy as a routine primary 
treatment for IA, while some favorable effects were reported as salvage 
therapy. By combining antifungal agents with different modes of action, 
combination therapy may be useful before the IA species is specified. [196] 
Given the heterogeneity of the regimens, patient populations, primary and 
secondary endpoints in the limited number of existing studies, more well-
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designed controlled, randomized, multicenter clinical trials are required to 
allow well-grounded conclusions on the usefulness of this approach. [196,197]  
 
1.5   Rationale of the project 
 
        Since the late 1970s, inhibitors of fungal cell wall biosynthesis have 
gained great attention all over the world as a new direction of drug design 
for the treatment of IFIs because of their distinct mode of action. So far, 
glucan synthesis remains the only component of cell wall synthesis for 
the development of antifungal agents with BDG as the drug target in 
particular. Echinocandin B 5 (Figure 1.6), one of the cyclic lipopeptides 
in this class, was reported in 1974. [142] Later on, efforts in natural product 
screening led to the discovery of the pneumocandin series. In 1987, 
pneumocandin A0 5a was isolated and its structure was then determined. 
Its antifungal activity was shown to be achieved by inhibiting the 
synthesis of the fungal cell wall, via inhibition of BDG synthase. [198] 
Right after the study of pneumocandin A0, pneumocandin B0 5b was 
isolated and characterized as the desmethyl congener. [198] Pneumocandin 
B0 became the key for further development of BDG inhibitors. [141,199] 
Pneumocandins that mainly include pneumocandin A0 5a, pneumocandin 
B0 5b and pneumocandin C0 5c, are derived from fermentation of fungus 
Glarea lozoyensis (originally called Zalerion arboricola). [200,201] The 
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structures of echinocandin B 5 and the three pneumocandins are 
illustrated in Figure 1.8.  
        Nevertheless, the research on pneumocandin A0 and B0 was not 
completed due to a shortage of material and the fact that the 
pneumocandin A0 lead had been lost owing to its poor oral bioavailability, 
water solubility and a lack of broad antifungal spectrum, as well as 
discovery of its semisynthetic analog, cilofungin 5d (Figure 1.8). The 
clinical trial for cilofungin was actually halted in 1988, owing to the 
toxicity of a co-solvent used for oral administration, which led the focus 
of research back to pneumocandin A0 and B0. Later that year, based on 
findings of DNA studies, it was suggested that Pneumocystis was a 
fungus rather than a protozoan (the pathogen in humans is P. jiroveci). [198] 
It is worth noting that the wall of the cyst form of P. jiroveci was reported 
to contain high levels of BDG. With all the information together, the 
program of pneumocandin A0 and B0 was reinvigorated in 1989 with a 
test in an immunosuppressed rat model of P. carinii pneumonia using 
pneumocandin A0. [198] Subsequently, pneumocandin B0 became the lead 
compound in a medicinal chemistry program for further development. [198] 
In order to improve the solubility, stability, antifungal spectrum and 
pharmacokinetic profiles, semisynthetic optimization of pneumocandin B0 
has been explored.  
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        Among the three members in the class of echinocandins described 
earlier, caspofungin (MK-0991) and micafungin (FK-463) are 
pneumocandin B0 analogues and anidulafungin was derived from 
echinocandin B. [198] The semisynthetic nature of echinocandins not only 
demands procedures like fermentation, isolation and purification, but also 
brings additional cost, making echinocandins more expensive than other 
classes of antifungal agents. [202] Another limitation that comes along with 
echinocandins is their poor oral bioavailability, which makes them only 
available for intravenous use. [202] Considering the broad antifungal 
spectrum, outstanding safety properties, potential in combination therapy 
and also the limitations of the current echinocandins, efforts were made to 
design peptidomimetic analogues of echinocandin B that can be fully 
synthesized and are smaller molecules. 
        The target for echinocandins is the protein complex responsible for 
the synthesis of one of the essential fungal cell wall components, BDG 
polysaccharides. [203] The enzyme complex has been extensively studied 
in S. cerevisiae and Fks1p, Fks2p and Rho1p are indicated to be subunits 
of the complex. Among the three fractions, Fks1p is thought to be the 
target and binding site of echinocandins and may also be the catalytic 
center of BDG synthase. [203] Meanwhile, both Fks1p and Fks2p are 
regulated by elements of the calcineurin pathway, and by Rho1p, a GTP-
binding peptide, which also interacts with protein kinase C. [203] Given the 
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possible interaction of echinocandins with the catalytic component of 
BDG synthase to achieve the inhibition of enzymatic activity, it was 
intended to use smaller linear or cyclic peptidomimetic molecules to 
mimic the backbone of echinocandins. [202] However, it turned out that the 
lipophilic side chain and the homotyrosine moiety of echinocandin are 
essential for their antifungal activity. [202,204,205] Even the relative orientation 
of the homotyrosine ring with the lipophilic side chain may have a 
significant impact on the activity of echinocandins as well. [202]  
        By adopting computer-aided drug design, a series of structurally 
related natural and synthetic analogues of homotyrosine were examined 
by Daneshtalab [202] by overlapping with echinocandin B. It was found 
that chlorogenic acid (CGA) 10 with a para-alkoxyphenylamido side-
chain (CGA derivative 11) was the best match and it has the most 
favorable spatial relationship of the essential groups with those of 
echinocandin B. [206] As a natural product, CGA exists widely in many 
vegetables and plants, and is known as an antioxidant. [202,206] Being an 
ester of caffeic acid and quinic acid, CGA can be considered as a 
bioisostere of homotyrosine-hydroxyproline, which is very similar to a 
part of echinocandin B, as shown in Figure 1.9. Hence, with lipophilic 
side chains, CGA derivatives could be potentially useful bioisosteric 
replacements for the particular part of echinocandin B, and could possess 
potential useful antifungal activity. [202,206] 
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        Therefore, a series of CGA derivatives (Scheme 1.1) were 
synthesized and their activities were assessed. Their in vitro BDG 
synthase inhibitory activities were compared with that of aculeacin A 6 
(Figure 1.6), which is also, like echinocandin B, a prototype inhibitor of 
BDG synthase. [206,207] Results expressed as IC50 values represent the 
concentrations that inhibit 50% of the enzyme activity. [207] When CGA 
was modified to form the octyloxyanilido derivative having a long alkyl 
chain to afford CGA derivative 11 (Figure 1.9), its IC50 was 23 µg/ml, 
which is better than that of CGA (>32 µg/ml), but still much higher than 
that of aculeacin A (9 µg/ml). [207] 
        In order to improve the enzymatic inhibitory activity, further 
structural modifications were conducted with the incorporation of 
different amino acids into the structure of CGA. [207] The synthetic routes 
for the preparation of these CGA derivatives 12a-l are shown in Scheme 
1.1, in which the p-octyloxyaniline was modified with the various 
protected amino acids.  
        Among these compounds, CGA derivative 12l showed the best 
activity with an IC50 value of 10 µg/ml, which is very close to that of the 
positive control compound (aculeacin A). [206,207] The specific structure of 
CGA derivative 12l is illustrated in Figure 1.9. It was found that the 
incorporation of ornithine in CGA derivative 12l resulted in greater 
overlap with echinocandin B than the previous molecules studied.    
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 Scheme 1.1. Synthesis of CGA derivatives 12a-l 
                     Reagents and conditions: (i) CMC, HOBt; (ii) acetone-H2O,  
                     0.67 M HCl, rt, 1h; (iii) 90% TFA, rt, 30 min. [206] 
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        The comparison between the overlap of 11 and 5 and that of 12l and 
5 is shown in Figure 1.10. 
 
        
 
 
 
 
 
 
 
        As illustrated in Figure 1.11 (a), CGA derivative 12l can be divided 
into various sections, including the octyloxyaniline grouping with a 
lipophilic side chain, the ornithine, the quinic acid and caffeic acid. 
Although proven to have a good enzymatic inhibitory activity in vitro, 
subsequent findings regarding CGA derivative 12l showed that the ester 
bond could be easily broken in vivo during metabolism and the quinic 
acid derivative part would be released into the blood as shown in Figure 
1.11 (b). [207] 
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        Consequently, it became important to investigate if the quinic acid 
derivative 14b was active. If so, the CGA derivatives could still be 
developed as parent drugs. Subsequently, quinic acid derivatives 14a-e 
were synthesized as shown in Scheme 1.2 and their in vitro activity was 
evaluated. It was found that quinic acid derivative 14b was the most 
active of the quinic acid derivatives, with an IC50 of 27 µg/ml. However, 
it is not as active as CGA derivative 12l (10 µg/ml). [207]  
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        Due to the reactivity of the ester bond in CGA derivative 12l and the 
hydrolytic product, quinic acid derivative 14b, is not as active as CGA 
derivative 12l. It was therefore considered necessary to remove the quinic 
acid section from the CGA derivatives in order to improve their stability 
and activity. In accordance with the above hypothesis, synthesis of the 
derivative 16g of caffeic acid 15 as shown in Figure 1.12 was then 
pursued.  
 
 
 
 
   
 
        Since there is no ester bond in the structure of the targeted caffeic 
acid derivatives, a better stability was expected. [207] Hence, a series of 
caffeic acid derivatives (16a-i) were synthesized as shown in Scheme 1.4, 
and their BDG synthase inhibitory activities and stabilities were assessed. 
It was found that the activity of caffeic acid derivative 16g (11 µg/ml) 
was similar to that of CGA derivative 12l, yet better than that of the 
quinic acid derivative 14b. [207] 
CGA derivative 12l Caffeic acid derivative 16g 
Figure 1.12. Comparison of CGA derivative 12l with caffeic acid 
derivative 16g. 
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        Table 1.2 is a summary of the bioassay results of CGA and its 
derivative 12l, caffeic and quinic acid derivatives. A more recent follow-
up study investigated the metabolism of CGA derivative 12l, quinic acid 
  BDG synthase 
inhibitory activity 
 
 
In vitro antifungal 
activity 
 
Compound IC50* 
(µg/ml) 
MIC** 
(µg/ml) 
IC50  (µM) MIC (µM) 
Caffeic acid 
derivative 16d 
31 16 52 27 
Caffeic acid 
derivative 16g 
11 2 22 4 
Quinic acid 
derivative 14b 
27 8 53 16 
Chlorogenic acid 
derivative 12l 
10 4 15 6 
Chlorogenic acid 
        10 
>32 >64 >90 >181 
Aculeacin A 
         6 
9 0.25 8 0.23 
Table 1.2. BDG synthase inhibitory and antifungal activities 
*IC50: the concentration needed to inhibit a biological or biochemical function by 
half. 
**MIC: the lowest concentration of an antimicrobial that will inhibit the visible 
growth of a microorganism after overnight incubation.  
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derivative 14b, and caffeic acid derivative 16g conjugated with an H2N- 
Orn-4-octyloxyaniline in rats after oral and intravenous administration 
using ultra-performance liquid chromatography–atmospheric-pressure-
chemical ionization–tandem mass spectrometry (UPLC-APCI-MS/MS) 
with negative ion polarity mode. [208] The metabolic pathway in rats for 
chlorogenic, quinic and caffeic acid derivatives inferred from molecular 
fragments detected by MS is believed to be as shown in Scheme 1.4. The 
results in that study, not only revealed the metabolic pathway of those 
compounds in a rat model, but also pointed out a critical problem. After 
CGA derivative 12l was administered orally or intravenously to rats, 
caffeic acid was detected in the plasma samples, which verified that the 
ester bond linked to caffeic acid in the CGA derivative 12l did break to 
release quinic acid derivative and caffeic acid into the systemic 
circulation. [208] In the case of caffeic acid derivative 16g, the parent 
compound was detected in the plasma sample after intravenous 
administration. However, from 15min to 4h following oral administration, 
both the substrate (the molecule after a loss of proton, m/z 496 [M-H]-) of 
caffeic acid derivative 16g (Mw=497.29) and caffeic acid were detected in 
the plasma samples. Therefore, it was found that the caffeic acid fraction 
in the caffeic acid derivative also had a tendency to dissociate. [208] 
Specifically, no caffeic acid or the substrate was found in the plasma 
samples collected at 30 min, 1 h and 1.5 h after oral administration of 
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caffeic acid derivative 16g. However, 2 h after oral dose, both caffeic and 
isomerized caffeic acid derivative 16g were detected in plasma sample, 
which indicated that caffeic acid derivative 16g could take part in the 
systemic circulation while only for a limited time and amount. [208] 
Comparing the metabolic profiles of CGA derivative 12l with caffeic acid 
derivative 16g, the results are consistent with the well-accepted theory that 
amides are more stable than esters, though still less than ideal. [208]  
        As the metabolites of caffeic acid derivative 16g were found to be 
inactive in vivo, it was necessary to re-examine the structure of caffeic 
acid derivative 16g seeking ideas to improve the stability. In the structure 
of caffeic acid derivative 16g, there is a double bond located next to the 
amide bond, which constitutes a conjugation system that might result in 
increasing reactivity of the amide bond. Due to keto-enol tautomerization, 
the amide bonds are endowed with partial-double bond character, which 
is stabilizing. With tautomerization, the nitrogen is enabled to donate its 
lone pair of electrons to the carbonyl carbon and push electrons from the 
carbonyl double bond towards the oxygen, forming the oxygen anion. By 
delocalizing the electrons over several atoms, the double bond resonance 
form of the peptide bond helps to increase stability and decrease rotation 
about that bond as shown in Figure 1.13. 
       On the other hand, either resonance form of the amide bond in caffeic 
acid derivative 16g (-C=N or -C=O double bond) could form a conjugated 
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system with the double bond beside it, which has a region of overlapping 
p-orbitals, bridging the interjacent single bond that allows electrons 
delocalized across all of the adjacent aligned p-orbitals. Although a 
conjugated system originally may lower the overall energy of the 
molecule and increase stability, conjugation with a resonance form of 
amide bond could actually weaken the resonance that was playing the 
most important role to stabilize the amide bond resulting in increased 
amide reactivity. Therefore, further structural modification on caffeic acid 
derivative 16g to remove the double bond next to the amide bond should 
be conducted to prepare a more stable molecule. As a result, a new 
molecule, a dihydrocaffeic acid (i.e. 3,4-dihydroxyhydrocinnamic acid) 
derivative, became one of the target compounds in this project, aiming at 
better stability. Its synthesis is described in section 3.2.4. 
  
Figure 1.13. Resonance structures of amide bond (with and without 
double bond) 
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Scheme 1.4. The deduced metabolic scheme for CGA derivative 12l, 
quinic acid derivative 14b, and caffeic acid derivative 16g, in rats. [208] 
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Chapter 2. Objectives 
 
The objectives of this research project conducted by this author were as 
follows: 
1. To repeat and refine previously synthesized caffeic acid derivative 16g. 
2. To synthesize and characterize novel caffeic acid derivatives of      
    improved stability. 
3. To evaluate the novel caffeic acid derivative synthesized. 
 
        The work described in this thesis is a part of a larger overall project 
and was based on previous findings, which has been conducted in our 
research group. The main compounds of this project were caffeic acid 
derivative 16g and dihydrocaffeic acid derivative 20c as shown in Figure 
2.1.  
        Although the synthesis and metabolism of caffeic acid derivative 
16g had been previously reported, it was still necessary to repeat and 
optimize some of the synthetic details and to design better compounds. 
The aims of optimization were not only to improve the yield and purity of 
the product, but also to achieve higher efficiency and simplification.  
        Caffeic acid derivative 16g was synthesized according to the method 
that was previously reported, [207] but with efforts made to improve it. 
After several attempts of using different reaction conditions and methods 
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to substitute the original operations, some techniques were verified to be 
effective in improving yield, purity and efficiency. Including inert gas 
(argon, nitrogen) protection to reactions, adopting longer reaction times 
and performing purification steps for final products were included in the 
optimizations undertaken.  
   
 
        
 
 
 
 
        In order to characterize both caffeic acid derivative 16g and 
dihydrocaffeic acid derivative 20c, infrared (IR) vibrational spectroscopy, 
liquid chromatography-mass spectrometry (LC-MS) and nuclear magnetic 
resonance (NMR) spectroscopy were used to identify molecules by 
analysis of their constituent bonds, functional groups, determining 
elemental composition and providing structural and dynamic information 
to elucidate the chemical structures of these products.   
O
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N
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Caffeic acid derivative 16g Dihydrocaffeic acid derivative 20c 
Figure 2.1. Structures of caffeic acid derivative 16g and dihydrocaffeic 
acid derivative 20c 
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Chapter 3. Materials and Methods 
 
3.1   Materials 
 
        The glassware used for all of the experiments were dried overnight 
in an oven (100°C). Most of the reactions were carried out under argon 
atmosphere unless aqueous solutions were involved. The low temperature 
(below 0°C) required in some of the reactions was obtained by using an 
ice-salt bath, where sodium chloride (NaCl) or calcium chloride (CaCl2) 
was used. A thermometer was used to check the inner temperature of the 
reaction mixture, making sure that it reached the desired temperature. The 
reaction flask was usually stirred and heated on an adjustable dual-
purpose magnetic stirrer-hot plate.  
        Extractions of products were conducted with organic solvents 
followed by a drying process using anhydrous sodium sulfate (Na2SO4), 
filtering through a glass funnel with a filter paper (qualitative filter paper 
for technical use, medium speed) and concentrated to dryness under 
reduced pressure with a rotary evaporator.  
        Thin layer chromatography (TLC) was performed using pre-coated 
aluminium sheets with 0.20 mm silica gel 60 with fluorescent indicator 
UV254 (Fisher Chemical Company) to monitor the reaction progress, 
identify compounds present in a given mixture, and determine the purity 
of a substance. Caffeic and dihydrocaffeic derivatives with protecting 
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groups on the functional groups were examined under ultraviolet (UV) 
light, and unprotected derivatives were located by exposure to iodine 
vapor. Silica gel (60-200µm, 70-230 mesh) was used for column 
chromatography for isolation and purification. Due to the relatively high 
polarity of the compounds in this project, reversed-phase chromatography 
was necessary, where an octadecyl-functionalized silica gel (ODS) (200-
400 mesh, Sigma-Aldrich, Inc.) was used.  
 
Reagents:  
        Caffeic acid, 4-octyloxyaniline, 4-dimethylamino pyridine (DMAP), 
N,N-dimethylformamide (DMF) and all other reagents used were 
purchased from Sigma-Aldrich, Inc. and Tokyo Chemical Industry (TCI) 
Co., Ltd. The reagents that were involved in the experiments were either 
of American Chemical Society (ACS) reagents grade, high-performance 
liquid chromatography (HPLC) grade or anhydrous (99.8%). All reagents 
were used without further purification unless otherwise specified.  
 
Solvents: 
        All solvents used in this research (except LC-MS and NMR analyses) 
were purchased from Caledon Laboratories Ltd., which were all reagent 
grade and tested by gas chromatography (GC) to be at least 99.5% in 
purity to meet the ACS specifications. All solvents used for LC-MS 
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analyses were of HPLC grade. The solvents used for NMR analyses 
included chloroform-d (CDCl3) and methanol-d4 (CD3OD), which were 
all deuterated solvents with the isotopic purity of 99.96 atom% D 
containing 0.03% (v/v) tetramethylsilane (TMS) as internal standard for 
calibrating chemical shifts.  
 
NMR Spectroscopy: 
        Proton nuclear magnetic resonance spectra (1H NMR) were 
determined at 300 MHz on a Bruker AVANCE III 300 instrument and 
CDCl3 and/or CD3OD were used as solvent to dissolve the sample. 1H 
shifts were referenced to residual CDCl3 (δ=7.26). The signal splitting 
patterns were represented as follows: “s” for singlet, “d” for doublet, “t” 
for triplet, “q” for quartet and “m” for multiplet.  
 
IR Spectroscopy: 
        The IR spectra of solid substances were conducted on a Bruker 
Tensor 27 FT-IR spectrometer, which allows for direct analysis of solids, 
liquids and powders. The results were measured in transmittance mode 
that is suitable even for very thin specimens. The IR spectra are very 
useful in identification of functional groups of molecules, which can be 
particularly used in verification of whether the deprotection step was 
successful or not.  
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LC-MS: 
        The mass spectra were obtained using a LC/MSD (Trap) Agilent 
1100 series SL with HPLC (1100 series) interfaced to an ion trap mass 
analyzer (model G2445D SL). Specifically, the HPLC is equipped with a 
vacuum degasser, quaternary pump, thermostatted auto sampler and UV-
VIS diode array detector (wavelength range 190-900 nm), so that the data 
of UV absorption could be collected simultaneously. In addition, the mass 
spectrometry has two methods of ionization, electrospray (ESI) and 
atmospheric pressure chemical ionization (APCI), which can produce 
both monocharged and multiply-charged ions owing to the distinct 
mechanisms of ionization. Besides the MS mode, the LC/MSD (Trap) 
also has scan and multiple ion monitoring modes. Any one of the modes 
listed can be run in positive, negative or alternating polarity for ion 
detection. 
3.2   Chemical synthesis 
 
3.2.1   Synthesis of 3,4-diacetoxycinnamoyl chloride 15a 
        The acylation of caffeic acid 15 with acetic anhydride (≥99.5%) 
(Ac2O) in pyridine to form 15b, followed by chlorination with two 
equivalents of oxalyl chloride provided 3,4-diacetoxycinnamoyl chloride 
15a as shown in Scheme 3.1. 
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        Following acetylation, extraction using ethyl acetate was performed 
to separate 15b from the aqueous reaction solution, followed by drying 
over anhydrous Na2SO4, filtering and evaporating to dryness on a rotary 
evaporator. The subsequent reaction involved using the moisture sensitive 
oxalyl chloride ((COCl)2) to form 15a, which was used as shown in 
Scheme 1.3.  
3.2.2   Synthesis of H2N-Orn(Boc)-octyloxyaniline 13a 
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Scheme 3.1. Synthesis of 3,4-diacetoxycinnamoyl chloride 15a. 
Figure 3.1. Structure of 2-((((9H-fluoren-9-yl)methoxy)carboyl)amino)-
5((tert-butoxycarbonyl)amino)pentanoic acid (Fmoc-Orn(Boc)-OH) 17. 
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        The Fmoc-protected amino acid ornithine, Fmoc-Orn(Boc)-OH 17 
(Figure 3.1), was condensed with 4-octyloxyaniline 18 in the presence of 
1-cyclohexyl-3-(2-morpholinoethyl) carbo-diimidemetho-p-toluenesul-
fonate (CMC, Figure 3.2) and hydroxybenzotriazole (HOBt) to obtain the 
amino acid derivative 13d with the O-octyl lipophilic chain (Scheme 3.2). 
[206] The fluorenylmethyloxycarbonyl (Fmoc) and tert-butyloxycarbonyl 
(Boc) groups were used as the protecting groups for the two amino groups 
in ornithine (Figure 3.1). CMC, used in this reaction, is a water-soluble 
condensing reagent for peptide synthesis.  
 
 
 
Scheme 3.2. Synthesis of H2N-Orn(Boc)-octyloxyaniline 13a 
Figure 3.2. Structure of CMC 
Reagents: (a) CMC, HOBt; (b) 10% Et2NH, DMF 
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      Before conducting the subsequent reactions, the product 13d was 
purified from the reaction mixture by using regular silica gel column 
chromatography and reversed-phase column chromatography with ODS 
gel according to the previous findings. [206] Alternatively, another method 
can be used to replace the ODS column chromatography by adopting a 
series of washing steps to eliminate polar impurities. The compound was 
then treated with diethylamine (Et2NH) for removal of the Fmoc group, to 
produce the product 13a with the free secondary amino group.  
 
3.2.3   Synthesis of caffeic acid derivative 16g 
 
  
 
 
 
 
 
 
        Scheme 3.3. Synthesis of caffeic acid derivative 16g. 
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        With the two compounds (3,4-diacetoxycinnamoyl chloride 15a and 
H2N-Orn(Boc)-octyloxyaniline 13a) generated above, caffeic acid 
derivative 16g with protecting groups was obtained by coupling the two 
reactants with DMAP in pyridine (Scheme 3.3). [207] The addition of 
pyridine not only provides basic conditions for the coupling reaction to 
occur and for the removal of generated HCl, but also helps to activate the 
carboxylic acid halides. The product of the coupling procedure was 
separated from the reaction mixture through extraction with 
dichloromethane (CH2Cl2) followed by purification using regular silica 
gel column chromatography before conducting the deprotection steps.  
        The deacetylation of 16a to form 16d was achieved with aqueous 
potassium hydroxide (KOH). The removal of the Boc group from 16d 
was accomplished with trifluoroacetic acid (TFA) in CH2Cl2 to afford the 
product 16g as the TFA salt. The mechanism of Boc deprotection with 
TFA is demonstrated in Scheme 3.4.  
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Scheme 3.4. Mechanism of Boc deprotection 
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        In order to obtain caffeic acid derivative 16g with a free primary 
amino group, the TFA salt prepared above was extracted using ethyl 
acetate following treatment with aqueous saturated sodium bicarbonate 
(NaHCO3).  
 
3.2.4   Synthesis of 3,4-diacetoxydihydro-caffeoyl chloride 19b 
 
        Instead of caffeic acid, 3,4-dihydroxyhydrocinnamic acid 19 is used 
as the starting material in this reaction. It was dissolved in pyridine, and 
then treated with Ac2O at 0°C in the presence of DMAP to afford the 3,4-
diacetoxydihydro-caffeoyl acid 19a. Oxalyl chloride was then added to 
the solution of the product of acetylation in toluene with DMF to form 
product 19b.  
 
3.2.5   Synthesis of dihydrocaffeic acid derivative 20c 
       To prepare the dihydrocaffeic acid derivative 20c, 3,4-
diacetoxydihydro-caffeoyl chloride 19b was allowed to react with 
previously synthesized H2N-Orn(Boc)-octyloxyaniline 13a in the presence 
of pyridine and DMAP to afford the dihydrocaffeic acid derivative 20a 
Scheme 3.5. Synthesis of 3,4-diacetoxydihydro-caffeoyl chloride 19b 
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with protecting groups, as shown in Scheme 3.6. The aqueous phase 
was separated from the reaction mixture and re-extracted with CH2Cl2.  
 
 
 
 
 
 
 
             
 
 
       The combined organic extracts were purified by regular silica gel 
column chromatography to yield the desired product 20c. The polarity of 
this dihydrocaffeic acid derivative 20c is different to that of caffeic acid 
derivative 16g. Consequently, the difference in polarity resulted in 
changes in the elution solvent system needed for both TLC and column 
chromatography. With the same deprotection procedures as was applied 
for caffeic acid derivative 16g, aqueous KOH and TFA were sequentially 
used to remove the acetyl and Boc groups, respectively. The TFA salt was 
subsequently neutralized by aqueous saturated NaHCO3 to obtain 
dihydrocaffeic acid derivative 20c with a free primary amino group.   
Scheme 3.6. Synthesis of dihydrocaffeic acid derivative 20c 
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Chapter 4. Results and Discussion 
 
4.1   Synthesis of 3,4-diacetoxycinnamoyl chloride 15a  
 
         The attempts to reproduce procedures for acetylation went smoothly 
without any complications, regardless of the scale of the synthesis (from 
0.2 to 5g). The chemical yield of the first several attempts was around 
80%, likely due to inadequate control of temperature and rate of addition. 
Subsequently, the reaction was maintained at -5°C using an ice-salt bath 
and checking the temperature inside the reaction mixture during the 
dropwise addition of the acetic anhydride to the mixture, while being 
mixed with a magnetic stirrer. Owing to these measures, the isolated yield 
of 15b was increased to 90-96%.  
        In order to achieve better chlorination to form 15a, it is important to 
ensure the dryness of the acetylated product, since oxalyl chloride itself 
can react with water giving off hydrogen chloride (HCl), carbon dioxide 
(CO2) and carbon monoxide (CO). As a result, the acetylated product was 
triturated with hexane and filtered from the mixture to afford 3,4-
diacetoxycinnamoyl acid 15b as a colorless powder, and was used 
immediately for the next reaction without further purification.  
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        For the chlorination step to form 15a, oxalyl chloride was used 
together with a catalytic amount of DMF. The mechanism of this reaction 
is illustrated in Scheme 4.1.  
  
  
 
 
        As above, by-products from this reaction are gaseous (CO, CO2), 
which simplifies the purification of the product. Meanwhile, attention 
should be paid to keep the reaction from getting violent due to the 
generation of by-products. Thus, oxalyl chloride needs to be added 
dropwise at a low temperature (-5°C, ice-salt bath with NaCl or CaCl2) to 
produce 3,4-diacetoxycinnamoyl chloride 15a as a pale yellow powder. 
Toluene was used as a solvent in this reaction. In order to remove the 
solvent thoroughly (boiling point (Bp) being 111°C), it was necessary to 
triturate the product with hexane. The yield of 15a was found to be 85%.  
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Scheme 4.1. Mechanism of acyl chloride formation with oxalyl chloride. 
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4.2   Synthesis of H2N-Orn(Boc)-octyloxyaniline 13a 
 
        The synthesis of 13a was initially conducted according to previous 
findings. [206] Before the removal of the Fmoc group from 13d to form 
13a, purification of 13d was required. For the initial attempts, both 
regular silica gel column chromatography and reversed-phase column 
chromatography were used to separate polar and nonpolar impurities from 
13d, based on the procedures described in the literature. [206] The 
advantage of this technique is that a dependable purity of the product can 
be achieved via the use of both regular and reversed-phase 
chromatography. At the end of the purification, a large amount of 
colorless crystalline precipitate of product appeared in the collected 
component from the column chromatography. However, despite the good 
separation obtained with relatively polar impurities, the reversed-phase 
chromatography using ODS gel was associated with problems, such as 
slow elution and relatively low yields. The high mesh value (200-400) of 
ODS may have caused the separation to be so slow that it usually took a 
few days to collect all of the components. The yield of Fmoc-Orn(Boc)-
octyloxyaniline 13d was found to be 53% (after the use of both regular 
and reversed-phase chromatography).  
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        Being aware of the possibility of improvements to the synthetic 
procedure used, several techniques were tested to remove the polar 
impurities in this reaction. Eventually, one of the methods was verified to 
be effective by providing satisfactory separation results in a shorter period 
of time. In this method, the reversed-phase chromatography was 
substituted with two washing procedures “II” as shown in Scheme 4.2.  
        Due to the difference between the product and impurities in their 
reactivity with NaHCO3 and their solubility in aqueous solution, the 
washing procedures were able to separate polar impurities from the 
Scheme 4.2. Preparation of Fmoc-Orn(Boc)-octyloxyaniline 13d with the 
previously reported method and newly developed technique. 
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product. In addition, the process only took less than an hour, which makes 
it much more time-saving than the ODS column chromatography. After 
the optimization, the yield of Fmoc-Orn(Boc)-octyloxyaniline 13d was 
increased to 76% (after purification).  
       Generally, the Fmoc group is susceptible to removal using weak 
bases, such as piperidine or piperazine. The removal also occurs to be 
more rapid in a relatively polar medium like DMF, compared to a 
relatively nonpolar one, such as CH2Cl2. The subsequent development of 
the procedures for the cleavage of Fmoc group has led to milder 
alternatives, by replacing piperidine with the use of Et2NH in DMF. 
Although the polarity of DMF is helpful for deprotection of the Fmoc 
group, its high Bp (153°C) was an obstacle to obtain a dry product. As a 
result, DMF, together with the cleavage reagent, were washed out very 
carefully after Fmoc removal using water to afford the product as a pale 
yellow solid.  The yield for the deprotection step to form product 13a was 
found to be 87%.  
 
4.3   Synthesis of caffeic acid derivative 16g 
 
        Based upon the procedures described in the literature, [207] a few 
details have been optimized to carry out the coupling reaction in this 
study. The reaction of 3,4-diacetoxycinnamoyl chloride 15a with H2N-
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Orn(Boc)-octyloxyaniline 13a, in the presence of DMAP and pyridine in 
CH2Cl2 was conducted under Argon atmosphere.  
        After the complete consumption of H2N-Orn(Boc)-octyloxyaniline 
13a as monitored by TLC, the reaction mixture was acidified and 
subjected to extraction with CH2Cl2. The concentrated residue, which was 
a yellow oil, was then purified by silica gel column chromatography. By 
using gradient elution (hexane-ethyl acetate), the eluent was collected in a 
series of fractions, so that different compounds can be separated 
effectively. Along with the increase in the proportions of ethyl acetate to 
hexane, colorless precipitates started to appear in some of the fractions. 
TLC was used to identify the compounds that were collected in the 
different fractions. It turned out that all of the fractions with precipitation 
contained the same compound, namely the desired product 16a, the Boc-
acetyl caffeic acid derivative 16g. The yield of product 16a obtained was 
determined to be 93%.  
        To remove the acetyl protecting groups on the phenolic hydroxy 
groups, aqueous KOH was used and the mechanism for this reaction is 
shown in Scheme 4.3.  
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Scheme 4.3. Mechanism for the base-catalyzed hydrolysis of acetoxy group. 
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        As a protecting group, the acetyl group is stable to acid and mild 
base, but is not compatible with strong nucleophiles. In this study, 
compound 16a was treated with aqueous KOH solution in a mixture of 
methanol and tetrahydrofuran (THF) to remove the protecting groups, 
followed by acidification to form 16d, the mono-Boc protected compound.   
        In the initial attempts, the reaction mixture was stirred at room 
temperature for one hour followed by acidification with aqueous HCl. 
However, the reaction time was found to be too short for the deprotection 
process to complete. Consequently, after several experiments, the reaction 
time was extended, so that the reaction mixture was stirred overnight, to 
afford the complete removal of acetyl groups. The results were verified 
by IR and LC-MS. The yield of product 16d was 70%.  
        When it comes to the removal of the Boc group, it could be 
accomplished by using neat TFA as described in the literature. [207] 
However, it was found to be difficult, even with sodium hydroxide, to 
neutralize the excess of TFA to obtain product 16g with free amino group. 
The removal of the Boc group with neat TFA was compared with using 
55% TFA in CH2Cl2, and was found to obtain a better purity of product. 
[209] Therefore, the procedures for removal of the Boc group in compound 
16d were modified to allow the product to be dissolved in a minimum 
amount of CH2Cl2, followed by addition of TFA. The excess of TFA was 
then neutralized with aqueous saturated NaHCO3 solution. After 
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extraction from the aqueous solution, and the organic solution was 
concentrated to dryness, the yield of caffeic acid derivative 16g was 
found to be 89%. Due to the high polarity of the product, it could be 
completely dissolved in a mixture of CDCl3 and CD3OD, or CD3OD 
alone, for NMR spectroscopy.  
 
4.4   Synthesis of 3,4-diacetoxydihydro-caffeoyl chloride 19b 
 
        By using a different starting material, 3,4-dihydroxyhydrocinnamic 
acid 19, instead of caffeic acid, a novel compound without a double bond 
beside the carbonyl group was able to be obtained. The difference in 
structure also resulted in a change in the polarity of the molecule, which 
further led to changes in some of the experimental phenomena.  
        For the acetylation of 3,4-dihydroxyhydrocinnamic acid 19, acetic 
anhydride was added into the reaction mixture at 0°C that was achieved 
with the use of an ice-salt bath (NaCl) for cooling, and the monitoring 
inner temperature of the reaction mixture was conducted with a 
thermometer. After extraction of the reaction mixture with ethyl acetate 
and THF, the organic solvent was removed by a rotary evaporator, to 
produce 3,4-diacetoxydihydro-caffeoyl acid 19a. The isolated product 
19a was a pale yellow solid. Its yield after drying in a vacuum oven was 
determined to be 95%.  
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        To prepare the corresponding di-O-acetylated dihydrocaffeoyl 
chloride, compound 19a was suspended in toluene with a few drops of 
DMF. Oxalyl chloride was added dropwise into the reaction mixture. 
Owing to the generation of gaseous by-products, this reaction should not 
be performed in a closed system and the temperature should be carefully 
kept constant at -5°C. The resulting solution was clear and pale yellow 
when all the materials dissolved and reacted as monitored by TLC. After 
being concentrated under reduced pressure, a colorless crystalline 
precipitate appeared in the flask. After drying overnight in the vacuum 
oven, the yield of product 19b was found to be 83%.  
 
4.5   Synthesis of dihydrocaffeic acid derivative 20c  
 
        The preparation of Boc-acetyl dihydrocaffeic acid derivative 20a 
was carried out by allowing di-O-acetylated dihydrocaffeoyl chloride 19b 
generated previously to react with H2N-Orn(Boc)-octyloxyaniline 13a in 
CH2Cl2 with DMAP in pyridine under argon atmosphere. After stirring 
overnight at ambient temperature, aqueous HCl was added into the 
mixture to remove the remaining reactants (pyridine, DMAP). The 
acidification turned the mixture cloudy, due to the poor solubility of the 
product in water. After extraction of the reaction mixture with CH2Cl2 
and drying the extract in the usual way with anhydrous Na2SO4 and 
filtering, the solution turned clear. Then the clear yellow solution was 
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subjected to rotary evaporation to remove the solvent and afford the 
residue as light brown oily and viscous crude product.  
        This residue was dissolved with a minimum amount of CH2Cl2 and 
was purified by a regular silica gel chromatography using gradient elution 
(from hexanes to hexanes-ethyl acetate) to afford Boc-acetyl 
dihydrocaffeic acid derivative 20a as a pale brown viscous solid. The 
yield of compound 20a was determined to be 57%, after purification. This 
yield was not very impressive, which could be due to inadequate reaction 
time of the coupling step and/or unsatisfactory separation results from the 
silica column chromatography.  
        For the removal of the acetyl groups in the compound 20a, several 
attempts were made to determine the most favorable reaction time for the 
deprotection process. With the compound 20a dissolved in a mixture of 
methanol and THF, aqueous KOH solution was still used to restore the 
hydroxy groups. According to the literature procedure, [207] the reaction 
mixture was stirred for only one hour at room temperature, which was 
found to be too short in the present work.  
        Therefore, in the initial attempt, the reaction mixture of Boc-acetyl 
dihydrocaffeic acid derivative 20a with the base was stirred for two hours 
at room temperature, followed by acidification with aqueous HCl and 
extraction with chloroform. However, the resulting yield of 20b was only 
34%, indicating insufficient time to complete the deprotection. 
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Consequently, the reaction time was extended to three hours, but the yield 
was still not good enough as 57%. Eventually, after the addition of 
aqueous KOH, the mixture was stirred for overnight to ensure adequate 
time for deprotection. The resulting yield of 20b was found to be 
improved to 74%. During the experimental development, it was critical to 
have the correct analytic method to determine the completion of 
deprotection process. In this case, IR spectroscopy was the most efficient 
technique to verify the removal of the acetyl groups, which was indicated 
by the reappearance of an absorption peak of hydroxy groups at ~3330 
cm-1 (broad, s) in IR spectrum (see A-16 and A-20).  
        The dihydrocaffeic acid derivative with Boc group 20b was then 
dissolved in CH2Cl2 and treated with TFA for 1 hour to remove the Boc 
group. Due to the exothermic nature of this reaction, an ice bath should be 
applied during the addition of TFA to control the temperature. In order to 
reduce the consumption of the aqueous NaHCO3 solution to neutralize the 
excessive TFA, the reaction mixture was directly subjected to rotary 
evaporation to remove some of the TFA (Bp: 72.4°C). By adding aqueous 
saturated NaHCO3 solution, the pH of the mixture was changed to 8 as 
measured with pH test strips.  
        Owing to the high polarity of the resulting compound, ethyl acetate 
was used to extract the product from the aqueous phase. After 
concentration of the solvent to dryness, the yield of dihydrocaffeic acid 
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derivative 20c was found to be 93%. For the compound’s characterization, 
CD3OD and methanol were used respectively to dissolve the product for 
NMR and LC-MS tests.  
        While the current work has indicated the synthesis of caffeic acid 
and dihydrocaffeic acid derivatives and their potential as antifungal 
agents, there are many directions for further development of this work. 
Further chemical modifications of caffeic acid and dihydrocaffeic acid 
derivatives may be carried out to achieve better activity and stability. 
More importantly, proper stability tests should be conducted to determine 
if the dihydrocaffeic acid derivative has better stability than caffeic acid 
derivatives. For biological tests, the evaluation of the products should be 
conducted with both the BDG synthase inhibition assay (with fungal 
membrane enzyme) and antifungal assay (in vitro cell-based).  
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Chapter 5. Experimental Procedures and Characterization 
 
5.1   Synthesis of 3,4-diacetoxycinnamoyl chloride 15a  
 
 
 
        To a solution of caffeic acid 15 (900 mg≅5.00 mmol) and DMAP 
(15.8 mg≅0.125 mmol) in pyridine (2.5 mL) was added acetic anhydride 
(1.2 mL≅13 mmol) at 0 °C. The reaction mixture was stirred at room 
temperature under argon atmosphere overnight. The resultant mixture 
(clear, almost colorless) was then poured onto crushed ice (turned cloudy 
right away). The aqueous phase was acidified with aqueous 2.0 M HCl to 
change the pH to about 2 (even more cloudy). The mixture was extracted 
with ethyl acetate/THF (3:1; 3 × 30 mL) and organic parts were collected 
(clear, colorless). The combined extracts were dried over anhydrous 
Na2SO4 and filtered. The solution was then subjected to evaporation on a 
rotary evaporator (Bp: 50-60 °C) and the residue was triturated with small 
amount of hexane to afford 3,4-diacetoxycinnamic acid 15b (1.28 g ≅4.84 mmol; 96%) as a colorless powder. This product was used directly 
for the next reaction without further purification.  
 
OAc
OAc
Cl
O
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        The di-O-acetylated caffeic acid 15b was suspended in toluene (25 
mL) with 3 drops of DMF (cloudy, milky white). Being kept in an ice-salt 
bath (NaCl and/or CaCl2), oxalyl chloride (1.0 mL≅12 mmol) was added 
dropwise at -5 °C to the mixture. After stirring for 3 h at room 
temperature, all materials were dissolved resulting in a clear and pale 
yellow solution. Solvent and unreacted oxalyl chloride were remove with 
rotary evaporator under reduced pressure (Bp: 70-75 °C). The residual 
yellowish product was triturated with hexane containing a few drops of 
ethyl acetate to yield 3,4-diacetoxycinnamoyl chloride 15a as a pale 
yellow powder (1.16 g≅4.10 mmol; 85%). 1H NMR (CDCl3) data (see A-
2 for spectrum): δ = 7.72 (d, J = 15.8 Hz, 1H), 7.45 (d, J = 2.1 Hz, 1H), 
7.43 (d, J = 2.1 Hz, 1H), 7.25 (d, J = 8.2 Hz, 1H), 6.43 (d, J = 16.0 Hz, 
1H), 2.32 (s, 3H), 2.31 (s, 3H). APCI-MS (positive) m/z (see A-1): 284 
(M+H), 282, 247, 205, 163.  
 
5.2   Synthesis of H2N-Orn(Boc)-octyloxyaniline 13a  
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O
O NH2
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        A mixture of Fmoc-Orn(Boc)-OH 17 (1.82 g≅4.00 mmol), 4-
octyloxyaniline (0.890 g≅4.00 mmol), HOBt (0.820 g≅6.00 mmol) and 
CMC (2.54 g≅6.00 mmol) in 30.0 mL DMF was stirred at room 
temperature overnight.  
Previous method:  
        The resultant mixture was directly chromatographed on a silica gel 
column. After running the column with hexanes for several times to 
remove nonpolar impurities (checked by TLC), the column was eluted 
with chloroform to collect all components remaining. The chloroform 
eluted part was then re-chromatographed on a ODS column using 
gradient elution (from water neat to water : methanol = 1:9) to afford Fmoc-
Orn(Boc)-octyloxyaniline 13d as a colorless powder (1.42 g≅2.15 mmol, 
53.8%).  
 
Optimized method: 
        After stirring overnight, the mixture was diluted with 160 mL ethyl 
acetate, then washed by water (4 × 40 mL), saturated NaHCO3 solution (4 
× 40 mL), and dried with anhydrous Na2SO4. After removal of the solvent 
under reduced pressure, the residue was purified by silica gel column 
chromatography (continuous gradient from hexanes : ethyl acetate = 9:1 
to ethyl acetate) to yield Fmoc-Orn(Boc)-octyloxyaniline 13d (2.01 g ≅3.05 mmol, 76.3%).  
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        The resulting product 13d (2.01 g≅3.05 mmol) was then treated with 
3.0 mL Et2NH in 15 mL DMF at ambient temperature for 2 hours. The 
resultant mixture was diluted with 80 mL ethyl acetate, then washed with 
water (6 × 20 mL) and dried over anhydrous Na2SO4. After concentration 
of solvent to dryness, the H2N-Orn(Boc)-octyloxyaniline 13a (1.16 g ≅2.66 mmol, 87%) was used for further reaction without purification.  
 
5.3   Synthesis of caffeic acid derivative 16g  
 
 
 
 
 
        To a solution of H2N-Orn(Boc)-octyloxyaniline 13a (0.770 g≅1.75 
mmol) and DMAP (0.0800 g≅0.650 mmol) in CH2Cl2 (12 mL) and 
pyridine (4.5 mL), 3,4-diacetoxycinnamoyl chloride 15a (1.13 g≅4.00 
mmol) was added at room temperature. The reaction mixture (pale yellow 
solution) was stirred overnight under argon atmosphere. After checking 
the reaction progress with TLC, the pH value of the reaction mixture was 
changed to 3 by adding aqueous 1.0 M HCl. The aqueous phase was then 
extracted with more CH2Cl2 (3-4 times). The combined organic extracts 
were dried with anhydrous Na2SO4, filtered, and concentrated on a rotary 
O
HN
O
HN
NH2
O
OH
OH
16g 
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evaporator (Bp: 35-40°C). The residue was chromatographed on a silica 
gel column using gradient elution (10-90% ethyl acetate in hexanes) to 
afford caffeic acid derivative 16a (1.12 g≅1.64 mmol, 93%) as a colorless 
powder. 1H NMR (CDCl3) data (see A-3 for spectrum): δ = 7.59 (m, 1H), 
7.40 (m, 3H), 7.26 (d, J = 1.6 Hz, 1H), 7.17 (d, J = 8.4 Hz, 1H), 6.83 (d, J 
= 9.0 Hz, 2H), 6.37 (d, J = 15.9 Hz, 2H), 4.83 (s, 1H), 3.91 (t, J = 6.6 Hz, 
2H), 3.49 (m, 1H), 3.15 (m, 1H), 2.31 (m, 2H), 2.29 (s, 3H), 2.28 (s, 3H), 
1.59-1.82 (m, 6H), 1.43 (m, 9H), 1.28 (m, 8H), 0.87 (m, 3H), and NH 
signal. APCI-MS (positive) m/z (rel. intensity) (A-4): 682 (85), 664(100); 
APCI-MS (negative) (A-5): 680 (100).  
        The caffeic acid derivative 16a (0.620 g≅0.900 mmol) was dissolved 
in THF (2.6 mL) and methanol (2.6 mL). To the mixture was added 
aqueous-methanolic 0.2 M KOH (water : methanol = 9:1, 3.0 mL). The 
reaction mixture was stirred overnight at ambient temperature. The 
mixture was then acidified with aqueous 1.0 M HCl (2.0 mL), followed 
by extraction with chloroform (3 times). The combined chloroform 
extracts were dried over anhydrous Na2SO4, filtered, and concentrated to 
dryness under reduced pressure to yield caffeic acid derivative 16d 
(0.370g≅0.620 mmol; 70%). 1H NMR (CD3OD) data (see A-6 for 
spectrum): δ = 7.61 (s, 1H), 7.55 (d, J = 4.8 Hz, 2H), 7.44 (d, J = 4.2 Hz, 
1H), 7.06 (d, J = 2.1 Hz, 1H), 6.92 (s, 2H), 6.81 (d, J = 8.2 Hz, 2H), 6.22 
(d, J = 15.9 Hz, 1H), 4.61 (s, 1H), 3.95 (t, J = 6.5 Hz, 2H), 3.38 (m, 1H), 
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3.13 (m, 1H), 2.32 (m, 2H), 1.94-1.61 (m, 6H), 1.43 (m, 10H), 1.30 (m, 
9H), 0.88 (t, J = 6.5 Hz, 3H). APCI-MS (positive) m/z (rel. intensity) (A-
7): 598.3 (100, [M+H]-); APCI-MS (negative) (A-8): 596 (100, [M-H]-). 
        The caffeic acid derivative 16d with Boc group (0.370 g≅0.620 
mmol) was dissolved in 15 mL CH2Cl2. While stirring with an ice bath, 
2.0 mL TFA was added to the solution. The reaction mixture was then 
stirred at room temperature for 1 hour, followed by removal of unreacted 
TFA under reduced pressure (Temp: room temperature). To the residue 
was added 3.0 mL saturated NaHCO3 solution to change the pH to around 
8. The aqueous phase was extracted with ethyl acetate (3 times). The 
combined organic extracts were concentrated to dryness to obtain caffeic 
acid derivative 16g (0.270 g≅0.550 mmol; 89%). 1H NMR (CD3OD) data 
(see A-9 for spectrum): δ = 7.42 (d, J = 3.0 Hz, 2H), 7.28 (d, J = 4.6 Hz, 
1H), 6.94 (s, 1H), 6.77 (d, J = 8.2 Hz, 2H), 6.68 (s, 1H), 6.30 (d, J = 15.9 
Hz, 1H), 4.62 (s, 1H), 3.94 (t, J = 6.4 Hz, 2H), 3.75 (d, J = 1.5Hz, 2H), 
2.99 (s, 2H), 1.93 (m, 1H), 1.75 (m, 5H), 1.43 (m, 2H), 1.23-1.37 (m, 8H), 
0.89 (t, J = 6.7 Hz, 3H), and some OH and NH signals. APCI-MS 
(positive) m/z (rel. intensity) (A-10): 498.3 (100, [M+H]-); APCI-MS 
(negative) (A-11): 496.2 (100, [M-H]-).  
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5.4   Synthesis of 3,4-diacetoxydihydro-caffeoyl chloride 19b  
 
 
 
        To a solution of 3,4-dihydroxyhydrocinnamic acid 19 (1.82 g≅10.0 
mmol) and DMAP (0.0300 g≅0.250 mmol) in pyridine (5.0 mL) was 
added acetic anhydride (2.4 mL≅25 mmol) dropwise at 0 °C. The reaction 
mixture was stirred overnight at room temperature under argon 
atmosphere. The resultant mixture (pale yellow, not clear) was then 
poured onto crushed ice (turned cloudy quickly). The aqueous phase was 
acidified with aqueous 2.0 M HCl to change the pH to about 2 (even more 
cloudy). The mixture was then extracted with ethyl acetate/THF (3:1; 3 × 
30 mL) and organic parts were collected (clear, pale yellow). The 
combined extracts were dried over Na2SO4 and filtered. After the removal 
of the solvent on a rotary evaporator, 3,4-diacetoxydihydro-caffeoyl acid 
19a (2.38 g≅9.51 mmol; 95%) was obtained and immediately used for 
subsequent reaction.  
        The 3,4-diacetoxydihydro-caffeoyl acid 19a (2.38 g≅9.51 mmol) 
was suspended in toluene (50 mL) with 5 drops of DMF (cloudy, milky 
white). Being kept in an ice-salt bath (NaCl and/or CaCl2), oxalyl chloride 
(1.8 mL≅20 mmol) was added dropwise at -5 °C to the mixture. The 
reaction mixture was stirred for overnight at room temperature. The 
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resultant mixture was then subjected to rotary evaporation to remove the 
solvent and unreacted oxalyl chloride (Bp: 75-80 °C). The product was 
triturated with hexane containing a few drops of ethyl acetate to yield 3,4-
diacetoxydihydro-caffeoyl chloride 19b (2.27 g≅7.98 mmol; 83%). 1H 
NMR (CDCl3) data (see A-12 for spectrum): δ = 7.17 (dtd, J = 7.2, 1.5, 
0.7 Hz, 1H), 7.04 (d, J = 1.2 Hz, 1H), 6.96 (t, J = 1.2 Hz, 1H), 2.99 (d, J = 
7.4 Hz, 2H), 2.66 (dd, J = 4.8, 1.0 Hz, 2H), 2.28 (t, J = 1.4 Hz, 6H).  
 
5.5   Synthesis of dihydrocaffeic acid derivative 20c  
 
 
 
 
 
        To a solution of H2N-Orn(Boc)-octyloxyaniline (1.49 g≅3.42 mmol) 
and DMAP (0.140 g≅1.13 mmol) in CH2Cl2 (20 mL) and pyridine (8.0 
mL), 3,4-diacetoxydihydro-caffeoyl chloride (2.27 g≅7.98 mmol) was 
added at room temperature. The reaction mixture (dark yellow solution) 
was stirred overnight under argon atmosphere. The resultant mixture was 
acidified with aqueous 1.0 M HCl to change the pH to about 3 (more 
cloudy). The aqueous phase was extracted with more CH2Cl2. The 
combined organic extracts were dried over anhydrous Na2SO4, filtered, 
O
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and concentrated on a rotary evaporator (Bp: 35-40°C). Regular silica gel 
column chromatography (continuous gradient from hexanes to hexanes : 
ethyl acetate = 1:9) was carried out to purify the residue and afford 
dihydrocaffeic acid derivative 20a (1.32 g≅1.93 mmol; 57%). 1H NMR 
(CDCl3) data (see A-13 for spectrum): δ = 7.41 (d, J = 8.8 Hz, 1H), 7.14 
(d, J = 1.6 Hz, 1H), 7.10 (d, J = 1.1 Hz, 2H), 7.04 (d, J = 4.2 Hz, 2H), 
6.94 (m, 2H), 6.83 (m, 2H), 4.76 (d, J = 29.9 Hz, 2H), 3.92 (t, J = 6.6 Hz, 
2H), 3.30 (m, 1H), 3.04 (m, 1H), 2.95 (m, 2H), 2.88 (d, J = 7.2 Hz, 1H), 
2.70 (d, J = 4.8 Hz, 1H), 2.28 (s, 6H), 1.79-1.49 (m, 3H), 1.43 (d, J = 4.0 
Hz, 9H), 1.16 (m, 8H), 0.87 (t, J = 6.9 Hz, 3H), and NH signals. APCI-
MS (positive) m/z (rel. intensity) (A-14): 684 (43, [M+H]-), 584 (100); 
APCI-MS (negative) (A-15): 682 (57, [M+H]-), 640 (69), 598 (100).  
        The dihydrocaffeic acid derivative 20a (0.200 g≅0.290 mmol) was 
dissolved in 1.0 mL THF and 1.0 mL methanol (clear, yellow solution). 
Aqueous-methanolic 0.2 M KOH (water : methanol = 9:1, 1.4 mL) was 
added to the mixture. The reaction mixture was then stirred overnight at 
room temperature. The resultant mixture was acidified with aqueous 1.0 
M HCl (1.0 mL), followed by extraction with chloroform (3 times). The 
combined chloroform extracts were dried with anhydrous Na2SO4 (clear, 
dark yellow). After filtration and removal of the solvent, dihydrocaffeic 
acid derivative 20b was obtained as brown solid (0.130 g≅0.220 mmol; 
74%). 1H NMR (CDCl3) data (see A-17 for spectrum): δ = 7.11-6.77 (m, 
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1H), 6.73 (dd, J = 9.7, 3.0 Hz, 2H), 6.60 (dd, J = 8.1, 2.0 Hz, 1H), 4.72 
(m, 1H), 3.96 (m, 1H), 3.89 (t, J = 6.4 Hz, 1H), 3.26 (m, 1H), 2.94 (m, 
2H), 2.82 (t, J = 7.7 Hz, 1H), 2.57 (m, 1H), 1.82-1.64 (m, 3H), 1.43 (m, 
9H), 1.35-1.20 (m, 5H), 1.09 (td, J = 7.1, 3.1 Hz, 1H), 0.88 (m, 3H), and 
NH signals. APCI-MS (positive) m/z (rel. intensity) (A-18): 600 (48, 
[M+H]-), 610 (100); APCI-MS (negative) (A-19): 598 (100, [M+H]-), 608 
(48). 
        The dihydrocaffeic acid derivative 20b (0.0500 g≅0.0800 mmol) 
was dissolved in 2.0 mL CH2Cl2. To the solution, 0.3 mL TFA was added 
in the presence of an ice bath. After stirring at room temperature for 1 
hour, the reaction mixture was then subjected to rotary evaporation to 
remove unreacted TFA and solvent under reduced pressure (Temp: room 
temperature). To the residue was added 0.3 mL aqueous saturated 
NaHCO3 solution to change the pH to around 8. The aqueous phase was 
extracted with ethyl acetate (3 times). The combined organic extracts 
were concentrated to dryness to afford dihydrocaffeic derivative 20c 
(0.0400 g≅0.0700 mmol; 88%). 1H NMR (CD3OD) data (see A-21 for 
spectrum): δ = 6.93 (m, 2H), 6.67 (m, 2H), 6.65 (d, J = 1.3 Hz, 1H), 6.53 
(d, J = 2.1 Hz, 1H), 6.50 (m, 1H), 3.99 (m, 1H), 3.93 (t, J = 6.4 Hz, 2H), 
3.35 (s, 1H), 2.93 (m, 1H), 2.57 (m, 5H), 1.89 (m, 1H), 1.78-1.53 (m, 2H), 
1.48-1.26 (m, 10H), 1.23-1.01 (m, 2H), 0.89 (m, 3H) and some OH, NH 
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signals. APCI-MS (positive) m/z (rel. intensity) (A-22): 500 (82, [M+H]-), 
510 (100); APCI-MS (negative) (A-23): 498 (100, [M+H]-), 508 (30).  
 
 
 
  
Synthesis and characterization of caffeic and dihydrocaffeic acid derivatives as antifungal agents 119 
References
 
[1] U.S. National Institutes of Health. Understanding microbes in  
      sickness and in health. NIH Publication, 2009, No. 09-4914 
[2] Taylor T., Krings M., Taylor E. How old are the fungi. Fossil Fungi,  
      2015, 27-39 
[3] Hall L. Keeping up with emerging fungal infections. Clinical  
     Microbiology Newsletter, 2013, 35:22 
[4] Heitman P. Microbial pathogens in the fungal kingdom. Fungal  
      Biology Reviews, 2011, 25(1): 48-60 
[5] Barron S. Medical microbiology (4th edition). University of Texas  
     Medical Branch at Galveston, 1996 
[6] Low C., Rotstein C. Emerging fungal infections in  
      immunocompromised patients. F1000 Medicine Reports, 2011, 3:14 
[7] Walker D.H., McGinnis M.R. Diseases caused by fungi.  
      Pathobiology of Human Disease, 2014, 217-221 
[8] Rees J.R., Pinner R.W., Hajjeh R.A., Brandt M.E., Reingold A.L.  
      The epidemiological features of invasive mycotic infections in the  
      San Francisco Bay area, 1992–1993: results of population-based  
      laboratory active surveillance. Clinical Infectious Diseases, 1998,  
      27(5): 1138-1147 
[9] Hajjeh R.A., Sofair A.N., Harrison L.H., Lyon G.M., Arthington- 
      Skaggs B.A., Mirza S.A., Phelan M., Morgan J., Lee-Yang W.,  
     Ciblak M.A., Benjamin L.E., Sanza L.T., Huie S., Yeo S.F., Brandt  
     M.E., Warnock D.W. Incidence of bloodstream infections due to  
     Candida species and in vitro susceptibilities of isolates collected from  
     1998 to 2000 in a population-based active surveillance program.  
     Journal of Clinical Microbiology, 2004, 42(4): 1519-1527 
[10] Zaoutis T.E., Argon J., Chu J., Berlin J.A., Walsh T.J., Feudtner  
Synthesis and characterization of caffeic and dihydrocaffeic acid derivatives as antifungal agents 120 
                                                                                                                                       
        C. The epidemiology and attributable outcomes of candidemia in  
        adults and children hospitalized in the United States: a propensity  
        analysis. Clinical Infectious Diseases, 2005, 41:1232-1239 
[11] Wilson L.S., Reyes C.M., Stolpman M., Speckman J., Allen K.,  
        Beney J. The direct cost and incidence of systemic fungal infections.  
        Value in Health, 2002, 5(1): 26-34 
[12] Romani L. Immunity to fungal infections. Nature Reviews  
        Immunology, 2004, 4: 11-24 
[13] Pauw B.E., Picazo J.J. Present situation in the treatment of invasive  
        fungal infection. International Journal of Antimicrobial Agents,  
        2008, 32(S2): 167-171 
[14] Viscoli C., Castagnola E. Emerging fungal pathogens, drug  
        resistance and the role of lipid formulations of amphotericin B in the  
        treatment of fungal infections in cancer patients: A review.  
        International Journal of Infectious Diseases, 1998-1999, 3(2): 109- 
        118 
[15] Enoch D.A., Ludlam H.A., Brown N.M. Invasive fungal infections:  
        a review of epidemiology and management options. Journal of  
        Medical Microbiology, 2006, 55: 809-818 
[16] Martin G.S., Mannino D.M., Eaton S., Moss M. The epidemiology  
        of sepsis in the United States from 1979 through 2000. The New  
        England Journal of Medicine, 2003, 348:1546-1554 
[17] Neofytos D., Lu K., Hatfield-Seung A., Blackford A., Marr K.A.,  
        Treadway S., Ostrander D., Nussenblatt V., Karp J.  
        Epidemiology, outcomes, and risk factors of invasive fungal   
        infections in adult patients with acute myelogenous leukemia after  
        induction chemotherapy. Diagnostic Microbiology and Infectious  
        Disease, 2013, 75(2): 144-149 
Synthesis and characterization of caffeic and dihydrocaffeic acid derivatives as antifungal agents 121 
                                                                                                                                       
[18] Bodro M., Sabé N., Gomila A., Ayats J., Baliellas C., Roca J.,  
        Melilli E., Carratalà J. Risk factors, clinical characteristics, and  
        outcomes of invasive fungal infections in solid organ transplant  
        recipients. Transplantation Proceedings, 2012, 44(9): 2682-2685 
[19] Rangel-Frausto M.S., Wiblin T., Blumberg H.M., Saiman L.,  
        Patterson J., Rinaldi M., Pfaller M., Edwards J.E. Jr., Jarvis W.,  
        Dawson J., Wenzel R.P. National epidemiology of mycoses survey  
        (NEMIS): variations in rates of bloodstream infections due to  
        Candida species in seven surgical intensive care units and six  
        neonatal intensive care units. Clinical Infectious Diseases, 1999,  
        29(2): 253-258 
[20] Pappas P.G., Kauffman C.A., Andes D., Benjamin D.K. Jr.,  
       Calandra T.F., Edwards J.E. Jr., Filler S.G., Fisher J.F.,  
       Kullberg B., Zeichner L.O., Reboli A.C., Rex J.H., Walsh T.J.,  
       Sobe J.D. Clinical practice guidelines for the management of    
       candidiasis: 2009 update by the Infectious Diseases Society of  
       America. Clinical Infectious Diseases, 2009, 48(5): 503-535 
[21] Erjavec Z., Verweij P.E. Recent progress in the diagnosis of fungal  
        infections in the immunocompromised host. Drug Resistance  
        Updates, 2002, 5(1): 3-10 
[22] Schuetz A.N. Invasive fungal infection: biomarkers and molecular  
        approaches to diagnosis. Clinics in Laboratory Medicine, 2013,  
        33(3): 505-525 
[23] Lai C.C., Tan C.K., Huang Y.T., Shao P.L., Hsueh P.R. Current  
        challenges in the management of invasive fungal infections. Journal  
        of Infection and Chemotherapy, 2008, 14 (2): 77-85 
[24] Dhillon R.H., Clark J. Fungal infections in the critically ill. Trends  
        in Anaesthesia and Critical Care, 2011, 1: 210-218 
Synthesis and characterization of caffeic and dihydrocaffeic acid derivatives as antifungal agents 122 
                                                                                                                                       
[25] Otting K.A., Stover K.R., Cleary J.D. Drug-laboratory interaction  
        between beta-lactam antibiotics and the galactomannan antigen test  
        used to detect mould infections. The Brazilian Journal of Infectious  
        Diseases, 2014, 18(5): 544-547 
[26] Hadrich I., Makni F., Cheikhrouhou F., Neji S., Amouri I.,  
        Sellami H., Trabelsi H., Elloumi M., Ayadi A. Clinical utility and  
        prognostic value of galactomannan in neutropenic patients with  
        invasive aspergillosis. Patholgie Biologie (Paris), 2012, 60: 357-361 
[27] Van Der Veer J., Lewis R.J., Emtiazjoo A.M., Allen S.D., Wheat  
        L.J., Hage C.A. Cross-reactivity in the PlateliaTM Aspergillus  
        enzyme immunoassay caused by blastomycosis. Medical Mycology,  
        2012, 50(4): 396-398 
[28] Pfeiffer C.D., Fine J.P., Safdar N. Diagnosis of invasive  
        aspergillosis using a galactomannan assay: a meta-analysis. Clinical  
        Infectious Diseases, 2006, 42(10): 1417-1427 
[29] Swanink C.M., Meis J.F., Rijs A.J., Donnelly J.P., Verweij P.E.  
        Specificity of a sandwich enzyme-linked immunosorbent assay for  
        detecting Aspergillus galactomannan. Journal Clinical Microbiology,  
        1997, 35(1): 257-260 
[30] Adam O., Auperin A., Wilquin F., Bourhis J.H., Gachot B.,  
       Chachaty E. Treatment with piperacillin-tazobactam and false- 
        positive Aspergillus galactomannan antigen test results for patients  
        with hematological malignancies. Clinical Infectious Diseases, 2004,  
        38(6): 917-920 
[31] Viscoli C., Machetti M., Cappellano P., Bucci B., Bruzzi P., Van  
        Lint M.T., Bacigalupo A. False-positive galactomannan platelia  
        Aspergillus test results for patients receiving piperacillin-tazobactam.  
        Clinical Infectious Diseases, 2004, 38(6): 913-916 
Synthesis and characterization of caffeic and dihydrocaffeic acid derivatives as antifungal agents 123 
                                                                                                                                       
[32] Alhambra A., Cuétara M.S., Ortiz M.C., Moreno J.M., del  
        Palacio A., Pontón J. False positive galactomannan results in adult  
        hematological patients treated with piperacillin-tazobactam. Revista  
        Iberoamericana Micología, 2007, 24(2): 106-112 
[33] Zandijk E., Mewis A., Magerman K., Cartuyvels R. False- 
        Positive results by the platelia Aspergillus galactomannan antigen  
        test for patients treated with amoxicillin-clavulanate. Clinical and  
        Vaccine Immunology, 2008, 15(7): 1132-1133 
[34] Tanriover M.D., Metan G., Altun B., Hascelik G., Uzun O. False  
        positivity for Aspergillus antigenemia related to the administration  
        of piperacillin-tazobactam. European Journal of Internal Medicine,  
        2005, 16(7): 489-491 
[35] Mennink-Kersten M.A.S., Klont R.R., Ruegebrink D., Dencamp  
        H., Verweij P.E. Amoxicillin-clavulanic acid (AMC) and  
        piperacillin-tazobactam (PTZ) contain high molecular weight cross- 
        reacting aspergillus antigen. In: Late-Breaker Abstract of the Forty- 
        forth Interscience Conference on Antimicrobial Agents and  
        Chemotherapy, Abstract M-1684a, p. 17. American Society for  
        Microbiology, 2004, Washington, DC, USA 
[36] Ansorg R., Van den Boom R., Rath P.M. Detection of Aspergillus  
        galactomannan antigen in foods and antibiotics. Mycoses, 1997, 40:  
        353-357 
[37] Penack O., Schwartz S., Thiel E., Blau I.W. Lack of evidence that  
        false-positive Aspergillus galactomannan antigen test results are due  
        to treatment with piperacillin-tazobactam. Clinical Infectious  
        Diseases, 2004, 39(9): 1401–1402  
[38] Metan G., Ağkuș C., Buldu H., Koç A.N. The interaction between  
        piperacillin-tazobactam and assays for Aspergillus galactomannan  
Synthesis and characterization of caffeic and dihydrocaffeic acid derivatives as antifungal agents 124 
                                                                                                                                       
        and 1,3-beta-D-glucan in patients without risk factors for invasive  
        fungal infections. Infection, 2010, 38(3): 217-221 
[39] Xavier M.O., Pasqualotto A.C., Aquino V.R., Sukiennik T.C.,  
        Severo L.C. Galactomannan detection from piperacillin-tazobactam  
        brands available in the Brazilian market. The Brazilian Journal of  
        Infectious Diseases, 2009,13(5): 353-355 
[40] Ozkalemkas F., Ozcelik T., Ozkocaman V. Treatment with   
        piperacillin-tazobactam and Aspergillus galactomannan test results  
        for patients with hematological malignancies. European Journal of  
        Internal Medicine, 2007, 18(1): 79 
[41] Penack O., Rempf P., Graf B., Thiel E., Blau I.W. False-positive  
        Aspergillus antigen testing due to application of piperacillin- 
        tazobactam — is it still an issue? Diagnostic Microbiology and  
        Infectious Disease, 2008, 60(1): 117-120 
[42] Maerten J., Verhaegen J., Lagrou K., Van Eldere J., Boogaerts  
        M. Screening for circulating galactomannan as a noninvasive  
        diagnostic tool for invasive aspergillosis in prolonged neutropenic   
        patients and stem cell transplantation recipients: a prospective  
        validation. The American Society of Hematology, 2001, 97(6): 1604- 
        1610 
[43] Pazos C., Pontón J., Del Palacio A. Contribution of (1→3)-β-D- 
        glucan chromogenic assay to diagnosis and therapeutic monitoring  
        of invasive aspergillosis in neutropenic adult patients: a comparison  
        with serial screening for circulating galactomannan. Journal of  
        Clinical Microbiology, 2005, 43: 299-305 
[44] He S., Hang J.P., Zhang L., Wang F., Zhang D.C., Gong F.H. A  
        systematic review and meta-analysis of diagnostic accuracy of serum  
        1,3-β-d-glucan for invasive fungal infection: Focus on cutoff levels.  
Synthesis and characterization of caffeic and dihydrocaffeic acid derivatives as antifungal agents 125 
                                                                                                                                       
        Journal of Microbiology, Immunology and Infection, 2014,  
        doi:10.1016/j.jmii.2014.06.009 
[45] Kedzierska A., Kochan P., Pietrzyk A., Kędzierska J. Current  
        status of fungal cell wall components in the immunodiagnostics of  
        invasive fungal infections in humans: galactomannan, mannan and  
        (1à3)-beta-d-glucan antigens. European Journal of Clinical  
        Microbiology and Infectious Diseases, 2007, 26(11): 755-766 
[46] De Pauw B., Walsh T.J., Donnelly J.P., Stevens D.A., Edwards  
        J.E., Calandra T., Pappas P.G., Maertens J., Lortholary O.,  
        Kauffman C.A., Denning D.W., Patterson T.F., Maschmeyer G.,  
        Bille J., Dismukes W.E., Herbrecht R., Hope W.W., Kibbler  
        C.C., Kullberg B.J., Marr K.A., Muñoz P., Odds F.C., Perfect  
        J.R., Restrepo A., Ruhnke M., Segal B.H., Sobel J.D., Sorrell  
        T.C., Viscoli C., Wingard J.R., Zaoutis T., Bennett J.E.;  
        European Organization for Research and Treatment of  
        Cancer/Invasive Fungal Infections Cooperative Group; National  
        Institute of Allergy and Infectious Diseases Mycoses Study  
        Group (EORTC/MSG) Consensus Group. Revised definitions of  
         invasive fungal disease from the European Organization for  
         Research and Treatment of Cancer/Invasive Fungal Infections  
         Cooperative Group and the National Institute of Allergy and  
         Infectious Diseases Mycoses Study Group (EORTC/MSG)  
         Consensus Group. Clinical Infectious Diseases, 2008, 46(12): 1813- 
         1821 
[47] Obayashi T., Yoshida M., Mori T., Goto H., Yasuoka A., Iwasaki  
        H., Teshima H., Kohno S., Horiuchi A., Ito A. Plasma (1à3)- 
        beta-D-glucan measurement in diagnosis of invasive deep mycosis  
        and fungal febrile episodes. Lancet, 1995, 345:17-20 
Synthesis and characterization of caffeic and dihydrocaffeic acid derivatives as antifungal agents 126 
                                                                                                                                       
[48] Onishi A., Sugiyama D., Kogata Y., Saegusa J., Sugimoto T.,  
        Kawano S., Morinobu A., Nishimura K., Kumagai S. Diagnostic  
        accuracy of serum 1,3-β-D-glucan for pneumocystis jiroveci  
        pneumonia, invasive candidiasis, and invasive aspergillosis:  
        systematic review and meta-analysis. Journal of Clinical  
        Microbiology, 2012, 50(1): 7-15 
[49] Lu Y., Chen Y., Guo Y.L., Qin S.M., Wu C., Wang K. Diagnosis  
        of invasive fungal disease using serum (1à3)-β-D-glucan: a  
        bivariate meta-analysis. Internal Medicine, 2011, 50(22): 2783-2791 
[50] Hope W.W., Petraitis V., Petraitiene R., Aghamolla T., Bacher J.,  
        Walsh T.J. The initial 96 hours of invasive pulmonary aspergillosis:  
        histopathology, comparative kinetics of galactomannan and (1à3)  
        beta-d-glucan and consequences of delayed antifungal therapy.  
        Antimicrobial Agents and Chemotherapy, 2010, 54(11): 4879-4886 
[51] Lamoth F., Cruciani M., Mengoli C., Castagnola E., Lortholary  
        O., Richardson M., Marchetti O.; Third European Conference  
        on Infectious in Leukemia (ECIL-3). β-Glucan antigenemia assay  
        for the diagnosis of invasive fungal infections in patients with  
        hematological malignancies: a systematic review and meta-analysis  
        of cohort studies from the Third European Conference on Infections  
        in Leukemia (ECIL-3). Clinical Infectious Diseases, 2012, 54(5):  
        633-643 
[52] Marty F.M., Lowry C.M., Lempitski S.J., Kubiak D.W.,  
        Finkelman M.A., Baden L.R. Reactivity of (1à3)-beta-D-glucan  
        assay with commonly used intravenous antimicrobials.  
        Antimicrobial Agents and Chemotherapy, 2006, 50(10): 3450-3453 
[53] Walsh T.J., Anaissie E.J., Denning D.W., Herbrecht R.,  
        Kontoyiannis D.P., Marr K.A., Morrison V.A., Segal B.H.,  
Synthesis and characterization of caffeic and dihydrocaffeic acid derivatives as antifungal agents 127 
                                                                                                                                       
        Steinbach W.J., Stevens D.A., van Burlk J.A., Wingard J.R.,  
        Patterson T.F.; Infectious Diseases Society of America. Treatment  
        of aspergillosis: clinical practice guidelines of the Infectious  
        Diseases Society of America. Clinical Infectious Diseases, 2008,  
        46(3): 327-360 
[54] Wingard J.R. Have novel serum markers supplanted tissue  
        diagnosis for invasive fungal infections in acute leukemia and  
        transplantation? Best Practice & Research Clinical Haematology,  
        2012, 25: 487-491 
[55] Odabasi Z., Mattiuzzi G., Estey E., Kantarjian H., Saeki F.,  
        Ridge R.J., Ketchum P.A., Finkelman M.A., Rex J.H., Ostrosky- 
        Zeichner L. β-D-Glucan as a diagnostic adjunct for invasive fungal  
        infections: validation, cutoff development, and performance in  
        patients with acute myelogenous leukemia and myelodysplastic  
        syndrome. Clinical Infectious Diseases, 2004, 39(2): 199-205 
[56] Ellis M., Al-Ramadi B., Finkelman M., Hedstrom U., Kristensen  
        J., Ali-Zadeh H., Klingspor L. Assessment of the clinical utility of  
        serial beta-D-glucan concentrations in patients with persistent  
        neutropenic fever. Journal of Medical Microbiology, 2008, 57:287- 
        295 
[57] Senn L., Robinson J.O., Schmidt S., Knaup M., Asahi N.,  
        Satomura S., Matsuura S., Duvoisin B., Bille J., Calandra T.,  
        Marchetti O. 1,3-β-D-glucan antigenemia for early diagnosis of  
        invasive fungal infections in neutropenic patients with acute  
        leukemia. Clinical Infectious Diseases, 2008, 46(6): 878-885 
[58] Del Bono V., Delfino E., Furfaro E., Mikulska M., Nicco E.,  
        Bruzzi P., Mularoni A., Bassetti M., Viscoli C. Clinical  
        performance of the (1,3)-beta-D-glucan assay in early diagnosis of  
Synthesis and characterization of caffeic and dihydrocaffeic acid derivatives as antifungal agents 128 
                                                                                                                                       
        nosocomial Candida bloodstream infections. Clinical Vaccine  
        Immunology, 2011, 18(12): 2113-2117 
[59] Khot D.P., Fredricks N.D. PCR-based diagnosis of human fungal  
        infection. Expert Review of Anti-infective Therapy, 2009, 7(10):  
        1201-1221 
[60] Flahaut M., Sanglard D., Monod M., Bille J., Rossier M. Rapid  
        detection of Candida albicans in clinical samples by DNA  
        amplification of common regions from C. albicans-secreted aspartic  
        proteinase genes. Journal of Clinical Microbiology, 1998, 36(2):  
        395-401 
[61] Springer J., Einsele H., Loeffler J. Molecular techniques in  
        diagnosis of deep and systemic mycosis. Clinics in Dermatology,  
        2012, 30: 651-656 
[62] Melchers W.J., Verweij P.E., van den Hurk P., van Belkum A.,  
        De Pauw B.E., Hoogkamp-Korstanje J.A., Meis J.F. General  
        primer-mediated PCR for detection of Aspergillus species. Journal  
        of Clinical Microbiology, 1994, 32(7): 1710-1717 
[63] de Aguirre L., Hurst S.F., Choi J.S., Shin J.H., Hinrikson H.P.,  
        Morrison C.J. Rapid differentiation of Aspergillus species from  
        other medically important opportunistic molds and yeasts by PCR—  
        enzyme immunoassay. Journal of Clinical Microbiology, 2004,  
        42(8): 3495-3504 
[64] Kadmon G., Nahum E., Sprecher H., Stein J., Levy I., Schiller O.,  
        Schonfeld T. Polymerase-chain-reaction-based diagnosis of invasive  
        fungal pulmonary infections in immunocompromised children.  
        Pediatric Pulmonology, 2012, 47(10): 994-1000 
[65] Kourkoumpetis K.T., Fuchs B.B., Coleman J.J., Desalermos A.,  
        Mylonakis E. Polymerase chain reaction-based assays for the  
Synthesis and characterization of caffeic and dihydrocaffeic acid derivatives as antifungal agents 129 
                                                                                                                                       
        diagnosis of invasive fungal infections. Clinical Infectious Diseases,  
        2012, 54(9): 1322-1331 
[66] Wengenack L.N., Binnicker J.M. Fungal molecular diagnostics.  
        Clinics in Chest Medicine, 2009, 30(2): 391-408 
[67] Halliday C., Hoile R., Sorrell T., James G., Yadav S., Shaw P.,  
        Bleakley M., Bradstock K., Chen S. Role of prospective screening  
        of blood for invasive aspergillosis by polymerase chain reaction in  
        febrile neutropenic recipients of haematopoietic stem cell transplants  
        and patients with acute leukaemia. British Journal of Haematology,  
        2006, 132(4): 478-486 
[68] Florent M., Katsahian S., Vekhoff A., Levy V., Rio B., Marie J.P.,  
        Bouvet A., Cornet M. Prospective evaluation of a polymerase chain  
        reaction-ELISA targeted to Aspergillus fumigatus and Aspergillus  
        flavus for the early diagnosis of invasive aspergillosis in patients  
        with hematological malignancies. Journal of Infectious Diseases,  
        2006, 193(5): 741-747 
[69] Sugawara Y., Nakase K., Nakamura A., Ohishi K., Sugimoto Y.,  
        Fujieda A., Monma F., Suzuki K., Masuya M., Matsushima Y.,  
        Wada H., Nobori T., Katayama N. Clinical utility of a panfungal  
         polymerase chain reaction assay for invasive fungal diseases in  
         patients with haematologic disorders. European Journal of  
         Haematology, 2013, 90(4): 331-339 
[70] White P.L., Bretagne S., Klingspor L., Melchers W.J.,  
        McCulloch E., Schulz B., Finnstorm N., Mengoli C., Barnes R.A.,  
        Donnelly J.P., Loeffler J., European Aspergillus PCR Initiative.  
        Aspergillus PCR: one step closer to standardization. Journal of  
        Clinical Microbiology, 2010, 48(4): 1231-1240 
[71] Cuchacovich R. Clinical applications of the polymerase chain  
Synthesis and characterization of caffeic and dihydrocaffeic acid derivatives as antifungal agents 130 
                                                                                                                                       
        reaction: An update, Infectious Disease Clinics of North America,  
        2006, 20(4): 735-758 
[72] Metcalf S.C., Dockrell D.H. Improved outcomes associated with  
        advances in therapy for invasive fungal infections in immuno- 
        compromised hosts. Journal of Infection, 2007, 55(4): 287-299 
[73] Odds F.C., Brown A.J., Gow N.A. Antifungal agents: mechanisms  
        of action. Trends in Microbiology, 2003, 11(6): 272-279 
[74] Brajtburg J., Powderly W.G., Kobayashi G.S., Medoff G.  
        Amphotericin B: Current understanding of mechanisms of action.  
        Antimicrobial agents and Chemotherapy, 1990, 34(2): 183-188 
[75] Dupont B. Overview of the lipid formulations of amphotericin B.  
        Journal of Antimicrobial Chemotherapy, 2002, 49(Suppl. 1): 31-36 
[76] Slain D. Lipid-based amphotericin B for the treatment of fungal  
        infections. Pharmacotherapy, 1999, 19(3): 306-323 
[77] Barrett J.P., Vardulaki K.A., Conlon C., Cooke J., Daza- 
        Ramirez P., Evans E.G., Hawkey P.M., Herbrecht R., Marks  
        D.I., Moraleda J.M., Park G.R., Senn S.J., Viscoli C.;  
        Amphotericin B Systematic Review Study Group. A systematic  
         review of the antifungal effectiveness and tolerability of  
         amphotericin B formulations. Clinical Therapeutics, 2003, 25(5):  
         1295-1320 
[78] Sun H.Y., Alexander B.D., Lortholary O., Dromer F., Forrest  
       G.N., Lyon G.M., Somani J., Gupta K.L., del Busto R., Pruett  
       T.L., Sifri C.D., Limaye A.P., John G.T., Klintmalm G.B., Pursell  
       K., Stosor V., Morris M.I., Dowdy L.A., Munoz P., Kalil A.C.,  
       Garcia-Diaz J., Orloff S., Houston S., Wray D., Huprikar S.,  
       Johnson L.B., Humar A., Razonable R.R., Husain S., Singh N.  
       Lipid formulations of amphotericin B significantly improve outcome  
Synthesis and characterization of caffeic and dihydrocaffeic acid derivatives as antifungal agents 131 
                                                                                                                                       
        in solid organ transplant recipients with central nervous system  
        cryptococcosis. Clinical Infectious Diseases, 2009, 49(11): 1721- 
        1728 
[79] Hamill J.R. Amphotericin B formulations: A comparative review of  
        efficacy and toxicity. Drugs, 2013, 73(9): 919-934 
[80] Flückiger U., Marcbetti O., Bille J., Eggimann P., Zimmerli S.,  
        Imhof A., Garbino J., Ruef C., Pittet D., Täuber M., Glauser M.,  
        Calandra T.; Fungal Infection Network of Switzerland  
        (FUNGINOS). Treatment options of invasive fungal infections in  
         adults. Swiss Medical Weekly, 2006, 136(29-30): 447-463 
[81] Thompson R.G., Cadena J., Patterson F.T. Overview of antifungal  
        agents. Clinics in Chest Medicine, 2009, 30(2): 203-215 
[82] Bossche H.V., Koymans L., Moereels H. P450 inhibitors of use in  
        medical treatment: Focus on mechanisms of action. Pharmacology  
        &Therapeutics, 1995, 67(1): 79-100 
[83] Carrillo-Muñoz A.J., Giusiano G., Ezkurra P.A., Quindós G.  
        Antifungal agents: Mode of action in yeast cells. Revista Española  
        de Quimioterapia, 2006, 19(2): 130-139 
[84] Sheehan J.D., Hitchcock A.C., Sibley M.C. Current and emerging  
        azole antifungal agents. Clinical Microbiology Reviews, 1999, 12(1):  
        40-79 
[85] Akins R.A. An update on antifungal targets and mechanisms of  
        resistance in Candida albicans. Medical Mycology, 2005, 43(4): 285- 
        318 
[86] Kramer M.R., Marshall S.E., Denning D.W., Keogh A.M.,  
        Tucker R.M., Galgiani J.N., Lewiston N.J., Stevens D.A.,  
        Theodore J. Cyclosporine and itraconazole interaction in heart and  
         lung transplant recipients. Annals of Internal Medicine, 1990,  
Synthesis and characterization of caffeic and dihydrocaffeic acid derivatives as antifungal agents 132 
                                                                                                                                       
        113(4): 327-329 
[87] Varis T., Kaukonen K.M., Kivistö K.T., Neuvonen P.J. Plasma  
        concentrations and effects of oral methylprednisolone are  
        considerably increased by itraconazole. Clinical Pharmacology and  
        Therapeutics, 1998,64(4): 363-368 
[88] Tucker R.M., Denning D.W., Hanson L.H., Rinaldi M.G.,  
       Graybill J.R., Sharkey P.K., Pappagianis D., Stevens D.A.  
        Interaction of azoles with rifampin, phenytoin, and carbamazepine:  
        in vitro and clinical observations. Clinical Infectious Diseases, 1992,  
        14(1): 165-174 
[89] Kanafani Z.A., Perfect J.R. Antimicrobial resistance: resistance to  
        antifungal agents: mechanisms and clinical impact. Clinical  
        Infectious Diseases, 2008, 46(1): 120-128 
[90] Pemán J., Cantón E., Espinel-Ingroff A. Antifungal drug  
        resistance mechanisms. Expert Review of Anti-infective Therapy,  
        2009, 7(4): 453-460 
[91] Lupetti A., Danesi R., Campa M., Del Tacca M., Kelly S.  
        Molecular basis of resistance to azole antifungals. Trends in  
        Molecular Medicine, 2002, 8(2): 76-81 
[92] Löffler J., Kelly S.L., Hebart H., Schumacher U., Lass-Flörl C.,  
        Einsele H. Molecular analysis of cyp51 from fluconazole-resistant  
        Candida albicans strains. FEMS Microbiology Letters, 1997, 151(2):  
        263-268 
[93] Lopez-Ribot, J.L., McAtee R.K., Lee L.N., Kirkpatrick W.R.,  
       White T.C., Sanglard D., Patterson T.F. Distinct patterns of gene  
       expression associated with development of fluconazole resistance in  
       serial Candida albicans isolates from human immunodeficiency  
       virus-infected patients with oropharyngeal candidiasis. Antimicrobial  
Synthesis and characterization of caffeic and dihydrocaffeic acid derivatives as antifungal agents 133 
                                                                                                                                       
        Agents and Chemotherapy, 1998, 42(11): 2932-2937 
[94] Pfaller A.M. Antifungal drug resistance: mechanisms, epidemiology,  
        and consequences for treatment. The American Journal of Medicine,  
        2012, 125(Suppl. 1): S3-13 
[95] Kelly S.L., Lamb D.C., Kelly D.E., Loeffler J., Einsele H.  
        Resistance to fluconazole and amphotericin in Candida albicans  
        from AIDS patients. Lancet, 1996, 348(9040): 1523-1524 
[96] DeMuria D., Forrest A., Rich J., Scavone J.M., Cohen L.G.,  
        Kazanjian P.H. Pharmacokinetics and bioavailability of fluconazole  
        in patients with AIDS. Antimicrobial Agents and Chemotherapy,  
        1993, 37(10): 2187-2192 
[97] Lass-Flörl C. Triazole antifungal agents in invasive fungal  
        infections: a comparative review. Drugs, 2011, 71(18): 2405-2419 
[98] Andriole V.T. Current and future antifungal therapy: new targets for  
        antifungal therapy. International Journal of Antimicrobial Agents,  
        2000, 16(3): 317-321 
[99] Arndt C.A., Walsh T.J., McCully C.L., Balis F.M., Pizzo P.A.,  
        Poplack D.G. Fluconazole penetration into cerebrospinal fluid:  
        implications for treating fungal infections of the central nervous  
        system. The Journal of Infectious Diseases, 1988, 157(1): 178-180 
[100] Foulds G., Brennan D.R., Wajszczuk C., Catanzaro A., Garg  
          D.C., Knopf W., Rinaldi M., Weidler D.J. Fluconazole  
          penetration into cerebrospinal fluid in humans. Journal of Clinical  
          Pharmacology, 1988, 28(4): 363-366 
[101] Pfaller M.A., Diekema D.J., Messer S.A., Boyken L., Hollis R.J.,  
          Jones R.N.; International Fungal Surveillance Participant  
          Group. In vitro activities of voriconazole, posaconazole, and four  
          licensed systemic antifungal agents against Candida species  
Synthesis and characterization of caffeic and dihydrocaffeic acid derivatives as antifungal agents 134 
                                                                                                                                       
          infrequently isolated from blood. Journal of Clinical Microbiology,  
          2003, 41(1): 78-83 
[102] Sabatelli F., Patel R., Mann P.A., Mendrick C.A., Norris C.C.,  
         Hare R., Loebenberg D., Black T.A., McNicholas P.M. In vitro  
         activities of posaconazole, fluconazole, itraconazole, voriconazole,  
         and amphotericin B against a large collection of clinically important  
         molds and yeasts. Antimicrobial Agents and Chemotherapy, 2006,  
         50(6): 2009-2015 
[103] Petrikkos G., Skiada A. Recent advances in antifungal  
          chemotherapy. International Journal of Antimicrobial Agents, 2007,  
          30(2): 108-117 
[104] Johnson L.B., Kauffman C.A. Voriconazole: a new triazole anti-  
          fungal agent. Clinical Infectious Diseases, 2003, 36(5): 630-637 
[105] Sabo J.A., Abdel-Rahman S.M. Voriconazole: a new triazole     
          antifungal. Annals of Pharmacotherapy, 2000, 34(9): 1032-1043 
[106] Theuretzbacher U., Ihle F., Derendorf H. Pharmacokinetic/  
          pharmacodynamic profile of voriconazole. Clinical  
          Pharmacokinetics, 2006, 45(7): 649-663 
[107] Purkins L., Wood N., Kleinermans D., Greenhalgh K., Nichols  
          D. Effect of food on the pharmacokinetics of multiple-dose oral  
          voriconazole. British Journal of Clinical Pharmacology, 2003,  
          56(Suppl. 1): 17-23 
[108] Lazarus H.M., Blumer J.L., Yanovich S., Schlamm H., Romero  
          A. Safety and pharmacokinetics of oral voriconazole in patients at  
          risk of fungal infection: a dose escalation study. Journal of Clinical  
          Pharmacology, 2002, 42(4): 395-402 
[109] Ghannoum M.A., Kuhn D.M. Voriconazole better chances for  
          patients with invasive mycoses. European Journal of Medical  
Synthesis and characterization of caffeic and dihydrocaffeic acid derivatives as antifungal agents 135 
                                                                                                                                       
          Research, 2002, 7(5): 242-256 
[110] Groll A.H., Gea-Banacloche J.C., Glasmacher A., Just- 
          Nuebling G., Maschmeyer G., Walsh T.J. Clinical pharmacology  
          of antifungal compounds. Infectious Diseases Clinics of North  
          America, 2003, 17(1): 159-191 
[111] Dodds-Ashley E. Management of drug and food interactions with  
          azole antifungal agents in transplant recipients. Pharmacotherapy,  
          2010, 30(8): 842-854 
[112] Patterson B., Roffey S., Jezequel S.G., Jones B. UK-109, 496, a  
          novel, wide-spectrum triazole derivative for the treatment of fungal  
          infections: disposition in man. Presented at the 35th Interscience  
          Conference on Antimicrobial Agents and Chemotherapy, San  
          Francisco, CA, September 17–20, 1995, Abstract F79, 126 
[113] Hoffman H.L., Rathbun R.C. Review of the safety and efficacy of  
          voriconazole. Expert Opinion on Investigational Drugs, 2002,  
          11(3): 409-429 
[114] Herbrecht R., Denning D.W., Patterson T.F., Bennett J.E.,  
         Greene R.E., Oestmann J.W., Kern W.V., Marr K.A., Ribaud P.,  
         Lortholary O., Sylvester R., Rubin R.H., Wingard J.R., Stark P.,  
         Durand C., Caillot D., Thiel E., Chandrasekar P.H., Hodges  
         M.R., Schlamm H.T., Troke P.F., de Pauw B.; Invasive Fungal  
         Infections Group of the European Organization for Research  
         and Treatment of Cancer and the Global Aspergillus Study  
          Group. Voriconazole versus amphotericin B for primary therapy of  
          invasive aspergillosis. The New England Journal of Medicine, 2002,  
          347(6): 408-415 
[115] Purkins L., Wood N., Ghahramani P., Greenhalgh K., Allen  
         M.J., Kleinermans D. Pharmacokinetics and safety of voriconazole  
Synthesis and characterization of caffeic and dihydrocaffeic acid derivatives as antifungal agents 136 
                                                                                                                                       
          following intravenous-to oral-dose escalation regimens.  
          Antimicrobial Agents and Chemotherapy, 2002, 46(8): 2546-2553 
[116] Rubenstein M., Levy M.L., Metry D. Voriconazole-induced  
          retinoid-like photosensitivity in children. Pediatric Dermatology,  
          2004, 21(6): 675-678 
[117] Denning D.W., Ribaud P., Milpied N., Caillot D., Herbrecht R.,  
          Thiel E., Haas A., Ruhnke M., Lode H. Efficacy and safety of  
          voriconazole in the treatment of acute invasive aspergillosis.  
          Clinical Infectious Diseases, 2002, 34(5): 563-571 
[118] Kenilworth, NJ: Schering-Plough, Schering-Plough announces  
          FDA approval of NOXAFIL® (posaconazole) for prevention of  
          invasive fungal infections, Schering-Plough News Release,  
          September 2006 
[119] Courtney R., Wexler D., Radwanski E., Lim J., Laughlin M.  
          Effect of food on the relative bioavailability of two oral  
          formulations of posaconazole in healthy adults. British Journal of  
          Clinical Pharmacology, 2003, 57(2): 218-222 
[120] Nagappan V., Deresinski S. Reviews of anti-infective agents:  
          posaconazole: a broad-spectrum triazole antifungal agent. Clinical  
          Infectious Diseases, 2007, 45(12): 1610-1617 
[121] Dodds-Ashley E.S., Lewis R., Lewis J.S., Martin C., Andes D.  
          Pharmacology of systemic antifungal agents. Clinical Infectious  
          Diseases, 2006, 43(Suppl. 1): S28-39 
[122] Courtney R., Wexler D., Radwanski E., Lim J., Laughlin M.  
          Effect of food on the relative bioavailability of two oral  
          formulations of posaconazole in healthy adults. British Journal of  
          Clinical Pharmacology, 2004, 57(2): 218-222 
[123] Schiller D.S., Fung H.B. Posaconazole: an extended-spectrum  
Synthesis and characterization of caffeic and dihydrocaffeic acid derivatives as antifungal agents 137 
                                                                                                                                       
          triazole antifungal agent. Clinical Therapeutics, 2007, 29(9): 1862- 
          1886 
[124] Courtney R., Sansone A., Smith W., Marbury T., Statkevich P.,  
          Martinho M., Laughlin M., Swan S. Posaconazole  
          pharmacokinetics, safety, and tolerability in subjects with varying  
          degrees of chronic renal disease. Journal of Clinical Pharmacology,  
          2005,45(2): 185-192 
[125] Ghosal A., Hapangama N., Yuan Y., Achanfuo-Yeboah J.,  
          Iannucci R., Chowdhury S., Alton K., Patrick J.E., Zbaida S.  
          Identification of human UDP-glucuronosyltransferase enzyme(s)  
          responsible for the glucuronidation of posaconazole (Noxafil).  
          Drug Metabolism and Disposition, 2004, 32(2): 267-271 
[126] Krieter P., Flannery B., Musick T., Gohdes M., Martinho M.,  
          Courtney R. Disposition of posaconazole following single-dose  
          oral administration in healthy subjects. Antimicrobial Agents and  
          Chemotherapy, 2004, 48(9): 3543-3551 
[127] Hachem R.Y., Langston A.A., Graybill J.R., Perfect J.R.,  
          Pedicone L.D., Patino H., Raad I.I. Posaconazole as salvage  
          treatment of invasive fungal infections in patients with underlying  
          renal impairment. Journal of Antimicrobial Chemotherapy, 2008,  
          62(6): 1386-1391 
[128] Groll A.H., Walsh T.J. Posaconazole: clinical pharmacology and  
          potential for management of fungal infections. Expert Review of  
          Anti-infective Therapy, 2005, 3(4): 467-487 
[129] Wexler D., Courtney R., Richards W., Banfield C., Lim J.,  
          Laughlin M. Effect of posaconazole on cytochrome P450 enzymes:  
          a randomized, open-label, two-way crossover study. European  
          Journal of Pharmaceutical Sciences, 2004, 21(5): 645-653 
Synthesis and characterization of caffeic and dihydrocaffeic acid derivatives as antifungal agents 138 
                                                                                                                                       
[130] Worth L.J., Blyth C.C., Booth D.L., Kong D.C., Marriott D.,  
          Cassumbhoy M., Ray J., Slavin M.A., Wilkes J.R. Optimizing  
          antifungal drug dosing and monitoring to avoid toxicity and  
          improve outcomes in patients with haematological disorders.  
          Internal Medicine Journal, 2008, 38(6b): 521-537 
[131] Noxafil (posaconazole) oral suspension package insert], Summit,  
          NJ: Schering-Plough, 2006 
[132] Torres H.A., Hachem R.Y., Chemaly R.F., Kontoyiannis D.P.,  
          Raad I.I., Posaconazole: a broad-spectrum triazole antifungal.  
          Lancet Infectious Diseases, 2005, 5(12): 775-785 
[133] Raad I.I., Graybill J.R., Bustamante A.B., Cornely O.A.,  
          Gaona-Flores V., Afif C., Graham D.R., Greenberg R.N.,  
          Hadley S., Langston A., Negroni R., Perfect J.R., Pitisuttithum  
          P., Restrepo A., Schiller G., Pedicone L., Ullmann A.J. Safety of  
          long-term oral posaconazole use in the treatment of refractory  
          invasive fungal infections. Clinical Infectious Diseases, 2006,  
          42(12): 1726-1734 
[134] Ullmann A.J., Lipton J.H., Vesole D.H., Chandrasekar P.,  
          Langston A., Tarantolo S.R., Greinix H., Morais de Azevedo  
          W., Reddy V., Boparai N., Pedicone L., Patino H., Durrant S.  
          Posaconazole or fluconazole for prophylaxis in severe graft-versus- 
          host disease. The New England Journal of Medicine, 2007, 356(4):  
          335-347 
[135] Walsh T.J., Raad I., Patterson T.F., Chandrasekar P., Donowitz  
          G.R., Graybill R., Greene R.E., Hachem R., Hadley S.,  
          Herbrecht R., Langston A., Louie A., Ribaud P., Segal B.H.,  
          Stevens D.A., van Burik J.A., White C.S., Corcoran G., Gogate  
          J., Krishna G., Pedicone L., Hardalo C., Perfect J.R. Treatment  
Synthesis and characterization of caffeic and dihydrocaffeic acid derivatives as antifungal agents 139 
                                                                                                                                       
          of invasive aspergillosis with posaconazole in patients who are  
          refractory to or intolerant of conventional therapy: an externally  
          controlled trial. Clinical Infectious Diseases, 2007, 44(1): 2-12 
[136] Chen S.C., Playford E.G., Sorrell T.C. Antifungal therapy in  
          invasive fungal infections. Current Opinion in Pharmacology, 2010,  
          10(5): 522-530 
[137] Klis F.M., de Groot P., Hellingwerf K. Molecular organization of  
          the cell wall of Candida albicans. Medical Mycology, 2001,  
          39(Suppl. 1): 1-8 
[138] Bernard M., Latgé J.P. Aspergillus fumigatus cell wall:  
          composition and biosynthesis. Medical Mycology, 2001, 39(Suppl.  
          1): 9-17 
[139] Cappelletty D., Eiselstein-McKitrick K. The echinocandins.  
          Pharmacotherapy, 2007, 27(3): 369-388 
[140] Bachmann S.P., Patterson T.F., Lopez-Ribot J.L. In vitro  
          activity of caspofungin (MK-0991) against Candida albicans  
          clinical isolates displaying different mechanisms of azole resistance.  
          Journal of Clinical Microbiology, 2002, 40(6): 2228-2230 
[141] Kurtz M.B., Rex J.H. Glucan synthase inhibitors as antifungal  
          agents. Advances in Protein Chemistry, 2001, 56: 423-475 
[142] Nyfeler R., Keller-Schierlein W. Metabolites of microorganisms.  
          143. Echinocandin B, a novel polypeptide-antibiotic from  
          Aspergillus nidulans var. echinulatus: isolation and structural  
          components. Helvetica Chimica Actaca, 1974, 57(8): 2459-2477 
[143] Lamaris G.A., Lewis R.E., Chamilos G., May G.S., Safdar A.,  
          Walsh T.J., Raad I.I., Kontoyiannis D.P. Caspofungin-mediated  
          beta-glucan unmasking and enhancement of human  
Synthesis and characterization of caffeic and dihydrocaffeic acid derivatives as antifungal agents 140 
                                                                                                                                       
          polymorphonuclear neutrophil activity against Aspergillus and non- 
          Aspergillus hyphae. Journal of Infectious Diseases, 2008, 198(2):  
          186-192 
[144] Theuretzbacher U. Pharmacokinetics/pharmacodynamics of  
          echinocandins. European Journal of Clinical Microbiology and  
          Infectious Diseases, 2004, 23(11): 805-812 
[145] Denning D.W. Echinocandin antifungal drugs. Lancet, 2003,  
          362(9390): 1142-1151 
[146] Balani S.K., Xu X., Arison B.H., Silva M.V., Gries A., DeLuna  
          F.A., Cui D., Kari P.H., Ly T., Hop C.E., Singh R., Wallace  
          M.A., Dean D.C., Lin J.H., Pearson P.G., Baillie T.A.  
          Metabolites of caspofungin acetate, a potent antifungal agent, in  
          human plasma and urine. Drug Metabolism and Disposition, 2000,  
          28(11): 1274-1278 
[147] Stone J.A., Holland S.D., Wickersham P.J., Sterrett A.,  
          Schwartz M., Bonfiglio C., Hesney M., Winchell G.A., Deutsch  
          P.J., Greenberg H., Hunt T.L., Waldman S.A. Single- and  
          multiple-dose pharmacokinetics of caspofungin in healthy men.  
          Antimicrobial Agents and Chemotherapy, 2002, 46(3):739-745 
[148] Holland S., Stone J.A., Li S., Wickersham P., Deutsch P.,  
         Winchell G., Hesney M., Bi S., Friel M., Mistry G., Dilzer S.  
          Effect of hepatic insufficiency on the pharmacokinetics of  
          caspofungin. Program and abstracts of the 41st Interscience  
          Conference on Antimicrobial Agents and Chemotherapy, 2001;  
          Chicago, USA: abstract A-14 
[149] Hebert M.F., Smith H.E., Marbury T.C., Swan S.K., Smith  
         W.B., Townsend R.W., Buell D., Keirns J., Bekersky I.  
          Pharmacokinetics of micafungin in healthy volunteers, volunteers  
Synthesis and characterization of caffeic and dihydrocaffeic acid derivatives as antifungal agents 141 
                                                                                                                                       
          with moderate liver disease, and volunteers with renal dysfunction.  
          Journal of Clinical Pharmacology, 2005, 45(10): 1145-1152 
[150] Hiemenz J., Cagnoni P., Simpson D., Devine S., Chao N., Keirns  
          J., Lau W., Facklam D., Buell D. Pharmacokinetic and maximum  
          tolerated dose study of micafungin in combination with fluconazole        
          versus fluconazole alone for prophylaxis of fungal infections in  
          adult patients undergoing a bone marrow or peripheral stem cell  
          transplant. Antimicrobial Agents and Chemotherapy, 2005, 49(4):  
          1331-1336 
[151] Stogniew M., Pu F., Henkel T., Dowell J. Anidulafungin  
          biotransformation in humans is by degradation not metabolism.  
          European Society of Clinical Microbiology and Infectious Diseases,  
          2003; 9(Suppl. 1): 291, abstract P-1223 
[152] Cleary J.D., Schwartz M., Rogers P.D., de Mestral J., Chapman  
          S.W. Effects of amphotericin B and caspofungin on histamine  
          expression. Pharmacotherapy, 2003, 23(8): 966-973 
[153] Stone J.A., Migoya E.M., Hickey L., Winchell G.A., Deutsch  
          P.J., Ghosh K., Freeman A., Bi S., Desai R., Dilzer S.C.,  
          Lasseter K.C., Kraft W.K., Greenberg H., Waldman S.A.  
          Potential for interactions between caspofungin and nelfinavir or  
          rifampin. Antimicrobial Agents and Chemotherapy, 2004, 48(11):  
          4306-4314 
[154] Petrovic J., Ngai A., Bradshaw S., William-Diaz A., Taylor A.,  
          Sable C., Vuocolo S., Kartsonis N. Efficacy and safety of  
          caspofungin in solid organ transplant recipients. Transplantation  
          Proceedings, 2007, 39(10): 3117-3120 
[155] Mora-Duarte J., Betts R., Rotstein C., Colombo A.L.,  
          Thompson-Moya L., Smietana J., Lupinacci R., Sable C.,  
Synthesis and characterization of caffeic and dihydrocaffeic acid derivatives as antifungal agents 142 
                                                                                                                                       
          Kartsonis N., Perfect J.; Caspofungin Invasive Candidiasis  
          Study Group. Comparison of caspofungin and amphotericin B for  
          invasive candidiasis. The New England Journal of Medicine, 2002,  
          347(25): 2020-2029 
[156] Maertens J., Raad I., Pettrikkos G., Boogaerts M., Selleslag D.,  
          Petersen F.B., Sable C.A., Kartsonis N.A., Ngai A., Taylor A.,  
          Patterson T.F., Denning D.W., Walsh T.J.; Caspofungin  
          Salvage Aspergillosis Study Group. Efficacy and safety of  
          caspofungin for the treatment of invasive aspergillosis in patients  
          refractory to or intolerant of conventional antifungal therapy.  
          Clinical Infectious Diseases, 2004, 39(11): 1563-1571 
[157] Walsh T.J., Teppler H., Donowitz G.R., Maertens J.A., Baden  
          L.R., Dmoszynska A., Cornely O.A., Bourque M.R., Lupinacci  
          R.J., Sable C.A., de Pauw B.E. Caspofungin versus liposomal  
          amphotericin B for empirical antifungal therapy in patients with  
          persistent fever and neutropenia. The New England Journal of  
          Medicine, 2004, 351(14): 1391-1402 
[158] Rogers T.R., Slavin M.A., Donnelly J.P. Antifungal prophylaxis  
          during treatment for haematological malignancies: are we there yet?  
          British Journal of Haematology, 2011, 153(6): 681-697 
[159] van Burik J.A., Ratanatharathorn V., Stepan D.E., Miller C.B.,  
         Lipton J.H., Vesole D.H., Bunin N., Wall D.A., Hiemenz J.W.,  
         Satoi Y., Lee J.M., Walsh T.J.; National Institute of Allergy and  
         Infectious Diseases Mycoses Study Group. Micafungin versus  
         fluconazole for prophylaxis against invasive fungal infections  
         during neutropenia in patients undergoing hematopoietic stem cell  
         transplantation. Clinical Infectious Diseases, 2004, 39(10): 1407- 
         1416 
Synthesis and characterization of caffeic and dihydrocaffeic acid derivatives as antifungal agents 143 
                                                                                                                                       
[160] Hiramatsu, Y., Maeda, Y., Fujii, N., Saito T., Nawa Y., Hara M.,  
          Yano T., Asakura S., Sunami K., Tabayashi T., Miyata A.,  
          Matsuoka K., Shinagawa K., Ikeda K., Matsuo K., Tanimoto  
          M.; West-Japan Hematology and Oncology Group. Use of  
          micafungin versus fluconazole for antifungal prophylaxis in  
          neutropenic patients receiving hematopoietic stem cell  
          transplantation. International Journal of Hematology, 2008, 88(5):  
          588-595 
[161] de Wet N., Lianos-Cuentas A., Suleiman J., Baraldi E., Krantz  
          E.F., Della Negra M., Diekmann-Berndt H. A randomized,  
          double-blind, parallel-group, dose-response study of micafungin  
          compared with fluconazole for the treatment of esophageal  
          candidiasis in HIV-positive patients. Clinical Infectious Diseases,  
          2004, 39(6): 842-849 
[162] de Wet N., Bester A.J., Viljoen J.J., Filho F., Suleiman J.M.,  
          Ticona E., Llanos E.A., Fisco C., Lau W., Buell D. A randomized,  
          double-blind, comparative trial of micafungin (FK463) vs.  
          fluconazole for the treatment of oesophageal candidiasis.  
          Alimentary Pharmacology & Therapeutics, 2005, 21(7): 899-907 
[163] Kuse E.R., Chetchotisakd P., da Cunha C.A., Ruhnke M.,  
          Barrios C., Raghunadharao D., Sekhon J.S., Freire A.,  
          Ramasubramanian V., Demeyer I., Nucci M., Leelarasamee A.,  
          Jacobs F., Decruyenaere J., Pittet D., Ullmann A.J., Ostrosky- 
          Zeichner L., Lortholary O., Koblinger S., Diekmann-Berndt H.,  
          Cornely O.A.; Micafungin Invasive Candidiasis Working  
          Group. Micafungin Invasive Candidiasis Working Group.  
          Micafungin versus liposomal amphotericin B for candidemia and  
          invasive candidiasis: a phase III randomized double-blind trial.  
Synthesis and characterization of caffeic and dihydrocaffeic acid derivatives as antifungal agents 144 
                                                                                                                                       
          Lancet, 2007, 369(9572): 1519-1527 
[164] Goto N., Hara T., Tsurumi H., Ogawa K., Kitagawa J.,  
          Kanemura N., Kasahara S., Yamada T., Shimizu M.,  
          Nakamura M., Matsuura K., Moriwaki H. Efficacy and safety of  
          micafungin for treating febrile neutropenia in hematological  
          malignancies. American Journal of Hematology, 2010, 85(11): 872- 
          876 
[165] Dowell J.A., Knebel W., Ludden T., Stogniew M., Krause D.,  
          Henkel T. Population pharmacokinetic analysis of anidulafungin,  
          an echinocandin antifungal. Journal of Clinical Pharmacology,  
          2004, 44(6): 590-598 
[166] Damle B.D., Dowell J.A., Walsky R.L., Weber G.L., Stogniew  
          M., Inskeep P.B. In vitro and in vivo studies to characterize the  
          clearance mechanism and potential cytochrome P450 interactions  
          of anidulafungin. Antimicrobial Agents and Chemotherapy, 2009,  
          53(3): 1149-1156 
[167] Dowell J.A., Stogniew M., Krause D., Damle B. Anidulafungin  
          does not require dosage adjustment in subjects with varying  
          degrees of hepatic or renal impairment. Journal of Clinical   
          Pharmacology, 2007, 47(4): 461-470 
[168] Reboli A.C., Rotstein C., Pappas P.G., Chapman S.W., Kett  
          D.H., Kumar D., Betts R., Wible M., Goldstein B.P., Schranz J.,  
          Krause D.S., Walsh T.J.; Anidulafungin Study Group.  
          Anidulafungin versus fluconazole for invasive candidiasis. The  
          New England Journal of Medicine, 2007, 356(24): 2472-2482 
[169] Kett D.H., Shorr A.F., Reboli A.C., Reisman A.L., Biswas P.,  
          Schlamm H.T. Anidulafungin compared with fluconazole in  
          severely ill patients with candidemia and other forms of invasive  
Synthesis and characterization of caffeic and dihydrocaffeic acid derivatives as antifungal agents 145 
                                                                                                                                       
          candidiasis: support for the 2009 IDSA treatment guideline for  
          candidiasis. Critical Care, 2011, 15(5): R253 
[170] Vazquez J.A., Schranz J.A., Clark K., Goldstein B.P., Reboli A.,  
          Fichtenbaum C. A phase 2, open-label study of the safety and  
          efficacy of intravenous anidulafungin as a treatment for azole- 
          refractory mucosal candidiasis. Journal of Acquired Immune  
          Deficiency Syndromes, 2008, 48(3): 304-309 
[171] Aguado J.M., Varo E., Usetti P., Pozo J.C., Moreno A., Catalán  
          M., Len O., Blanes M., Solé A., Muñoz P., Montejo M.;   
          TOSCANA Study Group. Safety of anidulafungin in solid organ  
          transplant recipients. Liver Transplantation, 2012, 18(6): 680-685 
[172] Wingard J.R. Empirical antifungal therapy in treating febrile  
          neutropenic patients. Clinical Infectious Diseases, 2004, 39(Suppl.  
          1): S38-43 
[173] Segal B.H., Almyroudis N.G., Battiwalla M., Herbrecht R.,  
          Perfect J.R., Walsh T.J., Wingard J.R. Prevention and early  
          treatment of invasive fungal infection in patients with cancer and  
          neutropenia and in stem cell transplant recipients in the era of  
          newer broad-spectrum antifungal agents and diagnostic adjuncts.  
          Clinical Infectious Diseases, 2007, 44(3): 402-409 
[174] Maertens J.A., Frère P., Lass-Flörl C., Heinz W., Cornely O.A.  
          Primary antifungal prophylaxis in leukaemia patients. European  
          Journal of Cancer Supplements, 2007, 5: 43-48 
[175] Cornely O.A., Böhme A., Buchheidt D., Einsele H., Heinz W.J.,  
          Karthaus M., Krause S.W., Krüger W., Maschmeyer G.,  
          Penack O., Ritter J., Ruhnke M., Sandgerr M., Sieniawski M.,  
          Vehreschild J.J., Wolf H.H., Ullmann A.J. Primary prophylaxis  
          of invasive fungal infections in patients with hematologic  
Synthesis and characterization of caffeic and dihydrocaffeic acid derivatives as antifungal agents 146 
                                                                                                                                       
          malignancies. Recommendations of the Infectious Diseases  
          Working Party of the German Society for Haematology and  
          Oncology. Haematologica, 2009, 94(1): 113-122 
[176] Goodman J.L., Winston D.J., Greenfield R.A., Chandrasekar  
          P.H., Fox B., Kaizer H., Shadduck R.K., Shea T.C., Stiff P.,  
          Friedman D.J., Powderly W.G., Silber J.L., Horowitz H.,  
          Lichtin A., Wolff S.N., Mangan K.F., Silver S.M., Weisdorf D.,  
          Ho W.G., Gilbert G., Buell D. A controlled trial of fluconazole to  
          prevent fungal infections in patients undergoing bone marrow  
          transplantation. The New England Journal of Medicine, 1992,  
          326(13): 845-851 
[177] Mikolajewska A., Schwartz S., Ruhnke M. Antifungal treatment  
          strategies in patients with haematological diseases or cancer: from  
          prophylaxis to empirical, pre-emptive and targeted therapy.        
          Mycoses, 2012, 55(1): 2-16 
[178] Pizzo P.A., Robichaud K.J., Gill F.A., Witebsky F.G. Empiric  
          antibiotic and antifungal therapy for cancer patients with prolonged  
          fever and granulocytopenia. The American Journal of Medicine,  
          1982, 72(1): 101-111 
[179] EORTC International Antimicrobial Therapy Cooperative  
          Group. Empiric antifungal therapy in febrile granulocytopenic  
          patients. The American Journal of Medicine, 1989, 86(6 Pt 1): 668- 
          672 
[180] Mahfouz T., Anaissie E. Prevention of fungal infections in the  
          immunocompromised host. Current Opinion in Investigational  
          Drugs, 2003, 4(8): 974-990 
[181] Kontoyiannis D.P. Invasive mycoses: strategies for effective  
          management. The American Journal of Medicine, 2012, 125(Suppl.  
Synthesis and characterization of caffeic and dihydrocaffeic acid derivatives as antifungal agents 147 
                                                                                                                                       
          1): S25-S38 
[182] Marchetti O., Cordonnier C., Calandra T. Empirical antifungal  
          therapy in neutropaenic cancer patients with persistent fever.  
          European Journal of Cancer Supplements, 2007, 5: 32-42 
[183] Bennet J.E., Powers J., Walsh T.J., Viscoli C., de Pauw B.,  
          Dismukes W., Galgiani J., Glauser M., Herbrecht R., Kauffman  
          C., Lee J., Pappas P., Rex J., Verweij P. Forum reports: issues in  
          clinical trials of empirical antifungal therapy in treating febrile  
          neutropenic patients. Clinical Infectious Diseases, 2003, 36(Suppl.  
          3): S117–122 
[184] Cordonnier C., Pautas C., Maury S., Vekhoff A., Farhat H.,  
          Suarez F., Dhédin N., Isnard F., Ades L., Kuhnowski F., Foulet  
          F., Kuentz M., Maison P., Bretagne S., Schwarzinger M.  
          Empirical versus preemptive antifungal therapy for high-risk,  
          febrile, neutropenic patients: a randomized, controlled trial.  
          Clinical Infectious Diseases, 2009, 48(8): 1042-1051 
[185] Martín-Peña A., Aguilar-Guisado M., Cisneros J.M. Does the  
          current treatment of invasive fungal infection need to be reviewed?  
          Enfermedades Infecciosas y Microbiología Clínica, 2014, 32(8):  
          523-528 
[186] Standiford H.C., Chan S., Tripoli M., Weekes E., Forrest G.N.  
          Antimicrobial stewardship at a large tertiary care academic medical  
          center: cost analysis before, during, and after a 7-year program.  
          Infection Control and Hospital Epidemiology, 2012, 33(4): 338-345 
[187] Schneider T., Halter J., Heim D., Passweg J., Stern M., Tichelli  
         A., Weisser M., Gerull S. Pre-emptive diagnosis and treatment of  
          fungal infections-evaluation of a single-center policy. Clinical  
          Microbiology and Infection, 2012, 18(2): 189-194 
Synthesis and characterization of caffeic and dihydrocaffeic acid derivatives as antifungal agents 148 
                                                                                                                                       
[188] Maertens J., Theunissen K., Verhoef G., Verschakelen J.,  
          Lagrou K., Verbeken E., Wilmer A., Verhaegen J., Boogaerts  
          M., van Eldere J. Galactomannan and computed tomography- 
          based preemptive antifungal therapy in neutropenic patients at high  
          risk for invasive fungal infection: a prospective feasibility study.  
          Clinical Infectious Diseases, 2005, 41(9): 1242-1250 
[189] Aguado J.M., Ruiz-Camps I., Muñoz P., Mensa J., Almirante B.,  
          Vázquez L., Rovira M., Martín-Dávila P., Moreno A., Alvarez- 
          Lerma F., León C., Madero L., Ruiz-Contreras J., Fortún J.,  
          Cuenca-Estrella M.; Grupo de Estudio de Micología Médica de  
          la SEIMC (GEMICOMED). Guidelines for the treatment of  
          Invasive Candidiasis and other yeasts, Spanish Society of  
          Infectious Diseases and Clinical Microbiology (SEIMC). 2010  
          Update. Enfermedades Infecciosas Microbiología Clínica, 2011,  
          29(5): 345-361 
[190] Fortún J., Carratalá J., Gavaldá J., et al., Guidelines for the  
          treatment of invasive fungal disease by Aspergillus spp. and other  
          fungi issued by the Spanish Society of Infectious Diseases and  
          Clinical Microbiology (SEIMC), 2011 Update, Enfermedades  
          Infecciosas Microbiología Clínica, 2011, 29:435-454 
[191] Maertens J., Marchetti O., Herbrecht R., Cornely O.A.,  
          Flückiger U., Frêre P., Gachot B., Heinz W.J., Lass-Flörl C.,  
          Ribaud P., Thiebaut A., Cordonnier C.; Third European  
          Conference on Infections in Leukemia. European guidelines for  
          antifungal management in leukemia and hematopoietic stem cell  
          transplant recipients: summary of the ECIL 3—2009 update. Bone  
          Marrow Transplant, 2011, 46(5): 709-718 
[192] Freifeld A.G., Bow E.J., Sepkowitz K.A., Boeckh M.J., Ito J.I.,   
Synthesis and characterization of caffeic and dihydrocaffeic acid derivatives as antifungal agents 149 
                                                                                                                                       
          Mullen C.A., Raad I.I., Rolston K.V., Young J.A., Wingard J.R.;  
          Infectious Diseases Society of America. Clinical practice  
          guideline for the use of antimicrobial agents in neutropenic patients   
          with cancer: 2010 update by the Infectious Diseases Society of  
          America (IDSA). Clinical Infectious Diseases, 2011, 52(4): 56-93 
[193] Rüping M.J., Vehreschild J.J., Cornely O.A. Patients at high risk  
          of invasive fungal infections: when and how to treat. Drugs, 2008,  
          68(14): 1941-1962 
[194] Kirkpatrick W.R., Perea S., Coco B.J., Patterson T.F. Efficacy  
          of caspofungin alone and in combination with voriconazole in a  
          guinea pig model of invasive aspergillosis. Antimicrobial Agents  
          and Chemotherapy, 2002, 46(8): 2564-2568 
[195] Nagasaki Y., Eriguchi Y., Uchida Y., Miyake N., Maehara Y.,  
          Kadowaki M., Harada M., Akashi K., Shimono N. Combination  
          therapy with micafungin and amphotericin B for invasive  
          pulmonary aspergillosis in an immunocompromised mouse model.  
          The Journal of Antimicrobial Chemotherapy, 2009, 64(2): 379-382 
[196] Panackal A.A., Parisini E., Proschan M. Salvage combination  
          antifungal therapy for acute invasive aspergillosis may improve  
          outcomes: a systematic review and meta-analysis. International  
          Journal of Infectious Diseases, 2014, 28: 80-94 
[197] Ostrosky-Zeichner L. Combination antifungal therapy: a critical  
          review of the evidence. Clinical Microbiology and Infection, 2008,  
          14(Suppl. 4): 65-70 
[198] Balkovec J.M., Hughes D.L., Masurekar P.S., Sable C.A.,  
          Schwartz R.E., Singh S.B. Discovery and development of first in  
          class antifungal caspofungin (CANCIDAS®)--a case study.  
          Natural Product Reports, 2014, 31(1): 15-34 
Synthesis and characterization of caffeic and dihydrocaffeic acid derivatives as antifungal agents 150 
                                                                                                                                       
[199] Schwartz R.E., Glacobbe R.A., Bland J.A., Monaghan R.L. L- 
          671,329, a new antifungal agent. I. Fermentation and isolation. The  
          Journal of Antibiotics (Tokyo), 1989, 42(2): 163-167 
[200] Schwartz R.E., Sesin D.F., Joshua H. Wilson K.E., Kempf A.J.,  
          Goklen K.A., Kuehner D., Gailliot P., Gleason C., White R.  
          Pneumocandins from Zalerion arboricola. I. Discovery and  
          isolation. The Journal of Antibiotics (Tokyo), 1992, 45(12): 1853- 
          1866 
[201] Bills G.F., Platas G., Peláez F., Masurekar P. Reclassification of  
          a pneumocandin-producing anamorph, Glarea lozoyensis gen. et sp.            
          nov., previously identified as Zalerion arboricola. Mycological  
          Research, 1999, 103(2): 179-192 
[202] Daneshtalab M. Discovery of chlorogenic acid-based  
          peptidomimetics as a novel class of antifungals. A success story in  
          rational drug design. Journal of Pharmacy & Pharmaceutical  
          Sciences, 2008, 11(2): 44S-55S 
[203] Douglas C.M. Fungal beta(1,3)-D-glucan synthesis. Medical  
          Mycology, 2001, 39(Suppl. 1): 55-66 
[204] Zambias R.A., Hammond M.L., Heck J.V., Bartizal K., Trainor  
          C., Abruzzo G., Schmatz D.M., Nollstadt K.M. Preparation and  
          structure-activity relationships of simplified analogs of the  
          antifungal agent cilofungin: a total synthesis approach. Journal of  
          Medicinal Chemistry, 1992, 35(15): 2843-2855 
[205] Taft C.S., Selitrennikoff C.P. Cilofungin inhibition of (1-3)-beta- 
          glucan synthase: the lipophilic side chain is essential for inhibition  
          of enzyme activity. The Journal of Antibiotics (Tokyo), 1990, 43(4):  
          433-437 
[206] Ma C.M., Kully M., Khan J.K., Hattori M., Daneshtalab M.  
Synthesis and characterization of caffeic and dihydrocaffeic acid derivatives as antifungal agents 151 
                                                                                                                                       
          Synthesis of chlorogenic acid derivatives with promising antifungal  
          activity. Bioorganic & Medicinal Chemistry, 2007, 15(21): 6830- 
          6833 
[207] Ma C.M., Abe T., Komiyama T., Wang W., Hattori M.,  
          Daneshtalab M. Synthesis, anti-fungal and 1,3-β-D-glucan  
          synthase inhibitory activities of caffeic and quinic acid derivatives.  
          Bioorganic & Medicinal Chemistry, 2010, 18(19): 7009-7014 
[208] Wang W., He X.L., Ma C.M. Metabolism schemes of chlorogenic,  
          quinic and caffeic acid derivatives in rats deduced by molecular  
          fragments detected with optimized UPLC-APCI-MS/MS conditions.  
          International Journal of Mass Spectrometry, 2013, 337: 34-42 
[209] Blondelle S.E., Houghten R.A. Comparison of 55% TFA/CH2Cl2  
          and 100% TFA for Boc group removal during solid-phase peptide  
          synthesis. International Journal of Peptide and Protein Research,  
          1993, 41(6): 522-527 
 
 Synthesis and characterization of caffeic and dihydrocaffeic acid derivatives as antifungal agents A-1 
Appendices 
 
1H NMR, LC-MS and IR spectra of synthesized compounds: 
 
3,4-diacetoxycinnamoyl chloride 15a: LC-MS 
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3,4-diacetoxycinnamoyl chloride 15a: 1H NMR 
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Caffeic acid derivative 16a: 1H NMR 
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Caffeic acid derivative 16a: LC-MS (APCI-positive) 
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Caffeic acid derivative 16a: LC-MS (APCI-negative) 
 
 
 
Synthesis and characterization of caffeic and dihydrocaffeic acid derivatives as antifungal agents A-6 
Caffeic acid derivative 16d: 1H NMR 
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Caffeic acid derivative 16d: LC-MS (APCI-positive) 
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Caffeic acid derivative 16d: LC-MS (APCI-negative) 
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Caffeic acid derivative 16g: 1H NMR 
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Caffeic acid derivative 16g: LC-MS (APCI-positive) 
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Caffeic acid derivative 16g: LC-MS (APCI-negative) 
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3,4-diacetoxydihydro-caffeoyl chloride 19b: 1H NMR 
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Dihydrocaffeic acid derivative 20a: 1H NMR 
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Dihydrocaffeic acid derivative 20a: LC-MS (APCI-positive) 
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Dihydrocaffeic acid derivative 20a: LC-MS (APCI-negative) 
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Dihydrocaffeic acid derivative 20a: IR 
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Dihydrocaffeic acid derivative 20b: 1H NMR 
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Dihydrocaffeic acid derivative 20b: LC-MS (APCI-positive) 
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Dihydrocaffeic acid derivative 20b: LC-MS (APCI-negative) 
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Dihydrocaffeic acid derivative 20b: IR 
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Dihydrocaffeic acid derivative 20c: 1H NMR 
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Dihydrocaffeic acid derivative 20c: LC-MS (APCI-positive) 
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Dihydro-caffeic acid derivative 20c: LC-MS (APCI-negative) 
 
 
